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ABSTRACT

Membranes and membrane-associated components are the target of approximately
60% of the current drugs, of synthetic materials, such as polymers, which are used for drug
delivery purposes and of other biomolecules, such as endotoxins, which gain entry into the
cell by disrupting the membrane. Therefore, the development of biomimetic membrane
assemblies allows the study of different biological processes in which cell membranes play
an important role, and the characterization and screening of drug delivery tools and other
membrane-bound components.
Since its development, membrane assemblies on planar silica surfaces have been the
method of choice to study membrane-associated and membrane-bound components.
However, the screening process of planar-substrate supported membranes has some
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limitations, as they rely on non-high-throughput or multiplexable technologies, like
microscopy or Surface Plasmon Resonance (SPR). This results in time consuming studies,
high cost, and high variability from sample to sample. Another biomimetic assembly
commonly used are giant unilamellar vesicles (GUVs), which has proven to be valuable,
as it better mimics the size and shape of cell membranes. Nevertheless, their assembly is
time consuming and presents polydispersity.
The need of a biomimetic platform amenable to high-throughput screening process
inspired the development of silica microsphere-supported membranes, as an alternative to
planar-supported membranes and GUVs. Microsphere-supported membranes can be
screened using flow cytometry, which is a laser-based high-throughput technology that
measures several thousand particles and their physical characteristics in a few seconds.
Moreover, flow cytometry has the advantage of being highly sensitive, accurate,
reproducible, and it uses small sample volumes, making the screening process faster and
more affordable.
To that end, we built and characterized multiplexable biomimetic membranes on silica
microspheres for flow-based screening applications. Furthermore, we demonstrated that
this new biomimetic construct could potentially constitute a more effective way of
performing target based screening assays for membrane-bound components. We used
microsphere-supported biomimetic membranes to screen: 1) membrane-protein
interactions, 2) membrane disruption assays, and 3) polymer membrane interactions.
Future areas for application of these methods are in areas such as, drug screening,
antimicrobial peptide screening, and protease assay development.
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Chapter 1.
Introduction

1.1 Present Studies
Developing biomimetic membrane assemblies for drug screening purposes is important
for the discovery of new drugs that target membrane bound components or bacterial
membranes, and for understanding how novel medical therapies, such as drug delivery
tools, interact with membranes. Currently 40-60% of drugs target membrane bound
components.1 For example, about 95% of psychotropic drugs target membrane proteins,
many novel cancer drugs use membrane proteins for entry into the cell, and novel classes
of anti-bacterial agents such as anti-microbial peptides (AMPs) specifically target bacterial
membranes. Other biological components, such as endotoxins and exotoxins, interact with
mammalian cells by first disrupting the cell membrane. Moreover, membranes are also the
target of some synthetic materials, such as polymers, as they are used for various
biomedical purposes such as drug delivery.
The development of membrane assemblies on planar silica surfaces has provided an
important route to study membrane-associated and membrane-bound components. Such
systems are widely studied and characterized and demonstrate the feasibility of building
supported bilayers on silica surfaces and the integration of membrane-bound proteins. An
alternative platform, giant unilamellar vesicles, has also proven to be valuable for the study
of the interaction of membranes with other biomolecules. However, membrane assemblies
on planar silica or the use of giant unilamellar vesicles have many limitations for highthroughput and multiplexable studies, which limit their applicability in drug screening.
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To that end, we propose the development of multiplexable biomimetic membrane
bilayers on silica microspheres for flow-based screening applications. Our development of
multiplexed biomimetic membranes on silica microspheres will provide a beneficial
platform to allow high-throughput screening of biomolecules that target membrane bound
components. The new biomimetic constructs that we will develop have the promise of
enabling application of high-throughput multiplexed flow cytometry techniques to study
membrane proteins, membrane disruption assays, and assess polymer membrane
interactions. Future areas for application of these methods are in areas such as protease
assay development, drug screening and antimicrobial peptide screening.
1.2 Cell membrane function, chemical composition, and physical properties.
All cells have a ~5-10 nm thick outer membrane,2 also known as the plasma membrane
or cytoplasmic membrane, which is a thin biological semi-permeable membrane that
surrounds, protects and separates the cytoplasm from the outside environment by
regulating what substances diffuse across the membrane and into the cell. Also, cell’s
membrane helps support and maintain the shape of the cell.3–5
The cell membrane’s major components are lipids in the form of phospholipids,
cholesterol and glycolipids,6,7out of which phospholipids constitute approximately half of
mammalian cell membranes.8,9
Phospholipids are composed of a phosphate hydrophilic head and two hydrophobic
hydrocarbon tails. They are insoluble in water and due to their amphiphilic nature, they
spontaneously arrange into a bilayer form in which the hydrophilic head faces towards the
aqueous cytosol and the extracellular fluid, while the hydrophobic tail areas face away.10
2

Some of the most common glycerophospholipids include phosphatidylcholine and
phosphatidylethanolamine, which in spite of their similar structure, have different
properties and tend to be in different leaflets of the membrane bilayer of the cell. Besides
phosphatidylethanolamine, the inner cytoplasmic leaflet of the membrane also contains
anionic phospholipids such as phosphatidylserine and phosphatidylinositol.6 Finally, the
fifth most abundant phospholipid on cell membranes is sphingomyelin, which
predominantly locates in the membrane’s outer leaflet.8
Cholesterol is also a membrane component in animal cells, but absent in bacterial and
mitochondrial membranes. At high temperatures, it serves the function of preventing
phospholipids from being too closely packed, resulting in a stiffer (less fluid)
membrane3,8,10 at low temperatures, it keeps the membrane fluid and it prevents its
freezing.8 Cholesterol, along with sphingolipids, plays an important role in the process of
lipid raft formation.11 Animal cells have been estimated to contain 25 mol% to 50 mol%
of cholesterol in their membranes,12 but these percentages change in aging cells.13 In
addition, there is an upper limit concentration for the cholesterol present in the membrane.
The cholesterol solubility limit in phosphatidylcholine bilayers is 66 mol% and in
phosphatidylethanolamine bilayers is 51 mol%.12,14
Finally, glycolipids are structures composed of a carbohydrate attached to a lipid
moiety by a glycosidic bond,15 which are located in the membrane’s outer leaflet and
constitute only 2% of the membrane’s lipids.8 They play an important role in cell
communication, recognition and adhesion,16 and in determining human blood type.17
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In addition to lipids, the cell membranes also contain membrane proteins that account
for almost half the mass of most cellular membranes.18 Membrane proteins are classified
as integral membrane proteins and peripheral membrane proteins.
Integral membrane proteins account for up to one-third of the lipid bilayer membrane’s
mass,19 and they play crucial roles in cell transportation,20 cell adhesion,21 and acting as
receptors and channels.22 They also comprise the majority of drug targets.23 Integral
membrane proteins can be partially (integral monotopic proteins), or completely
(transmembrane proteins) embedded in the lipid membrane. These proteins are usually
hard to remove from the membrane, and the disruption of the lipid is necessary for their
extraction. The solubilization of the membrane and subsequent extraction of the proteins
is done using harsh solvents, like detergents.8,24
Peripheral membrane proteins are temporarily bound to the lipid head groups 25 or to
the integral membrane proteins. They can be dissociated from the membrane without
perturbing the membrane structure. The dissociation process can be achieved by treatment
with surfactants, solutions with high salt content or solutions with very high or low pH.8
Peripheral membrane proteins play very important roles for the proper function of the
cell,18,26 playing a role in processes like signaling,25 and transportation.27
A very important characteristic of cell membranes is fluidity, which depends on the
membrane’s composition, pressure, ionic strength, pH, and temperature. The fluidity of the
membrane allows two different types of diffusion to take place: lateral (with proteins and
lipids moving sidewise within the membrane), or transverse (with molecules going from
one membrane leaflet to the other). At physiological temperatures, cell membranes usually
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exist in a fluid form where the hydrocarbon chains are disordered; at cooler temperatures,
the membranes exist in a more ordered gel-like state where the hydrocarbon chains are
fully extended and closely packed.28 At characteristic temperatures, all lipids, depending
on the charge, hydrocarbon length and head group, can undergo a phase transition (from
gel to liquid phase or vice versa). Change in the membrane’s fluidity can have effects on
its permeability,29,30 freezing point,31 and viscosity.32
1.3 Membrane as targets in development of drugs and medical devices.
Cell membranes have been widely studied since they serve many important functions
in different biological processes. They mainly provide a semi-permeable barrier between
the environment and the cytoplasm of the cell as well as barriers between the cytoplasm
and organelles, but they also play an important role in other biological processes such as
ion conductivity, cell adhesion, transfer of molecules across membranes, and cell
signaling.10,33 In addition, prior to reaching and interacting with the cytoplasm, toxins and
viruses must interact with cell membranes.34,35 These functions lead to membraneassociated components being the most druggable targets,36–38 and also account for
membranes and membrane components being very important in the development of
medical devices.39 Some of the most studied membrane-interacting biomolecules are
membrane proteins, membrane disruption agents and polymers. In this section, we explore
the importance of the interaction of these types of molecules with cell membranes.
1.3.1

Membrane-protein interactions

Membrane-protein interactions regulate several important processes such as transport
across membranes, enzymatic activity, and cell-cell recognition, making membrane
5

proteins of great interest for target-based drug screening. Developing new assays for target
based screening against membrane proteins is important because membrane proteins
constitute around 60% of today’s approved drug targets.40,41
There are various examples of studies related to membrane-protein interactions: drug
interactions with membrane and embedded membrane proteins,42 cell signaling and
membrane trafficking,43 biophysical studies of membrane-protein interactions,44,45 cell
adhesion to model-membranes containing transmembrane proteins studied on patterned
solid supported membranes,46 protein-induced membrane deformations studied in giant
unilamellar vesicles (GUVs),47 and many more.
Studies on membrane components are often done on model membranes supported on
planar silica surfaces,48,49 arrays of patterned membrane structures,50 or giant unilamellar
vesicles (GUVs).51 Model membranes provide a good tool for studying individual lipid
bilayers and some associated proteins, they also present some limitations. First, use of
membranes on planar surfaces becomes time consuming especially if multiple samples
need to be tested, and variability may occur from sample to sample.52 Second, membranes
supported on planar silica rely on relatively low-throughput detection methods such as
microscopy and surface plasmon resonance (SPR).53–56 Third, even though supported lipid
bilayer arrays are currently used to help increase throughput, they are limited by the size
of the array and the time-consuming process of fabrication.57–59 Finally, GUVs show some
structural stability and size polydispersity.60,61 In summary, studying membrane-protein
interactions on membranes supported on planar silica, arrays of patterned membrane
structures or GUVs do not provide a cost effective, quick, and high-throughput method
necessary for drug screening.62
6

Hence, another model membrane structure was developed: lipid membrane supported
on silica microspheres, which present the membrane in a manner appropriate for use with
high-throughput and multiplexable technologies like flow cytometry.63
1.3.2

Membrane disruption assays

The process of membrane disruption is of great interest as diverse biomolecules can
rupture, form holes or simply disturb the cell lipid membrane. Some of the best-known
disrupting bioparticles are: detergents and surfactants,64,65 antimicrobial peptides
(AMPs),66 metal nanoparticles,67 toxins,68,69 conjugated polyelectrolytes (CPEs),70 and
some drugs.71 Membrane disruption assays are used to perform mechanistic studies, guide
extraction and isolation of membrane-proteins, and to test the effect of possible disrupting
agents. Most of the disruption agents, like AMPs, show lipid selectivity between bacterial
and mammalian cell membranes.72 This selectivity is of extreme importance in the
screening process of new microbe-targeted drugs, as it is expected for the drug to induce
disruption in bacterial membranes and to have no disruption effect on mammalian cell
membranes.
Most membrane disruption assays are performed on actual cells,73,74 where target
identification is very difficult due to confounding factors such as membrane complexity
and a wide variety of different components including lipids, proteins, and carbohydrates.
Other

membrane

disruption

assays

are

performed

on

planar-solid-supported

membranes,75,76 which has some limitations; they rely on low-throughput screening
processes, which makes the measurement slower. Even if these assays are performed on
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systems that use arrays of patterned planar supported lipid bilayers, the preparation process
is still time consuming.69
To the best of our knowledge, there are limited studies showing microsphere-supported
lipid bilayers as a platform to perform membrane disruption assays.77 Therefore, studying,
exploring and expanding the use of this platform provides an interesting and useful
alternative method for the development of membrane disruption assays, one that could
enable the testing of different membrane compositions such as membranes containing
cholesterol or negatively charged lipids in a high-throughput or multiplexable manner.
1.3.3

Polymer-membrane interactions and block copolymers as an alternative to lipids
in membrane formation.

The interaction of polymers with lipid membranes and cell membranes is of key
importance for the development of novel medical devices, drug delivery mechanisms, and
the discovery of antimicrobials and antimicrobial surfaces.78 Polymers are used for various
biomedical purposes such as drug delivery, as biosensors, and for surgical sutures and
implants.79 Biodegradable polymers in particular are widely studied as scaffolds for tissue
engineering,80 they are used as drug encapsulants,81 in chemotherapeutics,82 in vaccines,83
as substrates or support to lipid membranes,84,85 and as drug delivery tools.86 The
incorporation of polymers into lipid membranes can alter the physiochemical properties of
the membrane, acting as membrane sealants,87 as protecting agents against lipid
peroxidation,88 and also as membrane disrupters.89 In many of these applications the
interaction of polymers with membranes plays an important role. In general, the interaction
of polymers and cell membranes depends on the cell type, membrane composition and the
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biochemical properties of the polymer. The study of interactions between polymers and
membranes and the development and testing of most biodegradable and cationic polymers
is done on whole cells, on planar silica supported lipid membranes, or on liposomes.
Although very effective, the aforementioned study platforms are very time consuming as
they rely on methods such as microscopy and SPR. Flow cytometry offers a good
alternative, as it is a faster option, analyzes a large number of parameter simultaneously, is
a standard technique in many laboratories, and rapidly produces detailed data.
There is one particular group of polymers known as the amphiphilic block copolymers
that have proven to have possible biological,90 and medical applications.91 For instance,
structures like polymersomes or amphiphilic block copolymer vesicles have been studied
as potential drug carriers,92,93 and are a synthetic alternative to lipid vesicles, both
containing a bilayer membrane structure.94,95 One major advantage offered by block
copolymers is that block copolymer membrane properties, like permeability and lateral
diffusivity, can be systematically tuned by varying the block copolymer molecular
weight96,97 and composition.91,98 In addition, there are many reported techniques for the
preparation of amphiphilic block copolymers, which result in diverse nanostructures.99
Polymersomes also are compatible with a wider variety of analysis technologies, including
flow cytometry.100
To the best of our knowledge, block copolymer membranes supported on microspheres
have not been studied. Their development and use would provide an alternative platform
to study synthetic membranes as cell membrane mimics, and the interaction of such
membranes with other biomolecules. Furthermore, such platforms could be expanded into
a multiplex set and would allow the use of high-throughput flow cytometry technologies.
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1.4 Screening processes of model membranes
Biological membranes are complex structures, and biophysical interactions between
membranes and other components, such as drugs and drug delivery systems,42 are very
challenging to investigate. Model lipid membranes have been developed as an alternative,
where a simplified artificial membrane can be tailored to have a certain composition,
geometry and structure that mimics a natural membrane.101–104
1.4.1

Planar silica supported membrane bilayers (SSMB)

Solid supported lipid bilayers are model lipid membranes that are deposited on solid
substrates, where there is a layer of trapped water, only a few Ångstrom-thick, between the
bilayer and the solid support.52 The most widely used substrate materials are silica, mica
and borosilicate glass.44 SSMB can be formed by applying one of three major techniques.
The first and simplest method is the adsorption and fusion of lipid vesicles, which is a
spontaneous process where the lipid vesicles first adhering to and then rupture on top of
the glass surface, forming the bilayer.56 The second is the Langmuir–Blodgett (LB)
technique, which uses a special barrier to assemble a monolayer of amphiphilic molecules
on a water surface, which is then transferred to a substrate. This step is followed by the
horizontal deposition of a second monolayer on top of the first monolayer.105,106 The third
method is a combination of the last two, where the first step is to form a monolayer using
the LB technique and the second step is the deposition of vesicles on top of the monolayer
to form the upper leaflet and/or multi layers.
SSMB have been widely used in multiple studies and for different purposes including
characterization

of

membrane

processes,107
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membrane

interaction

with

small

biomolecules,108 drug permeability,101,109 immunology studies,110 and other biological
applications.111–113
SSMB have major advantages. They are easy to ensemble and very stable, and they are
highly mobile, maintaining the fluidity observed in natural cell membranes and any
biomolecule linked to it.110 Nevertheless, SSMB also face some challenges. Incorporation
of transmembrane proteins is difficult in standard SSMBs, as the proteins come into direct
contact with the substrate and lose their function.103 To mitigate this problem, some groups
built and successfully used polymer-cushioned bilayers supported on solid substrates.114,115
SSBMs on planar surfaces can only be used with detection or characterization methods
such as microscopy or surface plasmon resonance. These are low to, at best medium
throughput, making any analytical study expensive and time consuming.
1.4.2

Patterned planar-SSMBs

As an alternative to regular SSMBs, patterned planar-SSMBs for analytical studies, and
lipid bilayer arrays were developed. This is achieved by micro116 or nano-patterning117 of
the substrate by using metals or plastic before the lipid bilayer formation.118 These
partitions allow scientists to tailor, organize and/or limit the bilayer formation,119 its lateral
diffusion,50,120 and its composition.121 A typical method to pattern the substrates is the
exposure of different regions of the surface to resisting materials (metal or plastic) using
photolithography or ebeam lithography, before membrane formation. Also, so-called
stamping methods or post-deposition masked UV exposure can create patterned
membranes.122
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Patterned planar-SSMBs have been used in diverse studies such as characterization of
the immune synapse,123 study of intracellular signaling,50 screening of interactions between
drugs or proteins with membranes,124 and cell-based biosensor technology,125,126 among
others. The main advantage of patterned planar-SSMBs is the fact that the
compartmentalization allows screening of different compositions, phases, and domains
against various biocomponents simultaneously.127 However, they are limited by the size of
the array, the time-consuming process of fabrication,57–59 and the cost of preparation and
analysis.118
1.4.3

Giant unilamellar vesicles (GUVs)

GUVs are vesicles in the range of 1 to 100 μm in diameter.128 These structures are well
suited for membrane-related studies as they mimic the curvature and size of cell
membranes,129 which makes them easily visible with an optical microscope.130 GUVs have
been used in various membrane-related studies,51 including membrane-protein
interactions,131 gene transcription,132 immunoassays,133 and biosensors.134
There are many techniques to form GUVs. The most common ones are: the solvent
evaporation method, the gentle hydration method and the electro-formation method.135
New, innovative and improved methods for preparation are also being published frequently
as there has been a great effort to optimize the assembly and production of GUVs. To name
a few, these include GUV formation by small vesicle fusion, from an initially planar
bilayer,134 or by gel-assisted formation.51 One advantage of GUVs, besides their size and
curvature, is that they are independent of a solid substrate, presenting a more natural and
cell-like structure. Nevertheless, studies using GUVs exhibit some important
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disadvantages. They are typically heterogenous in size and their structure is fragile,63,136
plus the production process can be time consuming.137 They are also not suitable for drug
delivery studies.134 Typically, analysis of GUVs also relies on low-throughput measuring
techniques, such as microscopy, although a few flow cytometry studies have been
published.138
1.4.4

Silica microsphere SMBs

Silica microspheres are commercially available monodisperse beads with multiple
biotechnology applications. These include biosensing,63,139 drug delivery,140,141 and as solid
substrates to support lipid membrane structures.142 The lipid bilayer formation on the silica
beads is achieved via lipid vesicle adsorption, a simple and time efficient process, or by
chemical crosslinking.63,119 The quality of the membranes is similar to those created on
planar surfaces.77,142–145 Silica microsphere-supported membranes are used in
microscopy,84 and flow-based assays.146,147
There are many advantages to this platform. They present a more natural membrane
environment relative to planar membranes since the curvature of the membrane mimics
that of an actual mammalian or bacterial cell.148 Also, compared to their planar counterparts
they present a higher quantity of membrane surface area when dispersed I solution. In
addition, they can be analyzed using high-throughput technologies like flow cytometry,
where poorly coated or defective membranes can be gated out. Unfortunately, this platform
also has some shortcomings. Most notably, silica is a dense material, so it is hard to keep
silica microspheres in suspension. To address this limitation, currently there are ongoing
efforts of modifying the surface chemistry of commercially available, naturally bouyant
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polystyrene microspheres to make them able to present membrane components in their
natural lipid environment. However, said efforts have not yet achieved positive results.149
1.5 Characterization processes of model membranes
To study lipid bilayers many analytical techniques have been used; fluorescence
microscopy,150,151 atomic force microscopy (AFM),152,153 spectroscopy,154,155 quartzcrystal microgravimetry (QCM),156 surface plasmon resonance (SPR),157,158 and
ellipsometry.159,160 Here we briefly review the most used characterization techniques.
1.5.1

Microscopy

The development of microscopy dates back to the 1600s and has radically influenced
scientific fields such as biology, geology and histology.161 Briefly, there are three branches
of microscopy: optical, electron, and scanning probe microscopy.162 Optical microscopy
(also known as light microscopy) is the most widely used and it has two major
subcategories: bright field and fluorescence.163 Fluorescence microscopy, in particular,
has many variants that allow the microscopes to better achieve different purposes, such as
fluorophore detection by epifluorescence or increased optical resolution by confocal
microscopy, among many others.164 Electron microscopy uses a beam of accelerated
electrons to create and enlarge the image of a sample.165 Some electron microscopes have
a magnification capability of 2 million times allowing scientists to observe much smaller
objects.166 There are 4 types of electron microscopes: Transmission Electron Microscope
(TEM), Scanning Electron Microscope (SEM), Reflection Electron Microscope (REM),
and Scanning Transmission Electron Microscope (STEM). These microscopes are very
expensive and require high maintenance. Scanning probe microscopy (SPM) uses a
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scanning process to move a nanostructured tip across the sample, allowing imaging of
surfaces at a nanometer length scale. The scanning probe gathers the information and sends
it to a computer where the software generates an image to represent the surface.167
Microscopy has been the technology of choice to study planar supported lipid
bilayers.137 These studies provided information about the membrane’s mechanical
properties and morphology using atomic force microscopy (AFM) and AFM-based force
spectroscopy (AFM-FS),168 the membrane’s phase using fluorescence recovery after
photobleaching (FRAP), the spatial relationships between molecules and the membrane by
means of contact-dependent fluorescence quenching and fluorescence resonance energy
transfer (FRET),169 and membrane interactions with membrane-bound components such as
proteins,170,171 enzymes,172 DNA molecules,173 and drugs.174,175 Furthermore, optical
microscopy and AFM, along with spectroscopy, have been the major technologies used for
the study of giant unilamellar vesicles (GUVs) as model membranes.137,176
As significant as microscopy has been for the study of biological and model
membranes, it still faces some limitations such as a slow measurement process and a
limited number of detection parameters, which leads to low to medium throughput.
Achieving high throughput using microscopy requires expensive and specialized imaging
instrumentation.
1.5.2

Surface Plasmon Resonance

Surface plasmon resonance (SPR) is an optical detection technique that monitors the
interaction between two label-free biomolecules. This is achieved by having one of the
molecules (the ligand) immobilized onto a thin metal film (sensor) and the other molecule
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(the analyte) is injected under continuous flow.177 As the binding takes place there is a
change in the local refractive index at the surface, which can be monitored in real time.
Analysis of rates of said changes quantitatively describes the affinity.178,179 SPR has been
used extensively to study the affinity and interaction of supported lipid bilayers (SSLBs)
and proteins,54,180,181 but also with some other biomolecules such as antimicrobial
peptides.182 Once major advantage of SPR is that it is label free and does not require adding
a fluorophore to the system. Nevertheless, SPR also has some major disadvantages. It is
not being high throughput, has a limited sensor area, suffers from mass transport
limitations, and most importantly, is very susceptible to complications from non-specific
binding.183,184
1.5.3

Ellipsometry

Ellipsometry is a very sensitive characterization technique that uses polarized light to
measure film thickness and optical constants. Ellipsometry can detect film thicknesses
ranging from a few angstroms to tens of microns, relying on optical models to fit the data.159
One of the applications of ellipsometry is the characterization of model lipid
membranes.185,186 Ellipsometry has several advantages such as being highly accurate, nonperturbative and label-free.187 However, it also has some disadvantages, most notably that
it is time consuming and not implemented in a high throughput manner. Also, the
characterization becomes more difficult if the films are non-uniform.188
1.6 Flow cytometry
Flow cytometry is a laser-based high-throughput technology that can individually
measure several thousand cells or particles suspended in a stream of fluid every second,189
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and can also simultaneously analyze multiple physical characteristics and surface
properties of each particle in “real time”.190 This technology has many advantages. It is
fast, reproducible, highly sensitive, accurate, and uses very small sample volumes.190 In
addition, several commercially available flow cytometers automatically can sample from
96 to 1536 well plates, making the screening process faster and more affordable.190,191
Briefly, flow cytometry works by passing cells or particles (~ 1μm -15μm) suspended
in a fluid through a laser beam.192 Then, the scattered light or fluorescence emitted by each
particle individually is collected and measured.193 In order to individually interrogates each
cell or particle, the flow cytometry’s fluidics system spatially focuses the sample into a
single-particle stream.194 Each particle’s emitted light is directed through the flow
cytometer’s optical system, measured by the detectors and converted into digital signals by
the computer system. The following paragraphs provide a more detailed description of each
of the components in a flow cytometer.
•

Fluidics system
The flow cytometer’s fluidic system consists mainly of a flow chamber that can be fully

closed for analyzing purposes only, or can be open air for analyzing and cell sorting.195 Via
a syringe pump system, the flow chamber injects the sample stream containing the cells or
particles into a flowing stream enclosed by an outer flow of water or buffer called sheath
fluid.

196

The combination of sample and sheath flow spatially focuses the particles to a

narrow diameter stream, so that they are passed through the laser beam one at a time. This
process is called hydrodynamic focusing, and it is used by most flow cytometers.195 Some
newer flow cytometers use an improved technology called acoustic focusing which uses
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ultrasonic radiation pressure to pre-focus the samples before using hydrodynamic
focusing.197
•

Light source
The most commonly used light sources are moderately low-power lasers, but arc lamps

and LED are used as well.194 To achieve optimal flow cytometric results, the light source
ideally needs to have a tight focus, making lasers the best candidate as a light
source.195,198,199 Most flow cytometers have at least one laser producing 10 to 25 mW of
blue light at 488 nm, and modern flow cytometers also have other lasers such as He-Ne,
He-Cd, and solid-state lasers.195,199
•

Optics
Once each sample particle passes through the interrogation point, the light scattered or

emitted by the particle is collected. There is a detector right in front of the laser beam that
collects the light scattered in the forward direction; this signal is known as the forward
scattered channel (FSC). The FCS measurement correlates with the size of the particle.
There is another detector at a 90° angle of the interrogation point called side scatter channel
(SSC). The SSC measurement correlates with the granularity and internal structure of the
particle. Moreover, fluorescent emission collected at different wavelengths can also be
measured. As each fluorescently-labeled particle passes through the interrogation point, a
fluorescent signal is generated and then it is directed through different mirrors and filters.
The major filters in flow cytometers are: Long pass (LP) filters allow the transmission
of light above a specific wavelength. Short pass (SP) filters allow the transmission of light
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below a specific wavelength. Band pass (BP) filters allow transmission of photons that
have wavelengths within a range of wavelengths (also known as band width).194,200
•

Detectors and electronics
As each cell or particle passes through the interrogation point, photons are emitted and

directed to a detector where it is translated into a voltage pulse.196,200 Typically,
photomultiplier tubes (PMT) are used for detection. The electric current produced by a
PTM when illuminated is translated into a voltage, so each particle’s passage through the
interrogation spot produces a voltage pulse. The signal can be amplified by increasing the
gain.201 However, not all signals detected are retained. Those due to debris, dust particles
or other interferents are excluded by setting a threshold on the signal intensity, so only
signal from the particles of interest is processed. Next, the voltage pulses are converted
from analogue to digital format by the Analogue-to-Digital Converter (ADC). Finally, the
data is stored in a flow cytometry standard (FCS) format and can be analyzed using
software programs such as FlowJo, FCS Express, and FCSalyzer, among others.
Overall, flow cytometry offers many advantages compared to other detection methods.
It is high throughput, with some cytometers being able to analyze up to 100,000
event/second,190 it can analyze multiple parameters simultaneously, due to its high
specificity it can distinguish discrete cell subsets and rare populations,189 it is fast,
reproducible, accurate, and it uses small sample volumes.200 In addition, some flow
cytometers are equipped with well plate readers, making drug screening faster and more
affordable.190 Flow cytometry is a technology traditionally used for cell screening and cell
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sorting, but all its aforementioned advantages make it a great candidate to optimize the
analysis of model membranes against various biological components.
1.7 Goals and Overview of this Work
Cell membranes have been widely studied since they serve many important functions
in different biological processes. They mainly provide a semi-permeable barrier between
the environment and the cytoplasm of the cell as well as barriers between the cytoplasm
and organelles, but they also play an important role in other biological processes such as
ion conductivity, cell adhesion, and cell signaling.10,33
The development of biomimetic membrane assemblies was crucial in the study of all
the aforementioned processes. The most commonly used membrane assemblies are solidsubstrate supported membrane constructs,157 which served as good platforms to investigate
membrane-associated and membrane-bound components.202 As an alternative to planarsupported membrane, some groups have worked with giant unilamellar vesicles (GUVs),
which better mimic the curvature and size of the cell membranes, and have been used in
various membrane-related studies.51
While planar-substrate supported membranes and GUVs have proven to be very
effective, studies done using both platforms rely on methods such as Surface Plasmon
Resonance (SPR) or microscopy which have limitations for screening purposes. In
particular, they are neither high-throughput nor multiplexable resulting in time consuming
studies, high cost, and high variability from sample to sample53–56 Therefore, there is a
technology need for the development of biomimetic membrane assemblies that will
enable high-throughput studies.
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Some scientists have worked on building membranes on silica microspheres,203 which
can be studied using high-throughput technologies, such as flow cytometry. Flow
cytometric studies have many advantages. They are fast, reproducible, highly sensitive,
accurate, and use small sample volumes. In addition, several commercially available flow
cytometers automatically can sample from well plates, making drug screening faster and
more affordable.190
Microsphere-supported membranes plus the advantages of flow cytometry would
potentially constitute a more effective technology for performing target based screening
assays for membrane bound components, studying the potential disruption effect of some
biomolecules (drugs, antimicrobial peptides, etc.), or studying the interaction of the
membrane and synthetic compounds such as polymers. To that end, we propose the
development of multiplexable biomimetic membrane assemblies on silica
microspheres for flow-based screening applications.
Our development of multiplexed biomimetic membranes on silica microspheres will
provide a beneficial platform that, ultimately, could allow high-throughput screening of
drugs that target membrane bound components. The new biomimetic constructs that we
will develop have the promise of enabling application of high-throughput multiplexed flow
cytometry techniques to study and assess: 1) membrane-protein interactions, 2)
membrane disruption assays, and 3) polymer-membrane interactions. Future areas for
application of these methods are in areas such as protease assay development, drug
screening and antimicrobial peptide screening. Chapters 3, 4 and 5 describe in detail work
we did in assessing the topics (1-3) just listed.
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The work detailed in Chapter 3 had the specific goal of developing and
characterizing multiplexed silica microsphere supported biomimetic membranes for
flow cytometry studies of membrane associated proteins. The results of this part of the
project was published as a research article in the ACS – Journal of Analytical Chemistry.
Briefly, we developed a multiplex system on silica microspheres by coating silica
microparticles with lipid bilayer membranes that contain variable amounts of fluorescently
tagged lipids. Each type of these labeled microspheres also contained varying
concentrations of other membrane components or potentially other integral membrane
components. These fluorescently-indexed silica microsphere supported lipid bilayer
architectures were characterized by flow cytometry and confocal microscopy to assess the
quality and uniformity of the supported membrane bilayer. The fluorescent nature of the
lipids let us observe, distinguish, and gate upon the populations of microspheres with wellformed lipid membrane structures, resulting in more trustworthy and robust statistics in a
high-speed detection format. To demonstrate this technology, we assessed the preferential
binding of fluorescently tagged soluble proteins to different membrane-associated ligands
present in the multiplex system.
In more detail, the characterization studies on the multiplexable silica microsphere
platform show that we can generate stable membrane assemblies. We performed initial
studies on the platform where fluorescently labeled Cholera toxin subunit B differentially
binds to lipid membranes with increasing amounts of GM1, and where fluorescently
labeled Streptavidin differentially binds to membranes with increasing biotin
concentration. The success of this work demonstrates that this technology can enable
multiplexed membrane-protein assays in flow-based methods.
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This chapter kept the format of the original publication and the supporting information
was added to the Appendix II 3 section.
Furthermore, the assembly of biomimetic lipid membranes supported on microspheres
discussed on chapter 3 was successfully used as a platform to implement DNA
nanotechnologies on a fluid lipid surface by members of Dr. Graves’ group at CBME. The
results of this work were published in the ACS Journal of Applied Material & Interfaces,204
and I am listed as a co-author.
The work detailed in Chapter 4 had the specific goal of developing technology to
enable microsphere-based membrane disruption assays with flow cytometric
detection. This chapter presents the ongoing efforts of characterizing the effect of different
membrane-disrupting agents (detergents, endotoxins, etc.) on microsphere supported
membranes.
First, we used the fluorescently tagged lipid membranes supported on silica
microspheres-assembly described in chapter 3, and some well-characterized surfactants
(LDAO, SDS and Triton X-100) that are widely used to disrupt cell membranes and that
have been also tested in planar-supported membrane assemblies. Then, relying on the flow
cytometric data, we found the correlation between the loss of fluorescence of the
microsphere-supported membranes, and the partial or complete disruption of the
membrane caused by the surfactants. Our conclusions were supported and corroborated by
the images obtained with confocal microscopy.
Second, we tested one of the most significant endotoxins, lipopolysaccharide (LPS),
and its effect on silica microsphere-supported membrane bilayers. We compared our
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observations with previously reported results by Dr. Montaño’s group, at CINT,69,205 which
were obtained relying on planar-supported lipid bilayers. Flow-based studies show that
LPS-induced hole formation resulted in loss of fluorescence of the microsphere-supported
membranes, and that we can backfill the holes with a secondary set of fluorescently-tagged
lipid vesicles. These studies are intended to be a stepping stone on the way to a faster and
more effective screening for membrane disrupting agents. Future studies will assess the
LPS effect in the presence of varying factors: pH, buffer composition, and most
importantly, against different lipid compositions. Supporting information for this study was
added to the Appendix II 4 section.
The work detailed in Chapter 5 had the specific goal of developing and
characterizing multiplexable block copolymer membrane assemblies supported on
silica microspheres as an alternative to lipid membranes. The results of this part of the
project was written as a manuscript and is ready to be submitted to the Journal ACSLangmuir.
Polymers are of great interest for biomedical applications due to their good
biocompatibility, light weight, flexibility, wide variety and commercial availability. In
particular, polymersomes or amphiphilic block copolymer vesicles present themselves as
a synthetic alternative to lipid vesicles, as polymersomes’ diffusivity and permeability can
be modified by changing the molecular weight or the composition of the polymersome.
Briefly, we first prepared different sets of diblock copolymer micelles, each set was
tagged with a different fluorescent lipid and a specific concentration of GM1. Then, relying
on a polymer equivalent process of vesicle fusion, we used the diblock copolymer micelles
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to form a polymer bilayer membrane supported on silica microspheres. Finally, as done in
chapter 3, we tested the differential binding of Cholera toxin subunit B to polymer
membranes with increasing concentrations of GM1. Finally, we tested the lateral mobility
of the polymer membranes supported on the microspheres and assessed the effect of
mobility on effective binding affinity. The success of this work demonstrates that polymer
membranes can be used as an alternative to some lipid membranes and can also enable
multiplexed membrane-protein assays in flow-based methods.
This chapter kept the format of the original manuscript and the supporting information
was added to the Appendix II 5 section.
Chapter 6 summarizes the present work, draws overall conclusions, and discusses
future directions of the project.
Appendix I. In addition to the work presented in chapter 4 and chapter 5, there is a
different set of experiments that were inconclusive, others that presented some limitation
and required re-designing, and others that are still in progress. This chapter aims to present
some of the work that was done in the past years to achieve the objectives and goals of the
present project.
Appendix II presents supplemental figures for chapters 3, 4, and 5.
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Chapter 2.
Materials and Methods
This chapter intends to explore, in great detail, the materials, methods and protocols
used in the experiments described in chapters 3-5, an Appendix I.
2.1 Materials
2.1.1

Buffers

When working with cells or cell-like structures a buffer is needed to provide an
environment of appropriate pH and ionic composition for biological compounds. For the
experiments detailed in Chapters 3-5, we used Phosphate buffered saline (PBS) and 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES buffer).
•

PBS
PBS is a commonly used buffer solution to maintain pH and osmotic balance. Usually,

PBS contains deionized water, disodium hydrogen phosphate (Na2HPO4), sodium chloride
(NaCl) and, in some formulations, potassium dihydrogen phosphate (KH2PO4) and
potassium chloride (KCl). The pH of PBS is set to be close to physiological pH (~7.4), its
osmolarity is kept close to that in the human body, and it is non-toxic.1 We purchased
Phosphate buffered saline (PBS) in powder form from Sigma Aldrich (P3813). After its
dilution in deionized Millipore water, the final concentration is 0.01 M PBS (NaCl 0.138
M; KCl 0.0027 M); pH 7.4, at 25 °C.
•

HEPES
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HEPES is a biological dipolar ionic buffering solution widely used in cell culture, as it
maintains a physiological pH despite the presence of carbon dioxide.2 HEPES can be
prepared in combination with different salts and it has a useful pH range of 6.8 - 8.2.
However, it can be toxic to some cell types at concentrations greater than 40 mM.3 We
purchased HEPES in powder form from Sigma Aldrich (Product code: H3375). After its
dilution in deionized Millipore water, and the addition of NaCl and CaCl2, the final
concentrations are: 10 mM HEPES, 10 mM NaCl, and 2.5 mM CaCl2; pH 7.35 (titrated
with NaOH). The solution was stored at 25 °C. We purchased CaCl2 ▪2(H2O) from
Millipore Sigma (Calbiochem) (Product code: 208290); NaCl from Suprapur (Product
code: 1064060050); and NaOH from Sigma Aldrich (Product code: S8045).
2.1.2

Microspheres

In this work we explore and discuss the use of microspheres as a substrate for
membranes, as well as the advantages and potentials of similar platforms. Briefly, unlike
planar-supported lipid bilayers, microsphere-supported lipid bilayers and their interaction
with different components can be studied using medium to high-throughput screening
processes. Most of the previous work done on microsphere-supported lipid bilayers was
done using porous microspheres,4 and although the pores can be used to be loaded, the nonporous microspheres offer a more uniform support, similar to planar silica.
Non-porous silica microspheres are produced in cGMP facilities, through different
processes, among which the most common is the Stöber method, in which silicates and
solvents like water, alcohol and ammonia are agitated, resulting in silica particles of
different sizes.5 On the other hand, polystyrene microspheres are generated by suspension,
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emulsion, precipitation and dispersion polymerizations.6 Polystyrene microspheres can be
functionalized by including certain groups to the microsphere surface, the most common
groups being amine and carboxyl groups.
For the experiments detailed in here, we used Spherotech’s microparticles, which are
kept in a buffer consisting of deionized water with 0.02% sodium azide. We purchased and
used the following products:
•

3.14 μm diameter (SIP-30-10) and 7.9 μm diameter (SIP-60-10) non-porous silica
microspheres, with a density of 1.96 g/ml. They maintain their shape and size when
exposed to aqueous or non-aqueous environments and can withstand temperatures of
up to 1000°C.

•

5.28 μm diameter (CP-50-10) non-porous carboxylated-polystyrene microspheres with
a density of 1.05 g/ml and a refractive index of 1.59. These beads are highly uniform
and monodisperse and are stable only in aqueous solvents and typically contain ~ 50
μeq/g of carboxyl groups on their surface.

2.1.3

Lipids

Since phospholipids are the major component of cell membranes, we use different
commercially available lipids to build membrane structures. Lipids are usually extracted
from cells, tissues or fluids. Then, they are separated from any other type of molecules,
such as proteins or amino acids, and finally are preserved. All the lipids used in the
experiments reported in chapters 3-5 were purchased in lyophilized form from Avanti Polar
Lipids. Following, there is the list of all the lipids we used:
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•

POPC (16:0-18:1 PC) (1-palmitoyl-2- oleoyl-sn- glycero-3- phosphocholine), is one of
the most common lipids used in model lipids for mammalian cell-mimicking
experiments7 since phosphatidylcholines are the major component of biological
membranes. Phosphatidylcholines are widely commercially available, as they can be
easily chemically extracted from soybeans, egg yolk and others.8 The POPC we
purchased is neutrally charged, it has a pKa ~ 1.0, and its phase transition temperature
is -2°C. We used POPC in the work described in chapter 3. Avanti Polar Lipids product
code: 850457.

•

Biotin-DOPE (18:1 Biotinyl-PE) (1,2-dioleoyl- sn-glycero- 3-phosphoethanolamineN- (biotinyl)). Phosphoethanolamine (PE) is the most abundant phospholipid in
bacterial membranes and the second most abundant in mammalian and plant cell
membranes.9 PE can be found in high quantities in the human nervous system and it
plays an important role in different biological processes such as cell division,10
membrane fusion,11 and protein modification,12 among others. Biotin is a B-complex
vitamin that plays an important role in processes such as fatty acid and amino acid
production, cell growth and the stabilization of blood sugar levels.13 Biotin’s small size
(MW = 244.31 Da) and its high affinity for avidin, streptavidin and NeutrAvidin make
biotin a widely used label for protein detection.14 Moreover, the biotin-streptavidin
binding is resistant to changes in pH and extreme heat.14 The Biotin-DOPE we
purchased is neutrally charged, it has two pKa values: 5.61 and 10.39, and its phase
transition temperature is −8.1°C. We used Biotin-DOPE in the work described in
chapter 3. Avanti Polar Lipids product code: 870282.
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•

NBD-DOPE (18:1 NBD-PE) (1,2-dioleoyl- sn-glycero- 3-phosphoethanolamine-N- (7nitro- 2-1,3- benzoxadiazol-4- yl) was the lipid we used for fluorescent tagging in
chapters 3, 4, 5 and Appendix I. NBD (7-nitro- 2-1,3- benzoxadiazol-4- yl) is a widely
used fluorophore in biochemical and cell biological assays due to its stability at varying
pH and its neutral charge.15 NBD has an excitation maximum of 460nm and an
emission maximum of 535 nm. In this product, the NBD label is attached to the head
groups of PE. Avanti Polar Lipids product code: 810145.

•

GM1 (monosialotetrahexosylganglioside) is a member of the Gangliosides family,
which are amphiphilic molecules located in the outer leaflet of the plasma
membrane.16,17 GM1 plays important roles in processes such as cell adhesion, cell-cell
recognition and neuroprotection.18,19 There is special interest in GM1 as it acts as the
binding site for Cholera toxin and E. coli heat-labile enterotoxin.20,21 We used GM1 in
the work described in chapters 3 and 5. The GM1 we purchase was extracted from
ovine brain. Avanti Polar Lipids product code: 860065.

•

DOPC (18:1 (Δ9-Cis) PC) (1,2-dioleoyl-sn-glycero-3-phosphocholine) is a naturally
occurring phospholipid. DOPC is the cis- counterpart of POPC, and it has been reported
that the Ld phase of DOPC is less ordered than that of POPC.22 We used DOPC in the
work described in chapters 4, 5 and Appendix I. The DOPC we purchased is neutrally
charged, and its phase transition temperature is -17°C. Avanti Polar Lipids product
code: 850375.

•

Lissamine Rhodamine B– DOPE (18:1 Liss Rhod PE) (1,2-dioleoyl-sn-glycero-3phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt)) was one
of the lipids used for fluorescent tagging in Appendix I. This fluorophore is stable at
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varying pH values,23 and it is neutrally charged. Lissamine Rhodamine B has an
excitation maximum of 560 nm and an emission maximum of 583 nm. In this product,
the Lissamine Rhodamine B label is attached to the head groups of PE. We used
Lissamine Rhodamine B– DOPE in the work described in chapter 4. Avanti Polar
Lipids product code: 810150.
•

Cholesterol (ovine wool, >98%) is one of the most important components in animal
cells, at it constitutes about 1/3 of their membranes and regulates membrane fluidity
and permeability. We used Cholesterol in the work described in Appendix I. Avanti
Polar Lipids product code: 700000.

•

DPPG (16:0 PG) (1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium
salt)) is an anionic lipid molecule preset in alveolar cells in humans.24 Its phase
transition temperature is 41°C. We used DPPG in the work described in Appendix I.
Avanti Polar Lipids product code: 840455.

•

DOTAP (18:1 TAP) (1,2-dioleoyl-3-trimethylammonium-propane) is a cationic lipid
molecule that has been shown to be effective DNA and RNA transfection. 25 Its phase
transition temperature is <5°C. We used DOTAP in the work described in Appendix I.
Avanti Polar Lipids product code: 890890.

•

(Texas

Red-DHPE)

(Texas

Red

1,2-Dihexadecanoyl-sn-Glycero-3-

Phosphoethanolamine, Triethylammonium Salt) was used in the work described in
chapter 5. Texas Red has an excitation maximum of 595 nm and an emission maximum
of 615 nm. In this product, the Texas Red label is placed in the head groups of PE.
ThermoFisher Scientific Lipid product code: T1395MP.
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Lipids are dissolved in non-polar solvents. One of the most common solvents is
chloroform (CHCl3), which is a colorless and volatile substance used also as a reagent in
industry. We purchased the chloroform from EMD Millipore (product code CX1055), that
contains 1%-5% of ethanol as a stabilizer.
2.1.4

Extruder

Extrusion is one of the most common methods to break multilamellar vesicles (MLVs)
into monodisperse unilamellar vesicles with the aid of filters and moderate pressure applied
by syringes.26
We purchased a Mini-Extruder set with a holder/ heating block, which included:
•

Extruder
o Extruder outer casing
o Retaining nut
o Teflon bearing
o 2 internal membrane supports
o 2 O-rings

•

2 syringes (1 ml volume)

•

Polycarbonated membranes (0.1 μm pore sizes)

•

Filter supports,

•

Holder/heating block.
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Avanti Polar Lipids product code: 610000. See Figure 2.1 to observe the assembly process.

Figure 2.1. A) Parts of the mini extruder. B) Assembly of the extruder.

2.1.5
•

Proteins

Cholera is a toxin produced by Vibrio cholerae and it has two types of subunits; the A
subunit carries the toxic part, and the pentameric B subunit binds to the high-affinity
GM1 receptors, usually located in the intestinal epithelial cell membranes.27,28 We
purchased cholera toxin B subunit (recombinant)-Alexa Fluor 647 (CTxB-Alexa 647)
from ThermoFisher in powder form. Alexa Fluor 647 has an excitation maximum of
650 nm and an emission maximum of 668 nm. We diluted the CTxB-Alexa 647 in PBS,
and it was stored at 2°C until use. ThermoFisher product code: C34778.

•

Streptavidin is a protein that binds to biotin with high affinity due to a very strong noncovalent interaction. Compared to similar proteins, like avidin, streptavidin has lower
non-specific binding.29 We purchased streptavidin-PE/Cy5 (SAv-Cy5) diluted in
phosphate-buffered solution, pH 7.2, (containing 0.09% sodium azide) from Biolegend.
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PE/Cy5 has an excitation maximum of 488 nm and an emission maximum of 670 nm.
We stored the solution at 2°C until use. Biolegend product code: 405205.
•

BSA (Bovine serum albumin) is a globular protein isolated from cows, and it is widely
used in various biochemical applications. BSA is used as a blocking agent, meaning
that BSA binds to nonspecific binding sites, and prevents the analyte from doing the
same.30 BSA has a negative net charge at physiological pH.31 We used BSA as a
blocking agent in the assays described in chapters 3, 4, 5 and Appendix I. We purchased
BSA from Sigma Aldrich (Product code: A3294) in powder form, protease free and at
pH 7.

•

BSA-FITC (Albumin bovine–fluorescein isothiocyanate conjugate) has the same
properties of regular BSA. The fluorescent tag FITC has an excitation maximum of 495
nm and an emission maximum of 520 nm. We purchased the BSA-FITC from Sigma
Aldrich (Product code: A9771) in powder form. We used BSA-FITC in part of the work
described in Appendix I.

•

Although propidium iodide (PI) is not a protein, we included it in this list as it was used
alongside the BSA-FITC. PI is a fluorescent stain that is not permeant to intact cell
membranes and such is used to detect apoptotic cells.32 We purchased PI from Sigma
Aldrich (Product code: P4170). PI has an excitation maximum of 533 nm and an
emission maximum of 617 nm. We used the PI for some of the experiments described
in Appendix I.

2.1.6
•

Membrane disruption agents

LDAO (N,N-Dimethyldodecylamine N-oxide) is a zwitterionic detergent commonly
used to gently disrupt the cell’s phospholipid bilayer, and to then extract the
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undisrupted membrane proteins that were embedded in the membrane.33 We purchased
the LDAO in powder form from Avanti Polar Lipids. We diluted in PBS, pH 7.34, and
we stored it at -20°C until use. LDAO has a critical micelle concentration (c.m.c.) of
~1-2mM. Avanti Polar Lipids product code: 850545.
•

LPS (Lipopolysaccharides) are macromolecules located on the outer membrane of
Gram-negative bacteria. They have a toxic effect on healthy mammalian cells, as they
induce a strong immune response.34 LPS are comprised of three parts: 1) The lipid A,
which is the hydrophobic moiety of LPS and it carries the toxic properties; 2) the core
polysaccharide chain, which usually contains phosphates or amino acids; and 3) the O
antigen, which is a repeating oligosaccharide chain, unique to each bacterial serotype.35
The reported c.m.c of LPS is ~ 15-25 μg/mL.36 The LPS we used in chapter 4 was
kindly provided by Dr. Montano’s group at CINT, and it was originally purchased from
Sigma Aldrich in a lyophilized form. LPS was purified by phenol extraction from
Escherichia coli O111:B4. Sigma Aldrich product code: L2630.

•

SDS (Sodium dodecyl sulfate) is a common anionic detergent used for cell lysing for
DNA or protein extraction.37 SDS has a c.m.c. of ~ 8-8.5mM.38 SDS is also present in
many household cleaning and hygiene products. We purchased SDS from Bio Rad at
10% (w/v). Bio Rad product code: 1610416.

•

Triton X-100 (C14H22O(C2H4O)n ; n= 9-10 ) is nonionic surfactant commonly used for
cell lysing for protein extraction. At high concentration or long exposure can be toxic
for the cells.39 Triton X-100 has a c.m.c. ~ 0.22 -0.24 mM.40 We purchased Triton X100 from OmniPur via Sigma Aldrich with a pH of 6.0-8.0. OmniPur product code:
9410.
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2.1.7
•

Polymers

pEO-b-pBD (Poly[butadiene(1,4 addtion or 1,2 addition)-b-ethylene oxide]) is an
amphilic block copolymer that can be directly synthesized using diverse methods, and
it is soluble in THF, chloroform, and toluene. We used this diblock copolymer in the
work described in chapter 5. pEO-b-pBD (1.2-b-1.3) was kindly provided by Dr.
Montaño’s group at CINT, and it was originally purchased from Polymer Source
(Product code: P6723-BdEO).

•

Chitosan is an extensively studied cationic polymer with non-toxicity, antibacterial
activity, antioxidant activity, and high biocompatibility.41 Chitosan is used in different
areas such as cosmetics and foods,42,43 but most importantly it has a variety of
pharmaceutical and biomedical applications.44 Moreover, chitosan has the advantage
of being widely commercially available at a low cost. We used chitosan in part of the
work described in Appendix I. We purchased low molecular weight chitosan from
Sigma Aldrich (Product code: 448869)

•

PLL (Poly-L-lysine) is a cationic synthetic polymer used to enhance the interaction and
attachment of cell membranes to solid culture surfaces.45 PLL has also applications as
a food preservative.46 We used PLL in part of the work described in Appendix I. We
purchased poly-L-lysine hydrobromide with a molecular weight 4,000-15,000 by
viscosity from Sigma Aldrich (Product code: P6516).

•

PLL-FITC (Poly-L-lysine hydrobromide–FITC Labeled) was used in part of the work
described in Appendix I, for detection purposes. We purchased PLL-FITC from Sigma
Aldrich (Product code: P3543). The PLL-FITC has a molecular weight of 15,00030,000 by viscosity, and an extent of labeling of 0.003-0.01 mole FITC per mole lysine
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monomer. FITC has an excitation maximum of 490 nm and an emission maximum of
525 nm.
•

FITC (Fluorescein isothiocyanate) is a widely used fluorescein-derivative
fluorochrome. FITC has an excitation maximum of 490 nm and an emission maximum
of 525 nm at neutral pH. FITC emission levels are pH sensitive (FITC fluorescence
intensity increases with increasing pH).47 We used FITC in the fluorescent tagging of
chitosan in the work described on Appendix I. We purchased FITC from Sigma Aldrich
(Product code: F7250).

•

THF (tetrahydrofuran) is a popular organic solvent and is commonly used in polymer
science. We used THF as a polymer solvent in the work described in chapter 5. THF
anhydrous was kindly provided by Dr. Montaño’s group at CINT, and it was originally
purchased from Sigma Aldrich (Product code: 401757).

2.1.8

Instruments

Flow cytometers. The main goal of this work was the development of multiplexable
biomimetic membrane assemblies on silica microspheres for flow-based screening
applications. Therefore, flow cytometry was our technology of choice for the analysis of
the proposed studies. We used the following two flow cytometers:
•

BD Accuri C6 is a highly sensitive flow cytometer that relies on low-pressure pumping
and hydrodynamic focusing to be able to screen as many as 10,000 events per second.
Its collection sip supports any tubes 75x12 mm or smaller, but it can also support the
BD CSampler that can hold 48- and 96-well plates, or 24-tube rack. Finally, this flow
cytometer can use laboratory-grade water as sheath fluid.48 The BD Accuri C6 is
equipped with two lasers with independent optical paths; a blue laser (488 nm) and a
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red laser (640 nm) and with 4 detection channels; three from the blue laser -- FL-1 (533
nm center with 30 nm bandpass (BP)); FL-2 (585 nm center with 40 nm BP); FL-3 (670
nm long-pass (LP)); and one from the red laser -- FL-4 (675 nm center wavelength/25
nm BP). Moreover, some other filters are available for purchase.48
We used the BD Accuri C6 for the work described in chapter 3 and part of Appendix I.
•

The Attune NxT flow cytometer by ThermoFisher Scientific relies on acoustic-assisted
hydrodynamic focusing, which significantly reduces the chance of clogging. This
technology’s effectiveness allows rapid detection of rare events and minimal data
variation regardless of sample rate. The Attune NxT has sample flow rates ranging from
12.5–1,000 μL/min, hence it can screen up to 35,000 events per second.49 The Attune
NxT is equipped with four lasers with independent optical paths: violet (405 nm); blue
(488 nm); yellow (561 nm); and red (637 nm); and a fifth laser is available for purchase:
green (532 nm). It can detect up to 14 colors, as it has many detection channels 49 (See
Appendix I, Figure AI-9 (Table)).

We used the Attune NxT for the work described in chapters 4, 5 and part of Appendix I.
Confocal microscope. We used laser-scanning confocal microscopy (LSCM) to obtain
complementary visual support to the flow cytometric data obtained in chapters 3, 4, 5 and
Appendix I. The images and FRAP experiments were done using FV-1000 inverted optical
microscope (Olympus, Tokyo, Japan).
UV cleaner. We used the UVO-Cleaner by Jelight Company, Inc. Model No 144AX. in
our first attempt to modify the surface of polystyrene beads (detailed in Appendix I).
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Ozone cleaner. We used a Harrick Plasma Cleaner PDC-32G in our second attempt to
modify the surface of polystyrene beads (detailed in Appendix I).
2.1.9

Data Analysis

To analyze all the data, we generated in the work described in chapters 3-5 and
Appendix I, we used the following software:
FlowJo software was used to the flow cytometric data (gating, compensation, statistics,
etc.).
MatLab and Excel were used for the numerical and statistical analysis. MatLab and Igor
were used to generate the plots.
In addition to all the materials listed above, we used basic laboratory equipment such
as micro-centrifuge vials, pipettes, glass vials, shaker, micro-centrifuge, syringes, syringe
pumps, quartz cuvettes, etc.
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2.2 Methods

2.2.1

Lipid bilayers on silica microspheres protocol.

2.2.1.1 Vesicle preparation
All the lipids were purchased in lyophilized form and they were dissolved and
resuspended in chloroform. The lipid solutions were stored in glass vials, sealed and
wrapped with parafilm and at -20 °C in the dark until use.

Figure 2.2. Lipid plaque formation with different lipid compositions.

In chapters 3-5 and Appendix I we prepared lipid vesicles with different compositions
by mixing the right amount of stock lipids with glass syringes in different glass vials. The
various mixtures of lipids were left under vacuum overnight to let the chloroform evaporate
and to form lipid plaques at the bottom of the vials (see Figure 2.2).
Then, the lipid plaques were rehydrated and resuspended in buffer at a final
concentration of 1mM. For all the liquid-phase lipids we worked with, the resuspension
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process only required vortexing the rehydrated lipid plaques, which forms multilamellar

NBD-PE

NBD-PE

NBD-PE

Figure 2.3. Lipid plaques with different lipid compositions resuspended in buffer.

vesicle (MLVs) solutions. As a visual example, Figure 2.3 show the picture of the
resuspended lipids used in the experiments described in chapter 3.
2.2.1.2 Extrusion
We formed large unilamellar vesicles (LUVs) by extruding the MLVs solution. Briefly,
we first wet the filter supports and 0.1 μm polycarbonate (PC) membranes with DI water
and assemble the mini-extruder part as shown in Figure 2.1. Then, we passed the rehydrated
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and resuspended lipids through the PC membrane 11 or 13 times. Finally, Figure 2.4 shows
the tubes with the lipids before and after extrusion; the solution before extrusion is cloudy
due to the presence of the MLVs and/or other large lipid particles, and after extrusion the
solution gets clearer, as it contains the LUVs which are approximately 100 nm in size.
Comparing both solutions is a good visual confirmation that the extrusion process was
successful.

Liposome solution
before extrusion

Liposome solution
after extrusion

Figure 2.4. Liposome solution before and after extrusion

2.2.1.3 Lipid coating on beads
Although all the purchased silica microspheres come suspended in a clean aqueous
solution, we made sure to keep the microsphere’s surface clean and debris-free. We
accomplished that by first suspending them in a basic solution (4% NH4OH), centrifuging
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and rinsing three times, then suspending them in an acidic solution (4% HCl), centrifuging
and rinsing five times.
We used siliconized polypropylene Eppendorf tubes that we passivated before use by
filling them with a 0.1 mg/mL BSA solution and placing them on a shaker for 45 min.
We formed lipid bilayers on the silica microspheres by incubating the suspension with
1mM LUVs solutions resulting from the extrusion process with the clean silica
microspheres to a final concentration of 105-106 beads/ml. The incubation process
consisted of placing the tubes with the LUVs and the microspheres on a shaker and
vortexing them on high speed at room temperature for 10 min and on low speed for 45 min
at 37 °C. These conditions promote the spontaneous fusion of the vesicles to the
microspheres’ surface to form the bilayers.
2.2.1.4 BSA-blocking
After incubating the beads with lipids, we added BSA to each sample to a final
concentration of 0.5 mg/mL and we let them vortex on low speed for 45 minutes at room
temperature. This was done to passivate the parts of the microspheres’ surface that may
have not been properly coated with the lipids. The presence of the BSA minimizes the
nonspecific binding of the membrane-bound component to the silica bead.
2.2.1.5 Rinsing
All the samples were washed and rinsed three times to remove the unbound liposomes
and extra BSA in solution. This was done by centrifuging the samples for 45 seconds at 10
000 rpm, removing the supernatant (leaving enough supernatant to keep the lipid-coated
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beads hydrated ~ 50 μL) and resuspending the samples in fresh buffer to bring them back
up to volume.
Figure 2.5 shows the different steps of the lipid bilayers on silica microspheres

Figure 2.5. Schematic of the assembly of biomimetic membranes on non-porous silica microspheres.

protocol.
2.2.2

Protein-Membrane interaction assay

This section includes a more in-depth description of the methods used in the work
described on chapter 3.
•

Multiplex set formation
After the lipid bilayer formation on silica microspheres (3 μm – diameter) is complete,

we form a multiplex set by adding equal volumes of the different membrane compositions
and fluorescent-tags to a single BSA-passivated Eppendorf tube.
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•

CTxB-Alexa 647 and GM1 binding.
We prepared the stock solution of CTxB-Alexa 647 by diluting the powdered toxin in

PBS to a final concentration of 175nM, and we also prepared dilutions with a 75nM
concentration. We stored the stock and dilution solutions at 2°C until use.
The membrane compositions on bilayers on the microspheres for this experiment
consisted of POPC membranes containing specific amounts of GM1 (0−0.5 mol %) and
NBD (0-2 mol%).
We used the 75nM CTxB-Alexa 647 aliquots to test the preferential binding of CTxBAlexa 647 to GM1-containing membranes on microspheres by adding the right volumes to
the individual and multiplex samples. The tested concentrations of CTxB-Alexa 647 were:
0nM, 2nM, 10nM and 20nM.
•

SAv-Cy5 and biotin binding
We prepared the stock solution of SAv-Cy5 by diluting the powdered toxin in PBS to

a final concentration of 421nM, and we also prepared dilutions with a 4.21nM
concentration. We stored the stock and dilution solutions stored at 2°C until use.
The membrane compositions on bilayers on the microspheres for this experiment
consisted of POPC membranes containing specific amounts of biotin-DOPE (0−0.5 mol
%) and NBD (0-2 mol%).
We used the 4.21nM SAv-Cy5 aliquots to test the preferential binding of SAv-Cy5 to
biotin-containing membranes on microspheres by adding the right volumes to the
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individual and multiplex samples. The tested concentrations of SAv-Cy5 were: 0nM,
0.25nM, 0.5nM and 2.5nM.
•

Cross reactivity assay
In this case, the multiplex set contained one sample with GM1 (0.5%mol), another one

with biotin-DOPE (0.5%mol), and a final one with neither (100% POPC); all with different
concentrations of NBD-DOPE.
We used the same aliquots described in the last two sub-sections to test the specific
binding of CTxB-Alexa 647 to GM1 and SAv-Cy5 to biotin. The tested concentrations
were: 20 nM CTxB-Alexa 647 and 2.5 nM SAv-Cy5.
2.2.3

Membrane disruption assays.

This section includes a more in-depth description of the methods used in the work
described on chapter 4.
•

Membrane composition of bilayers supported on microspheres.
The formation of lipid bilayers on silica microspheres was done following the same

protocol as describe before. For all these assays testing the effects of SDS and Triton-X100
we used the 3 μm-diameter microspheres, and for the assays testing the effect of LDAO
and LPS we used the 7.9 μm-diameter microspheres. The membrane compositions used
were: 1) 99.5%mol DOPC+0.5%mol NBD-DOPE, or 2) 99.9%mol DOPC+0.1%mol LissRhod-DOPE. The samples’ final concentration of microspheres coated with lipid bilayers
was ~105beads/ml.
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•

Membrane-disrupting agents
We tested the membrane disrupting effects of SDS on microsphere-supported

membranes with the following composition: 99.5%mol DOPC+0.5%mol NBD-DOPE.
The stock solution of SDS was 10% w/v (346.77mM) and we prepared a dilution of 1%
w/v (34.67mM); both were kept well-sealed and at room temperature. The tested SDS
concentrations were: 0 mM, 0.08 mM, 0.8mM and 8mM.
We tested the membrane disrupting effects of Triton X-100 on microsphere-supported
membranes with the following composition: 99.5%mol DOPC+0.5%mol NBD-DOPE.
The stock solution of Triton X-100 (~1.7M) and we prepared a dilution in DI water
(1.7mM); both were kept well-sealed and at room temperature. The tested Triton X-100
concentrations were: 0mM, 0.0024mM, 0.024mM and 0.24mM.
We tested the membrane disrupting effects of LDAO on microsphere-supported
membranes with the following composition: 99.5%mol DOPC+0.5%mol NBD-DOPE.
The stock solution of LDAO was 20mM which was kept well-sealed, in the dark at -20 °C
until use. and at room temperature. The tested LDAO concentrations were: 0 mM, 0.5mM,
0.75mM, 1mM, 1.25mM and 1.5mM.
We tested the membrane disrupting effects of LPS on microsphere-supported
membranes with the following compositions: 1) 99.5%mol DOPC+0.5%mol NBD-DOPE,
or 2) 99.9%mol DOPC+0.1%mol Liss-Rhod-DOPE. The stock solution of LPS was 2.5
mg/ml which was kept well-sealed at -20 °C until use. and at room temperature. The tested
LPS concentrations were: 0 μg/ml, 50 μg/ml, 150 μg/ml, 250 μg/ml, 350 μg/ml, and 500
μg/ml.
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•

Membrane disruption with LDAO
We tested the membrane disruption effect of LDAO on planar-supported membranes

and on microsphere-supported membranes, both with a membrane composition of
99.5%mol DOPC+0.5%mol NBD-DOPE. On both instances, we added the different
concentrations of LDAO and let incubate (without shaking or rotating) with the membranes
for 20, 40 and 60 min. We imaged both sets with a confocal microscope, and we collected
the flow cytometric data of the microsphere-supported membranes set.
•

Membrane disruption with LPS
First, we calculated the c.m.c of the LPS solution stock we used in chapter 4 by

preparing a series of dilutions and measuring the derived count rate of each dilution in a
Dynamic Light Scattering (DLS) machine, provided by CINT.
We tested the membrane disruption effect of LPS on planar-supported membranes and
on microsphere-supported membranes, both with a membrane composition of 99.5%mol
DOPC+0.5%mol NBD-DOPE. On both instances, we added the different concentrations
of LPS and let incubate (without shaking or rotating) with the membranes for 20, 40 and
60 min. We imaged both sets with a confocal microscope, and we collected the flow
cytometric data of the microsphere-supported membranes set.
Finally, we assembled membrane bilayers (99.9%mol DOPC+0.1%mol Liss-RhodDOPE) on planar silica and on silica microspheres, we induced hole formation on the
membranes by exposure to LPS and we backfilled the holes with lipid vesicles with a
different florescent tag (99.5%mol DOPC+0.5%mol NBD-DOPE) for detection purposes.
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We imaged the results on both platforms and we collected the flow cytometric data on the
silica microsphere set.
2.2.4

Block copolymer as an alternative to lipids.

This section includes a more in-depth description of the methods used in the work
described on chapter 5.
•

Block copolymer-lipid micelle formation
The formation of block copolymer micelles is achieved by self-assembly in aqueous

medium.50 For the work described on chapter 5, we prepared assemblies that included
mostly amphiphilic block copolymers (pEO-b-pBD) and small amounts of phospholipids
to add fluorescent tags and binding ligands.
Using glass syringes, we first dissolved the desired amount of copolymer and the lipids
in tetrahydrofuran (THF) in a glass vial to a final volume of 750 μl. Then, using 14.5 mmdiameter plastic syringes, we exchanged the solvent to molecular biology grade water by
gradual injection (2 ml/hr rate) to a final volume of 2.5 ml, while the THF is removed by
rotary evaporation. The process took place at room temperature and in the dark.
After the solvent exchange process was finalized, the samples were kept in the glass
vials, were covered with tightly sealed parafilm and were stored at 4 °C until use. (See
Figure 2.6.)
•

Polymer membrane formation on microspheres
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The polymer membrane formation on silica microspheres was done following the same

Figure 2.6. Block copolymer micelles solutions

protocol for lipid coating on silica beads, as described in Section 2.2.1, with some minor
differences. Briefly, in BSA-passivated Eppendorf tubes, we incubated the 1mM polymer
micelle solutions with clean silica microspheres (7.9 μm-diameter) to a final concentration
of 105-106 beads/ml. The incubation process consisted on placing the tubes with the
copolymer micelles and the microspheres on a shaker and vortexing them on medium speed
1 hour at 37 °C. These conditions promote the spontaneous fusion of the polymer micelles
to the microspheres’ surface forming the bilayers. Then, we added BSA, for blocking
purposes, to each sample to a final concentration of 0.5 mg/mL and we let them vortex on
low speed for 20 minutes at room temperature. Finally, all the samples were washed and
rinsed three times to remove the unbound micelles and extra BSA in solution. This was
done by centrifuging the samples for 45 seconds at 10 000 rpm, removing the supernatant
and resuspending the samples in fresh buffer to bring them back up to volume.
•

Multiplex formation
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After the polymer bilayer formation on silica microspheres (7.9 μm – diameter) process
is complete, we form a multiplex set by adding equal volumes of the different membrane
compositions to a single BSA-passivated Eppendorf tube.
•

Time stability test
The flow cytometric data of all the individual samples and the multiplex set were

recorded at times 0, 0.5, 1, 2, 4, 8, and 24 hours. The results show that both individual and
multiplex sets are stable for at least 4 hours.
•

Fluorescence recovery after photobleaching (FRAP)
The fluidity and lateral mobility of the polymer membranes on silica microspheres was

tested by photobleaching a specific area on the membrane supported on one of the silica
beads, and the fluorescence level of said area was tracked for 30 minutes. The immobility
of the polymer-lipid membranes was determined by the lack of recovery of the fluorescence
of the photobleached area. The FRAP experiment was done using the beads coated with
polymer membranes with the following composition: 1mM pBD-pEO, 0% GM1, 1%mol
Texas Red-DHPE.
•

Preferential binding of CTxB-Alexa to GM1 on polymer membrane on silica beads
For the work described in chapter 5, we assembled and tested five different

compositions of polymer membranes supported on microspheres: 1) 1mM pBD-b-pEO,
0% GM1, 1%mol Texas Red-DHPE; 2) 1mM pBD-b-pEO, 0.05% GM1, 0.2%mol NBDDOPE; 3) 1mM pBD-b-pEO, 0.1% GM1, 2%mol NBD-DOPE, 1%mol Texas Red-DHPE;
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4) 1mM pBD-b-pEO, 0.5% GM1, 0.01% Texas Red-DHPE; and 5) 1mM pBD-b-pEO, 1%
GM1, 2%mol NBD-DOPE.
Similar to lipid membranes on microspheres, we used 75nM CTxB-Alexa 647 aliquots
to test the preferential binding of CTxB-Alexa 647 to GM1-containing polymer membranes
on silica microspheres by adding the right volumes to the individual and multiplex samples.
The tested concentrations of CTxB-Alexa 647 were: 0nM, 5nM, 10nM, 50nM and 100nM.
2.2.5

Flow cytometry data collection

The flow cytometers we work with were cleaned and calibrated before and after use.
In all the work described in chapter 3-5 and Appendix I, the flow cytometric data is
presented in contour plots with a 10% probability contour and dotted outlying event.
The microsphere population was detected and gated using the forward scatter versus
side scatter plot. Then, the gated microsphere population was observed in bivariate plots
where the axes show the fluorescence intensity in two different fluorescence detection
channels or in the side scatter channel and a fluorescence detection channel. Said channels
are the ones able to detect the emission of the fluorophores present in the membranes at a
given assay. From the bivariate plots, we gated the event once more to only include the
microspheres with complete membrane coating, and exclude defective or incomplete
membrane coverage and outlier events. If two or more fluorophores are present,
compensation is run as necessary.
Gating, compensation and statistical data collection were done using FlowJoV10
software.
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3.1 Abstract
Most druggable targets are membrane components, including membrane proteins and
soluble proteins that interact with ligands or receptors embedded in membranes. Current
target-based screening and intermolecular interaction assays generally do not include the
lipid membrane environment in presenting these targets, possibly altering their native
structure and leading to misleading or incorrect results. To address this issue, an ideal assay
involving membrane components would (1) mimic the natural membrane environment, (2)
be amenable to high-throughput implementation, and (3) be easily multiplexed. In a step
toward developing such an ideal target-based analytical assay for membrane components,
we present fluorescently indexed multiplexed biomimetic membrane assays amenable to
high-throughput flow cytometric detection. We build fluorescently multiplexed
biomimetic membrane assays by using varying amounts of a fluorescently labeled lipid,
NBD-DOPE

[1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-

benzoxadiazol-4-yl)], incorporated into a phospholipid membrane bilayer supported on 3
μm silica microspheres. Using flow cytometry, we demonstrate this multiplexed approach
by measuring specific affinity of two well-characterized systems, the fluorescently labeled
soluble proteins cholera toxin B subunit-Alexa 647 and streptavidin-PE/Cy5, to
membranes containing different amounts of ligand targets of these proteins, GM1 and
biotin-DOPE, respectively. This work will enable future efforts in developing highly
efficient biomimetic assays for interaction analysis and drug screening involving
membrane components.
3.2 Introduction

75

Molecular interactions involving receptors or ligands in cell membranes are essential
for cell signaling, transport across membranes, cell−cell recognition, and virus or toxin
interactions with cells. As a result, most druggable targets are membrane-associated
components, which are of great interest for target-based interaction assays or drug
screening.1–3 Flow cytometry is an attractive method for high-throughput or multiplexed
target-based assays and can quickly investigate interactions or conduct large-scale screens
of potential drug candidates.4–10 For example, flow cytometers with automatic sampling
methods can rapidly screen high-density microwell plates, where each well contains
potentially active compounds and microspheres that present targets.7 An important element
of optimized flow-based assays is the use of multiplexed microspheres so that each sample
contains indexed beads that present different targets, as well as positive or negative
controls.4–10 Such multiplexing increases the efficiency of assays by minimizing the cost
of the reagents, assay time, and sample-to-sample variability.7–10 Commercially available
sets of polymer microspheres provide high multiplexing capacity (e.g., up to ∼500×
through combinations of intensity levels and spectral windows) and are widely used for
assays involving different types of soluble protein or nucleic acid targets presented through
attachment to the particle.7,11 However, commercially available multiplexed microspheres,
which are constructed from polystyrene, are unable to present membrane components in
their natural lipid environment.
In general, for interaction analysis involving membrane components, the relevant
biological molecules must be presented in either natural or biomimetic membranes, since
the structure of membrane components depends on the presence of a lipid bilayer.1,2,12 A
natural membrane environment is also important for functional reasons, including accurate
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assessment of apparent affinities in multivalent protein−ligand interactions. For example,
the natural interaction of cholera toxin with its GM1 ligand is multivalent, and the effective
affinity is influenced by the lateral mobility of ligands in the membrane.13
Substrate-supported membrane bilayers (SMBs), typically formed on silica or modified
gold surfaces, are widely used for presentation of membrane components in interaction
assays.14–18 These are the basis of biosensor platforms with transduction of binding events
through microscopy, surface plasmon resonance, ellipsometry, second-harmonic
generation or quartz crystal microbalance response.13,19–25 Unfortunately, while planar
SMBs mimic many aspects of natural cellular membranes, including incorporation of
membrane proteins, they are difficult to integrate with highly multiplexed methods. Some
work has developed patterned SMBs that contain different regions of membrane
composition,26–30 possibly allowing for multiple target presentation, but even for lowthroughput applications their use for assays requires complex surface patterning and fluidic
engineering.29–31
Motivated by these considerations, there is interest in producing a lipid bilayer
membrane architecture that will enable multiplexed and high-throughput flow cytometry.
Liposomes are one possibility, as membrane components can be readily integrated with
them, and they can, in principle, be labeled for multiplexed indexing.32 However, typical
liposomes of sizes ∼200 nm or smaller are challenging to analyze using flow cytometry,
and for assays, analytical limitations also arise from the mismatch between the size of the
analyte particle and the interrogation volume.33,34 Giant unilamellar vesicles (GUVs),
several micrometers or larger in size, are another alternative amenable to incorporation of
membrane components.35,36 Further investigation of GUVs in this context is warranted, but
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to date, GUVs have only rarely been used as a platform for flow cytometry, in part because
of complications arising from structural and size heterogeneities.37,38
An ideal platform for multiplexed flow-based studies of membrane components would
incorporate the best features of vesicles and particle-based multiplexing methods. Our
work presents an initial step toward that goal, relying upon SMBs formed on silica
microspheres. Monodisperse silica microspheres are commercially available and are easily
detected and analyzed using flow cytometry. SMBs on silica microspheres are used for
flow-based assays and are similar to SMBs on planar silica in membrane quality.39–43
However, to date, no studies have demonstrated multiplexing methods for SMBs on silica
microspheres, and there are no readily available sources of standardized multiplexed silica
particles optimized for use in flow cytometry.
As a proof-of-principle demonstration of multiplexing methods for membrane
components in flow cytometry, we present measurements that rely upon use of different
amounts of fluorescently tagged lipids incorporated into SMBs on silica microspheres to
index the particles. Each type of indexed particle presents a lipid membrane of different
composition. For the experiments reported here, each membrane contains different
amounts of lipid-based small-molecule ligands that bind to the fluorescently labeled
proteins cholera toxin (B subunit) and streptavidin. These two systems have been widely
studied and offer well-characterized test cases to validate the multiplexing technology we
are developing.13,22,24,25,44,45 This work demonstrates technology for multiplexed
membrane-based assays in flow cytometry and represents an initial step toward building
more efficient analysis methods for membrane-associated components.
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3.3 Materials and Methods
3.3.1

Liposome Preparation.

Liposomes were prepared as previously reported.46 Briefly, powdered 1-palmitoyl-2oleoylsn-glycero-3-phosphocholine

(POPC),

1,2-dioleoyl-sn-glycero-3-

phosphoethanolamine-N-(biotinyl)

(biotin-DOPE),

1,2-dioleoyl-sn-glycero-3-

phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl)

(NBD-DOPE),

and

ganglioside GM1 purchased from Avanti Lipids were dissolved in chloroform (EMD
Millipore) and stored in glass vials at −20 °C until use. Using glass syringes, stock lipids
were mixed in different glass vials in various final mixtures. The mixtures of chloroformdissolved lipids were dried overnight under vacuum to form lipid plaques. The lipid
plaques were then rehydrated to a final concentration of 1 mM in phosphate-buffered saline
(PBS, Sigma) at pH 7.4. Large unilamellar vesicles (LUVs) were formed by extrusion
using the Mini-Extruder, filter supports, and 0.1 μm polycarbonate (PC) membranes
(Avanti Polar Lipids) by passing rehydrated lipids through the PC membranes 13 times.
Microsphere Supported Bilayer Formation. All Eppendorf tubes were passivated with 0.1
mg/mL bovine serum albumin (BSA) for 45 min prior to use. The 3 μm nonporous silica
microspheres purchased from Spherotech were cleaned by first suspending them in a basic
solution (4% NH4OH), followed by slow centrifugation and rinsing with Millipore water
three times. Next, the beads were suspended in an acidic solution (4% HCl), followed by
slow centrifugation and rinsing with Millipore water five times.43 Cleaned beads were
suspended in PBS. The silica beads were coated with a lipid bilayer as previously
described, with some modifications.43 Briefly, the silica beads (1.5 μL of suspended beads)
were added to the LUVs (1 mM lipid concentration) to a final concentration ∼106 beads/mL
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in 0.5 mL final volume. The mixture of LUVs and microspheres was vortexed on high
speed at room temperature for 10 min and on low speed for 45 min at 37 °C. Under these
conditions, liposomes fuse to the surface, forming a uniform supported lipid bilayer.47 As
a precaution to minimize nonspecific binding, BSA was then added to samples at a
concentration of 0.5 mg/mL and the samples were vortexed on low speed at room
temperature for 45 min. Beads were then washed 4−5 times to remove unbound liposomes
by cycles of centrifugation at 10 000 rpm for 45 s, followed by removing the supernatant,
always leaving at least 50 μL in the tube to keep the lipid-coated beads hydrated. Beads
were resuspended in fresh PBS to bring the samples back up to volume. A multiplexed set
was formed by mixing beads coated with different membrane compositions in a BSApassivated tube. Following rinsing, resuspension, and addition of analyte solution (see
below), the final bead concentration for analysis was ∼105 beads/mL.
3.3.2

Protein Binding Assays.

Cholera toxin B subunit (recombinant)-Alexa Fluor 647 (CTxB-Alexa 647) purchased
from ThermoFisher at a concentration of 175 nM was diluted to a stock concentration of
75 nM in PBS and stored in aliquots at −20 °C until use. Streptavidin-PE/Cy5 (SAv-Cy5)
diluted in PBS purchased from Biolegend at a concentration of 421 nM was diluted in PBS
to a stock concentration of 4.21 nM and stored in aliquots at −20 °C until use.
Concentrations of GM1, CTxB-Alexa 647, biotin-DOPE, and SAv-Cy5 were chosen based
on previous literature.13,44,45 POPC membrane bilayers containing specific amounts of
GM1 (0−0.5 mol %) or biotin-DOPE (0−0.5 mol %), and as appropriate, NBD-DOPE (0−
2.0 mol %) as a fluorescent indexing label, were prepared on silica microspheres as single
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samples or, by mixing the single samples, as multiplexed sets. From microsphere size,
concentration and the membrane compositions, the maximum concentration of protein
binding sites is estimated to be of order 10−11 M. Different amounts of CTxB-Alexa 647 (0
−20 nM) and/or SAv-Cy5 (0−2.5 nM) were added in solution to both single samples and
multiplexed samples and incubated for 10 min before analysis. A multiplexed crossreactivity assay was also performed on silica microspheres coated with the following lipid
compositions: (1) 100 mol % POPC; (2) 0.5 mol % GM1, 0.2 mol % NBD-DOPE, and
99.3 mol % POPC; (3) 0.5 mol % biotin-DOPE, 2 mol % NBD-DOPE, and 97.5 mol %
POPC. Different proteins (2.5 nM SAv-Cy5, 20 nM CTxB-Alexa Fluor 647, or the
combination of 2.5 nM SAv-Cy5 and 20 nM CTxBAlexa) were added in solution to the
multiplexed beads and incubated for 10 min before analysis.
3.3.3

Flow cytometry.

Flow cytometric studies were done as previously described using an Accuri C6 flow
cytometer, with minor modifications to the protocol.48 This instrument has two lasers with
independent optical paths (488 and 640 nm) and four fluorescence detectors (three from
the 488 nm excitation line-FL-1, 533 nm center wavelength/30 nm bandpass; FL-2, 585
nm center wavelength/40 nm bandpass; FL-3, 670 nm long-pass emission; one from the
640 nm excitation line-FL-4, 675 nm center wavelength/25 nm bandpass emission). For
convenience, we sometimes describe filters using the center wavelength and bandpass, so
for example, FL-1 corresponds to 533/30. For each event, data were collected for forward
scatter (FSC) and side scatter (SSC) (from the 488 nm laser) and all four fluorescence
channels. The Accuri C6 was calibrated with eight-peak rainbow beads (Spherotech, Inc.),
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and fluorescence data were quite stable over time, as gauged by coefficient of variation
(CV) values. The instrument was back-flushed between sample types, and the system was
cleaned and decontaminated after each use. Collected data were analyzed, gated, and
compensated as necessary using FlowJoV10 software. Bivariate flow cytometry data are
presented as 10% contour levels of the probability density of events, with additional points
representing (outlying) events that occur outside the lowest 10% probability contour. Red
lines indicate gates that show populations selected for quantitative analysis. Median
fluorescence intensity measurements were obtained using FlowJoV10, and data were
analyzed and plotted using Microsoft Excel, Matlab, or Igor Pro software.
3.4 Results and Discussion
3.4.1

Fluorescently Indexed Silica Microsphere Supported Lipid Bilayers.

Multiplexed flow cytometry allows researchers to include several different samples,
including controls, in each sample well prior to screening.4–10 This approach decreases
sample-to-sample variation and lowers reagent cost. In this proof-of-principle study, we
use fluorescently tagged lipids to provide different fluorescent intensity levels to index 3
μm silica microspheres. To test this approach, we coat silica microspheres in lipid mixtures
containing 100% POPC, 99.8% POPC + 0.2% NBD-DOPE, or 98% POPC + 2% NBDDOPE. Next, we rinse the microspheres and combine the three samples into a single tube
to build a fluorescently indexed multiplex set (Figure 3.1A).
3.4.2

Flow Cytometric Characterization.

82

Figure 3.1. A) Schematic of supported lipid bilayers on non-porous silica microspheres. The microspheres are fluorescently
indexed by coating them with different concentrations of fluorescently labeled lipids, 100% POPC, 99.8% POPC and 0.2% NBDDOPE, and 98% POPC and 2% NBD-DOPE. The coated microspheres are then rinsed and combined in a microfuge tube to build
a multiplexed set of lipid-coated microspheres. Multiplex systems can be used for membrane-based assays such as membrane
composition dependent protein binding. B,C) Analysis and gating of fluorescently indexed membrane-coated microspheres in a
triplex system. Side scatter versus forward scatter data (Panel B) are used to gate or select events that correspond to microspheres
(red circle in Panel B, see text), and data from the gated events are then plotted as side scatter versus FL-1 (excitation laser 488
nm, emission filter 533/30) intensity in Panel C. Similar approaches are used in later experiments to detect protein binding to
surfaces of different lipid compositions.

We analyze fluorescently indexed microspheres by flow cytometry (Figure 3.1, parts
B and C). The population of events is gated using side scatter (Figure 3.1B, y-axis) versus
forward scatter (Figure 3.1B, x-axis) and the automated gating function in FlowJoV10
(Figure 3.1B, red line). Signals from the events selected in Figure 3.1B are plotted on a
bivariate plot of side scatter (Figure 3.1C, y-axis) versus green fluorescence (FL-1) (Figure
3.1C, x-axis), and the three different microsphere populations in the multiplexed system
are clearly identifiable. When the fluorescence of the multiplexed silica microspheres is
tracked over time, the signal intensities are stable over sufficiently long times for typical
assay measurements (in our case, assay times up to 30 min were used), and the stability of
the fluorescence intensities is comparable to that of the individual samples used to generate
the multiplexed samples (Appendix II 3, Figure A3.1). These data show that we produce
fluorescently indexed silica microspheres bearing lipid bilayers by varying the amounts of
NBD-DOPE lipids in each single sample and that a multiplexed sample is made when these
microspheres are combined.
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3.4.3

Multiplexed Protein Binding Assays.

Fluorescently indexed microspheres coated with different concentrations of GM1 in
POPC membrane bilayers show differential binding of CTxB-Alexa 647, a protein with a
multivalent association with the glycolipid GM1 ligand.13 Silica microspheres are coated
with increasing concentrations of GM1 and NBD-DOPE (100% POPC, 99.75 POPC +
0.05% GM1 + 0.2% NBDDOPE, or 97.5% POPC + 0.5% GM1 + 2% NBD-DOPE),
building a fluorescently multiplexed bead set to test the affinity of CTxB-Alexa 647 to
GM1-containing membranes. Next, different concentrations of CTxB-Alexa 647 ranging
from 0 to 20 nM are added to both the individual samples and the multiplexed sample and
analyzed after a 10-min incubation. The event population is first gated using a forward
scatter versus side scatter plot, as in Figure 3.1B, which selects a population of
microspheres. Then, data from the selected events are shown on a bivariate plot of FL-4
channel intensity (excitation, 640 nm; emission, 675/25 nm; CTxB-Alexa 647 detection
channel; Figure 3.2, y-axis) versus FL-1 channel intensity (excitation, 488 nm; emission,
533/30 nm; NBD-DOPE multiplexing channel; Figure 3.2, x-axis). From this plot, gates
are further refined to include only well-coated microspheres, excluding other debris or
particles with poorly formed membranes (Figure 3.2, red gates). When no CTxB-Alexa
647 is added to either the individual or multiplexed samples (0 nM CTxB-Alexa 647), the
FL-4 fluorescence intensity does not change (Figure 3.2, parts A, E, I, and M), consistent
with no CTxB-Alexa 647 binding.
Results from the addition of increasing concentrations of CTxB-Alexa 647 to samples
with no GM1 (Figure 3.2A−D) indicate little nonspecific binding of CTxB-Alexa 647 for
the main population of microspheres. However, a small subpopulation of events does show
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an increase in FL-4 signal, as would be observed for nonspecific interactions of CTxB-

Figure 3.2. Bivariate contour plots (FL-4 vs. FL-1). Individual samples: 0 mol% GM1: A) Plus 0 nM CTxB-Alexa 647. B)
Plus 2 nM CTxB-Alexa 647. C) Plus 10 nM CTxB-Alexa 647. D) Plus 20 nM CTxB-Alexa 647. 0.05 mol% GM1: E) Plus 0
nM CTxB-Alexa 647. F) Plus 2 nM CTxB-Alexa 647. G) Plus 10 nM CTxB-Alexa 647. H) Plus 20 nM CTxB-Alexa 647.
0.5 mol% GM1: I) Plus 0 nM CTxB-Alexa 647. J) Plus 2 nM CTxB-Alexa 647. K) Plus 10 nM CTxB-Alexa 647. L) Plus 20
nM CTxB-Alexa 647. Multiplexed samples: M) Plus 0 nM CTxB-Alexa 647. N) Plus 2 nM CTxB-Alexa 647. O) Plus 10 nM
CTxB-Alexa 647. P) Plus 20 nM CTxB-Alexa 647.

Alexa 647 with microspheres containing no GM1. A likely origin of this subpopulation is
apparent by inspection of the bivariate FL-4 versus FL-1 plots for the cases where DOPENBD is present (0.2% or 2.0% GM1 columns, Figure 3.2, parts E−H and I−L, respectively).
In these cases, a broadening of the population distribution toward lower FL-1 intensity
coinciding with FL-4 intensity above background level is consistent with nonspecific
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binding of CTxB-Alexa 647 to a subpopulation of microspheres that have nonuniform or
incomplete lipid coating. This result is also consistent with the observation (data not
shown) that some concentration-dependent nonspecific binding of CTxB-Alexa 647 to bare
silica microspheres occurs. Gating of the bivariate data to retain only the main populations
of microspheres, those with well-formed lipid membranes, removes much of this
complicating nonspecific interaction effect, illustrating a powerful aspect of multivariate
flow cytometry analysis of interactions of proteins and membranes. An increase of
fluorescence in FL-4 in single-composition beads with higher concentrations of GM1
indicates that CTxB-Alexa 647 interacts specifically with GM1 (Figure 3.2E−L). Separate
control experiments confirm the absence of concentration-dependent CTxB-Alexa 647
binding to NBD-DOPE on particles with well-formed membranes when no GM1 is present
(Appendix II 3, Figure A3.2).
In the multiplexed set with three fluorescently indexed bead populations in a single
tube, higher fluorescence in the multiplexing channel (FL-1; NBD-DOPE) is matched to
increasing GM1 content in the membrane (Figure 3.2M−P). Specifically, when increasing
concentrations of CTxB-Alexa 647 are added to multiplexed samples, the FL-4 signal
increases for beads with membranes that contain more GM1 (Figure 3.2M−P), consistent
with binding of CTxB-Alexa 647 to GM1. The bead population with no GM1 in its
membranes maintains low binding of CTxB-Alexa 647 (Figure 3.2M−P, red arrows).
Overall, these data indicate the specific binding of CTxB-Alexa 647 to GM1 in a multiplex
format.
The median FL-4 signal of the main bead populations (e.g., Figure 3.2M−P, red gates)
is used to measure the amount of CTxB-Alexa 647 bound to microspheres. A multiplexed
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data set thus consists of the median FL-4 signal of each microsphere population as a
function of CTxB-Alexa 647 concentration. Each microsphere population corresponds to
a different GM1 concentration, so a full multiplexed data set provides the amount of CTxBAlexa 647 bound to microspheres as a function of both CTxB-Alexa 647 concentration
(different panels of Figure 3.2M−P) and GM1 concentration (different populations within
each panel). For each GM1 concentration, the median FL-4 signal, S, as a function of
CTxB-Alexa 647 concentration, [CTxB], is fit to a first-order Hill equation including
background, B:
𝐾𝑒𝑓𝑓 [CTxB]
𝑆 = 𝐵 + (𝑀 − 𝐵) (
)
1 + 𝐾𝑒𝑓𝑓 [CTxB]
(3.1)
In eq. 3.1, Keff is an effective association constant and M is the maximum signal
predicted by the model. For each data set from a population of microspheres, this fit yields
values of B, M, and Keff for the GM1 concentration of those microspheres. Then, using the
value of M obtained for the maximum GM1concentration of 0.5 mol %, designated M0.5, a
normalized fractional signal for each data set is generated as
𝑓 =

𝐾𝑒𝑓𝑓 [CTxB]
𝑆−𝐵
=
𝑀0.5 − 𝐵
1 + 𝐾𝑒𝑓𝑓 [CTxB]
(3.2)

where f is the fraction of the maximum amount of CTxB-Alexa 647 binding that occurs for
GM1 membrane concentration of 0.5 mol %. This normalization process generates a family
of curves for each complete multiplexed and individual data set. Four complete replica
experiments are analyzed, and the f values are averaged and plotted to produce binding
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data (Figure 3.3).
Two major results are found. First, the multiplexed approach agrees well with the
results of individual samples. In fact, fitting
of the four data sets in Figure 3.3 that
correspond to nonzero values of GM1
concentration (red and blue curves of the
upper and lower panels) provides values of
Keff with 95% confidence intervals that all
overlap.

More

detailed

analysis

is

unwarranted, given the small number of
degrees of freedom in the nonlinear
regression models. Averaging the two
values of Keff obtained from the multiplex
Figure 3.3. Fractional binding of cholera toxin (CTxBAlexa 647) after 10 minutes of incubation of samples
containing lipids with 100% POPC + 0% GM1 (black,
triangles), 99.75% POPC + 0.2% NBD-DOPE + 0.05%
GM1 (red, squares) and 97.5% POPC + 2% NBD–
DOPE + 0.5% GM1 (blue, circles). The x-axis is
concentration of CTxB-Alexa 647 added to the system.
Data shown are the average of four replicates, and error
bars are plus/minus one standard deviation. Solid lines
are fits to the averaged data following the functional
form of Equation (3.2). The top panel presents results
from individual samples, while the bottom panel
presents results from the multiplex system.

fits yields a value of Keff = 0.25 ± 0.12
nM−1, corresponding to an effective or
apparent affinity of 1/ Keff = 4.0 ± 1.9 nM,
where the reported uncertainties are 95%
confidence intervals. Second, the multiplex
results found here are also in agreement

with previously published work. A detailed study by Lauer et al. presented a complete
analysis of the multivalent interaction of cholera toxin with GM1, describing both singlesite binding interactions and enhancement of apparent affinity through surface avidity.13
These authors report an effective affinity of approximately 5 nM, which agrees with our
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result. They also report the single-site affinity of GM1 for cholera toxin to be several
hundred times weaker. Their model demonstrates that observation of nanomolar effective
affinity is consistent with multivalent cholera−GM1 interaction arising from the
presentation of GM1 in a laterally fluid membrane. Our results thus confirm that the
important lateral fluidity function of natural membranes is maintained in the multiplex
assay.
To further validate the multiplexed detection approach, we also present protein binding
assays using biotin-DOPE lipids and streptavidin-PE/Cy5 (abbreviated as SAv-Cy5). Silica
microspheres coated with lipid mixtures containing varying concentrations of biotinylatedDOPE and NBD-DOPE (100% POPC, 99.75% POPC + 0.05% biotin-DOPE + 0.2%
NBDDOPE, or 97.5% POPC + 0.5% biotin-DOPE + 2.0% NBDDOPE) are combined into
a multiplexed set. Different concentrations of SAv-Cy5 from 0 to 2.5 nM are added to the
multiplex, incubated for 10 min, and flow cytometry data are collected. For the
fluorophores used in this study, there is some spectral overlap in the FL-1 (NBD-DOPE
detection) and FL-3 (SAv-Cy5 detection) channels. Therefore, flow cytometric data
compensation methods are applied (Appendix II 3, Figure A3.3).49 Following
compensation, bead populations are plotted on bivariate plots of FL-3 versus FL-1
intensities, gates are drawn around the main bead populations, and median fluorescence
intensities in FL-3 are obtained using FlowJoV10 (Appendix II 3, Figure A3.4, red gates).
Analysis of the median fluorescence FL-3 signal intensity is performed using a similar
procedure to that outlined above for four replicate experiments.
Figure 3.4 presents results for both multiplexed and individual samples. In both cases,
the median FL-3 signal increases slightly at high concentrations of SAv-Cy5 even when
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no biotin-DOPE is present, indicating some nonspecific binding of SAv-Cy5 to the beads
(Figure 3.4, lowest curves). However,
separate control experiments confirm the
absence
interaction

of

any
of

additional

SAv-Cy5

specific

with

the

multiplexing label NBD-DOPE when no
biotin-DOPE is present (Appendix II 3,
Figure A3.5). In this example, the
appreciable nonspecific binding of SAvCy5 to beads with no biotin-DOPE and the
increased

specific

binding

to

beads

containing biotin-DOPE in the multiplexed
set demonstrates the power of multiplexed

Figure 3.4. Fractional binding of streptavidin (SAvCy5) after 10 minutes of incubation of samples
containing lipids with 100% POPC + 0% Biotin (black,
triangles), 99.75% POPC + 0.2% NBD-DOPE + 0.05%
Biotin-DOPE (red, squares) and 97.5% POPC + 2%
NBD–DOPE + 0.5% Biotin-DOPE (blue, circles). The
x-axis is increasing concentration of SAv-Cy5: 0 nM,
0.25 nM, 0.5 nM, and 2.5 nM. Data shown are the
average of four replicates, and error bars are plus/minus
one standard deviation. Solid lines are fits to the
averaged data following the functional form of Equation
(3.2), modified for streptavidin and biotin
concentrations. The top panel presents results from the
individual samples, and the bottom panel presents results
from the multiplex system.

analysis. The multiplexed sample contains
all three biotin compositions and a single
SAv-Cy5 concentration, thus reducing
sample-to-sample

variability

in

quantitative determination of specific and
nonspecific responses. As for the case of

CTxB-Alexa 647 interaction with GM1, similar quantitative behavior in the individual and
multiplex samples confirms that fluorescently indexed membrane-coated silica
microspheres provide a reliable alternative to individual bead-based measurements.
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A similar analysis to that described above was carried out for the concentrationdependent binding data presented in Figure 3.4. The 95% confidence intervals of all the
effective affinities again overlap, and when averaged, the resulting effective affinity of the
two multiplexed results is 1/ Keff = 2.1 ± 1.6 nM (reported uncertainty is the 95% confidence
interval). The apparent affinity of streptavidin association with biotin- presenting surfaces
has been treated in detail by several investigators.44,45 Again, our goal is to demonstrate
that the multiplexed approach provides an accurate assessment of the effective affinity for
the chosen experimental conditions. To that end, our results are similar to previous reports
of an apparent affinity of ∼2.3 nM by Nguyen et al. or, for biotin covalently attached to
surfaces, of ∼6 nM by Seto et al.,44,45 providing additional evidence that the mulitplexed
approach produces accurate assessments of effective interactions involving membrane
components.
3.4.4

Binding Specificity in Multiplexed Protein Binding Assays.

For realistic multiplexed applications, each sample should contain beads with different
membrane components, and not just different concentrations of a single component. To
verify that we can use silica microspheres with different membrane components in a single
well, we coat the particles with membranes of 100% POPC (negative control), 0.5% GM1
and 0.2% NBD-DOPE (to bind CTxB-Alexa 647), or 0.5% biotin-DOPE and 2% NBDDOPE (to bind SAv-Cy5). The three fluorescently indexed membrane-coated silica
microspheres are mixed into a single tube, and 20 nM CTxB-Alexa 647 and 2.5 nM SAvCy5 are added to assess the binding specificity of each protein to membrane components.
Flow cytometry data is collected and analyzed as before, with compensation applied to
account for partial overlap of the FL-3 channel with both FL-1 and FL-4 signals (Appendix
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II 3, Figure A3.6). The bead population of each multiplexed sample is gated as in Figure

Figure 3.5. Bivariate contour plots (FL-3 or FL-4 vs. FL-1) of the multiplexed samples: A) Control on FL-4. B) Plus 20 nM
CTxB-Alexa 647 seen in FL-4. C) Plus 2.5 nM SAv-Cy5 seen in FL-4. D) Plus 20 nM CTxB-Alexa 647 and 2.5 nM SAv-Cy5
seen in FL-4. E) Control on FL-3. F) Plus 20 nM CTxB-Alexa 647 seen in FL-3. G) Plus 2.5 nM SAv-Cy5 seen in FL-3. H)
Plus 20 nM CTxB-Alexa 647 and 2.5 nM SAv-Cy5 seen in FL-3.

3.1B and plotted on bivariate plots of FL-4 (Figure 3.5A−D) or FL-3 (Figure 3.5E−H)
versus FL-1. In samples where neither protein is added, FL-3 and FL-4 signals are low
(Figure 3.5, parts A and E). In the presence of 20 nM CTxB-Alexa 647, fluorescence is
low on all bead populations in the FL-3 channel (Figure 3.5F) but increases in the FL-4
channel on the bead population containing 0.5% GM1 (Figure 3.5B). These results show
specific binding of CTxB-Alexa 647 to GM1. When 2.5 nM SAv-Cy5 is added, the
fluorescence intensity in the FL-3 channel increases on the bead population containing
0.5% biotin-DOPE (Figure 3.5G). Fluorescence also increases slightly on the other bead
populations in the FL-3 channel (Figure 3.5G), showing nonspecific binding of SAv-Cy5
to other lipid compositions as discussed previously. There is also a small increase in FL-4
fluorescence in the sample containing SAv-Cy5 (Figure 3.5C), attributed to Cy5
fluorescence spillover into the FL-4 channel. When both 20 nM CTxB-Alexa 647 and 2.5
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nM SAv-Cy5 are added, FL-4 fluorescence increases substantially on the bead population
containing GM1, slightly on the population containing biotin-DOPE (indicating
nonspecific binding), and not on the population containing 100% POPC (Figure 3.5D),
indicating the absence of any additional nonspecific binding beyond that observed in
Figure 3.5C. Additionally, fluorescence in the FL-3 channel increases similarly to the
sample containing only SAv-Cy5, indicating specific binding of the SAv-Cy5 to biotinDOPE (Figure 3.5H). The median intensities in FL-4 and FL-3 corresponding to the gated
data from Figure 3.5, averaged over four replicate experiments, are shown in Appendix II
3, Figure A3.7.
3.5 Conclusion
Our results demonstrate the use of multiplexed microsphere-based assays for
differential binding assays that involve membrane components. These methods are similar
to those required for screening applications. While we have presented a small multiplex,
expansion to large multiplexed sets (n ∼ 100 or larger) should be possible using strategies
similar to those implemented for polymer-based indexed microspheres.7 To achieve that
long-term goal in a commercially viable implementation, one of two materials
development paths can be followed. Since supported membrane bilayers on silica
microspheres are readily produced, one approach is to develop reliable labeling strategies
to index silica microspheres without altering the surface chemistry needed for stable
membrane assembly. An alternative approach is to develop well-characterized model
membranes on commercially available highly multiplexed polymer microspheres. To
conclude, our results show that fluorescently indexed membranes on silica microspheres
enable multiplexed differential binding assays using flow cytometry. For two test cases,
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the multiplexed methods we present yield results in good agreement with prior studies.
Overall, this study provides an initial step to building multiplexed high-throughput flow
cytometry assays involving membrane-associated components. Continued development of
this multiplexed lipid membrane platform will occur through investigation of methods to
generate larger multiplexed sets of targets and controls and in applications of this
technology to flow-cytometry-based interaction analysis or screening studies.
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Chapter 4.
Membrane disruption assays on silica microsphere supported lipid bilayer
membranes
4.1 Abstract
We report a set of membrane disruption assays performed on NBD-DOPE [1,2dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl)]

or

Lissamine Rhodamine B [1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine
rhodamine B sulfonyl] fluorescently-tagged 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC) lipid biomimetic membranes supported on 8 μm non-porous silica microspheres.
The membranes were presented to different concentrations of the surfactant (LDAO) and
the endotoxin (LPS), which through perturbation or disruption caused significant loss of
fluorescence in the membranes. All the samples were screened and analyzed using flow
cytometry and corroborated using confocal fluorescence microscopy. These studies
provide a proof-of-principle demonstration for a flow-based membrane disruption assay
that can be readily multiplexed to investigate multiple lipid compositions.
4.2 Introduction
Cell membranes serve many biological functions: they serve as a barrier that protects
the contents of the cell1, they serve as support for membrane proteins2, they control the
permeation of substances in and out of the cell3, and they are crucial in cell signaling
processes.4 Hence, cell membranes constitute important targets for drug screening
processes, and for mechanistic studies of antimicrobial peptides, nanoparticles, surfactants
or toxins, among other important biomolecules. An important step of these studies consists
of testing the potential membrane disruption effect of the screened drug or surfactant. This
is done via membrane disruption assays, which may be carried out on actual cells.5,6
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However, in such studies, target identification is very difficult due to confounding factors
such as membrane complexity and the wide variety of different components that are
present, including lipids, proteins, and carbohydrates. Studies can also be performed on
planar-solid-supported membranes,7,8 but this platform is limited to low to medium
throughput screening processes. The current study aims to demonstrate that the interaction
between surfactants or toxins and biomimetic membranes presented on alternative
platforms that would allow multiplexed or high-throughput screening is feasible.
In the present work, we initially investigated the surfactant lauryldimethylamine oxide
(LDAO) as it is a very common zwitterionic surfactant9 found in house cleaning and
personal hygiene products10,11. LDAO is widely used to solubilize integral proteins from
their native membranes12, as it is a non-denaturing agent. Since the disruption effects of
LDAO on membranes is well studied and characterized, the present work analyzes the
effects of LDAO on silica microsphere-supported lipid membranes as a control experiment
and as a proof-of-principle.
For the subsequent studies we chose lipopolysaccharides (LPS), which are heat stable
and highly potent mammalian amphiphilic endotoxins13, and also are a characteristic
component of the outer membrane of Gram-negative bacteria14, and Escherichia coli15. The
LPS structure has been shown to be altered by the presence of monovalent and divalent
cations, becoming more aggregated and less mobile in the presence of the latter16–18.
Furthermore, it has been reported that the treatment of fluid-phase planar-supported lipid
bilayers with LPS induces hole formation on the membrane, which depends on the
incubation time and LPS concentration.19. Moreover, Adams et al. demonstrated that the
ability of LPS to form pores on fluid lipid membranes can be used to generate microscale
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2-D array patterns of domains with pores that can be backfilled with other membrane
components20.
Hence, the present work aims to explore the possibility of running similar studies to
those presented by Adams et al. and to test and characterize the interaction of LPS with
lipid membranes supported on non-porous silica microspheres using flow cytometry as the
screening process.
4.3 Materials and Methods
4.3.1

Materials

The lipids 1,2-dioleoyl- sn-glycero- 3-phosphoethanolamine-N- (7-nitro- 2-1,3benzoxadiazol-4- yl (NBD-DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl
(Lissamine Rhodamine B– DOPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4yl (NBD-DSPE) were purchased from Avanti Polar Lipids in lyophilized form. As solvent
for lipids, we used chloroform that contains 1%-5% of ethanol as a stabilizer, purchased
from EMD Millipore. N,N-dimethyldodecylamine N-oxide (LDAO) was purchased in
powder form from Avanti Polar Lipids. Lipopolysaccharides (LPS) purified by phenol
extraction from Escherichia coli O111:B4 was purchased from Sigma Aldrich. The nonporous silica microspheres (7.9 μm) suspended in deionized water with 0.02% sodium
azide were purchased from Spherotech. Finally, all the experiments were performed using
phosphate-buffered saline (PBS) as the main buffer, and bovine serum albumin (BSA) as
a blocking and passivating agent; both were purchased from Sigma Aldrich.
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4.3.2

Formation of lipid membranes on silica microspheres.

The assembly of fluid lipid bilayers on silica microspheres were done following
previously reported protocols.21 Briefly, all the lyophilized lipids were dissolved in
chloroform and stored in glass vials at −20 °C until use. In separate glass vials, different
volumes of the stock lipids were mixed to achieve the desired final concentrations, and
they were left under vacuum overnight to let the chloroform evaporate. Next, the lipid
plaques were then rehydrated in PBS to a final concentration of 1 mM to later form 0.1 μm
large unilamellar vesicles (LUVs) by extrusion. The liposomes solution (1 mM lipid
concentration) are then incubated with ∼106 beads/mL of non-porous silica microspheres
by vortexing them together first at room temperature on high speed for10 minutes, and then
at 37 °C on low speed for 45 minutes. Afterwards, the samples were passivated with BSA
by incubation with 0.5 mg/mL BSA for 45 minutes at room temperature and low speed.
Finally, the samples were washed and rinsed 3 times to remove extra BSA and liposomes
in solution by centrifugation at 10,000 rpm for 45 s, followed by removing the supernatant
and resuspending the beads in fresh PBS.
4.3.3

Membrane disruption assays.

The samples consisted of silica microsphere-supported lipid membranes, which were
built with lipid fluorescent tags (either NBD-DOPE or Lissamine Rhodamine-DOPE) in
them. The samples were split into equal-amount aliquots to reduce sample to sample
experimental variation. The disruption effect of the surfactants was tested by incubating
sample aliquots with increasing amounts of the membrane disrupting agent, LPS or LDAO.
The incubation took place at room temperature and protected from light. The samples that
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were exposed to increasing concentrations of LDAO (0.5 -1.5 mM) or LPS (50 – 500
μg/ml) and the controls were measured with the flow cytometer after 20, 40 and 60 minutes
of incubation to evaluate the loss of fluorescence as an indication of membrane disruption.
Moreover, the sample that was exposed to the highest concentration of LDAO and the
control were imaged with a confocal microscope to provide visual proof of the damage on
the membrane caused by the surfactant.
4.3.4

Backfilling of LPS-induced membrane holes with lipid vesicles with a
secondary lipid fluorescent tag.

First, liquid-phase liposomes (99.5% DOPC + 0.5 mol% NBD-DOPE) were prepared
as described above, and gel-phase liposomes (99.5 mol% DSPC + 0.5 mol% NBD-DSPE)
were prepared by forming plaques under vacuum and resuspending them in PBS to later
go under three cycles of freeze-thaw and intermittent probe sonication for 10 minutes at
>60 °C, as a previously reported method describes.20 The gel-phase liposomes were kept
at ~60 °C until use.
Second, samples containing silica-supported lipid membranes with a composition of
99.9 mol% DOPC + 0.1 mol% Lissamine Rhodamine B-PE were incubated with LPS (0,
5, 50 or 500 μg/ml) for ~50 minutes. Next, the fluorescence levels of all the samples was
measured using flow cytometry. Then, the samples were incubated with either liquidphased liposomes (1 mM lipid concentration) or the gel-phase liposomes (1 mM lipid
concentration) for ~ 7minutes. Afterwards, the fluorescence intensity of the samples in the
channels detecting Lissamine Rhodamine and NBD channel was measured by flow
cytometry. Finally, the sample that was first incubated with 500 μg/ml and later backfilled
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with the gel-phased vesicles was imaged with a confocal microscope to provide visual
proof of the backfilling process.
4.3.5

Microscopy.

Confocal fluorescence microscopy imaging was performed using a Fluoview FV-1000
confocal laser scanning microscope (Olympus, Tokyo, Japan). The images were acquired
with a 40X objective (NA = 0.95) and a 6.0 zoom. The samples containing Lissamine
Rhodamine were imaged by exciting them by a 559 nm LD559 laser and collecting the
emitted light with a bandpass (BP) filter (570-605 nm). The samples containing NBD were
imaged by exciting them by a 488 nm Multi Argon laser and collecting the emitted light
with a bandpass (BP) filter (505-525 nm).
4.3.6

Flow cytometry.

All the flow cytometric data was collected using an Attune® NxT acoustic focusing
flow cytometer by Thermo Fisher Scientific. The Attune® NxT has four lasers (405, 488,
561, and 638 nm) with independent optical paths, and 14 different detection channels. The
channels used in the work presented here are: BL-1: 488 nm laser excitation, and emission
530 nm center/30 nm bandpass (BP), and YL-1: 561 nm laser excitation, and emission 585
nm center/16 nm BP. The flow cytometer went under regular maintenance, cleaning and
calibration before and after use.
For each sample, a total of 10,000 events were collected, out of which about 7,000
corresponded to the main population (fluorescently-tagged lipid membrane supported on
silica microspheres). All the collected data was saved as Flow Cytometry Standard (FCS)
files and was further analyzed using FlowJoV10 software. The gating was generated by the
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auto-gating tool and the software provided statistical information of the gated events.
Further numerical analysis and graph plotting was done using Microsoft Excel.
4.4 Results and Discussion
4.4.1

Formation of lipid membranes on silica microspheres.

The silica microsphere-supported membranes used in the present work had the
following compositions: 99.8 mol% DOPC + 0.2 mol% NBD-DOPE; 99 mol% DOPC+1%
Liss. Rhod-PE; and 99.9 mol% DOPC + 0.1 mol% Liss. Rhod. B-PE.
4.4.2

Membrane disruption assays.

Fluorescence microscopy images show a uniform and complete membrane coverage
on the microspheres (Figures 4.2A and 4.4A). Hence, the loss of fluorescence quantified
by flow cytometric screening was analyzed as a measurement of membrane disruption. The
correlation between membrane disruption and loss of fluorescence was qualitatively
corroborated with fluorescence microscopy imaging.
4.4.2.1 Membrane disruption with LDAO
The sample used to test the disrupting effects of LDAO, as proof of concept, consisted
of biomimetic lipid membranes supported on silica microspheres with a composition of
99.8%mol DOPC + 0.2%mol NBD-DOPE. After the splitting of the main sample into
smaller aliquots, the lipid-coated bead concentration in solution was ~105 beads/ml. One
aliquot served as a control and the rest were incubated with increasing concentrations of
LDAO (0.5, 0.75, 1, 1.25, 1.5 mM). These values were chosen to be around the c.m.c value
(the reported LDAO c.m.c. is ~1 mM).22 The samples were incubated with LDAO for 20,
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40 and 60 minutes before being analyzed in the flow cytometer. First, the bead population
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+1.5

Concentration of LDAO [mM]
Figure 4.1. Flow cytometry acquired median fluorescence intensity in BL-1 channel (NBD-detection channel) of DOPC+0.2%mol NBDDOPE membrane supported on silica beads in the presence of increasing concentrations of LDAO (0.5, 0.75, 1, 1.25, 1.5 mM) and
increasing incubation times (20, 40, and 60 minutes). Data shown are normalized to the 20-minute control (no LDAO) sample, and are
the average of three replicates, and error bars are plus/minus one standard deviation.

was gated from the side scatter versus forward scatter plot, and the gated population was
then observed in the side scatter versus BL-1 (NBD detection channel) where the gating
was further refined by selecting only the well-coated beads. Finally, the median
fluorescence intensity was recorded for all the samples. The experiment was repeated three
different times. The median fluorescence intensity (in the BL-1 channel) resulting from the
three replicates were averaged and normalized and are presented in Figure 4.1. The error
bars represent plus/minus one standard deviation.
Overall, Figure 4.1 shows a clear decrease in BL-1 fluorescence of the membranecoated microspheres in the presence of increasing concentrations of LDAO, and with
increasing incubation times. The control samples (first block of columns to the left) shows
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that there is a small natural decrease in fluorescence of the samples in time, possibly
reflecting some membrane instability, but that loss of fluorescence does not account for
more than ~ 10-15% after 60 minutes of initial assembly. After 20 minutes of incubation
(blue bars) there is a decrease in fluorescence ranging from ~10% (in presence of 0.5 mM
LDAO) to ~85% (in presence of 1.5 mM LDAO). After 40 minutes of incubation (orange
bars), there is an even higher decrease of in fluorescence ranging from ~20% (in presence
of 0.5 mM LDAO) to ~90% (in presence of 1.5 mM LDAO). Finally, after 60 minutes of
incubation (gray bars) the fluorescence values of the samples are very similar to those
observed at a 40-minute incubation process, indicating that the action of LDAO has
stabilized in the 30 to 60-minute time frame.
The fluorescently-tagged lipid membranes on silica microspheres were imaged with
the confocal fluorescent microscope before (Figure 4.2A) and after a 30-minute incubation
with 1.5 mM of LDAO (Figure 4.2B). These images provide a visual proof of what the
data of Figure 4.1 shows; at concentrations 1.25 and 1.5 mM there is, practically, a
complete disruption of the membrane. Finally, for further comparison, we tested the
disrupting effect of high concentration LDAO (1.5 mM) in planar-supported lipid bilayers
with the same composition of their microsphere-supported counterparts. Appendix II 4,
Figure A4.1 shows fluorescence microscopy images of the planar-supported membrane as
control (Appendix II 4, Figure A4.1), and plus LDAO after 25, 30 and 45 minutes of
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incubation (Appendix II 4, Figure A4 B-D). These images show the same qualitative loss
of fluorescence observed in the silica bead-supported membranes.

A

B

Figure 4.2. Confocal microscopy images of DOPC+0.2%mol NBD-DOPE membranes on silica microspheres. A) In absence
of LDAO. B) After a 30-minute incubation with 1.5 mM of LDAO. The images were acquired with a 40X objective (NA =
0.95) and a 6.0 zoom.

Finally, silica microsphere-supported lipid membranes with different composition were
incubated with increasing concentrations of LDAO and increasing incubation times. The
fluorescence loss was similar to those presented in Figure 4.1; however, there was no clear
difference in the disruptive effect of LDAO with respect to the different membrane
composition (Appendix II 4, Figure A4.2).
4.4.2.2 Membrane disruption with LPS
First, the c.m.c. of the LPS used in the work presented here was measured by
calculating the derived count rate versus LPS concentration using Dynamic Light
Scattering. Appendix II 4, Figure A4.3 shows that the c.m.c. of LPS is 10-20 μg/ml.
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As mentioned in the introduction, LPS reportedly induces hole formation on lipid
membranes supported on planar surfaces.19 Hence, this work explores the effect of LPS
on microsphere-supported lipid membranes. The sample used to test the disrupting effects
of LPS consisted of biomimetic lipid membranes supported on silica microspheres with a
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Figure 4.3. Flow cytometry acquired median fluorescence intensity of membrane supported on silica beads in the presence of
increasing concentrations of LPS (50, 150, 250, 350, 500 μg/ml) and increasing incubation times (20, 40, and 60 minutes). A)
Median fluoresce intensity in BL-1 (NBD-detection channel); membrane composition: DOPC+0.2%mol NBD-DOPE membranes.
B) Median fluorescence intensity in YL-1 (Lissamine Rhodamine B detection channel); membrane composition: DOPC+1%mol
Lissamine Rhodamine B-DOPE membranes.

composition of 99.8 mol% DOPC + 0.2 mol% NBD-DOPE (set 1) and 99 mol% DOPC +
1 mol% Liss. Rhod.-DOPE (set 2). Both sets were split into smaller aliquots with a lipidcoated bead concentration in solution of ~105 beads/ml. One aliquot served as a control
and the rest were incubated with increasing concentrations of LPS (50, 150, 250, 350, 500
μg/ml). These values were chosen to be above the c.m.c value. The samples were incubated
with LPS for 20, 40 and 60 minutes before being analyzed in the flow cytometer. The flow
cytometric gating and analysis was done as described above. Briefly, samples were first
gated from the side scatter versus forward scatter plot to later be further refined in the side
scatter versus BL-1 (NBD detection channel) for set 1, or in in the side scatter versus YL1 (Liss. Rhod. detection channel) for set 2. Figure 4.3A shows the median fluorescence
intensity in the BL-1 channel (set 1) of the NBD-containing samples after incubation with
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increasing amount of LPS and incubation times. Figure 4.3B shows the median
fluorescence intensity in the YL-1 channel (set 1) of the Liss-Rhod.-containing samples
after incubation with increasing amount of LPS and incubation times.
Both, Figures 4.3A and 4.3B show a clear decrease of fluorescence (in BL-1 and YL1 respectively) of the membrane-coated microspheres in the presence of increasing
concentrations of LPS, and increasing incubation times. In both cases, after 20 minutes of
incubation (green bars for NBD and light blue ones for Liss. Rhod.) the decrease of
fluorescence goes from ~5% (in the presence of 50 μg/ml) to ~ 25% (in the presence of
500 μg/ml). After 40 minutes (blue bars for NBD and gray ones for Liss. Rhod.) and 60
minutes (yellow bars for NBD and dark blue ones for Liss. Rhod.) of incubation the
fluorescence loss was around the same; it goes from 25% (in the presence of 50 μg/ml) to
~ 40% (in the presence of 500 μg/ml).

A

B

Figure 4.4. Confocal microscopy images of DOPC+0.2%mol NBD-DOPE membranes on silica microspheres. A) In absence
of LPS. B) After a 30-minute incubation with 500 μg/ml of LPS. The images were acquired with a 40X objective (NA = 0.95)
and a 6.0 zoom.
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The fluorescently-tagged lipid membranes on silica microspheres were imaged with
the confocal fluorescent microscope before (Figure 4.4A) and after the addition of 500
μg/ml of LPS (Figure 4.4B). The images show the LPS-induced holes of ~ 1 μm in diameter
on the membrane, which is consistent with the behavior observed of LPS effect on planar
supported-lipid membranes (Appendix II 4, Figure A4.4).
The loss of fluorescence shown in Figure 4.3 is much less compared to that observed
with LDAO. This is consistent with the fact that LDAO nearly fully disrupts and pulls the
membrane, but LPS induces the formation of sporadic holes throughout the surface of the
membrane, leaving much of the bilayer intact.
Finally, silica microsphere-supported lipid membranes with different composition were
incubated with increasing concentrations of LPS and increasing incubation times. The
fluorescence loss was similar to those presented in Figure 4.3; however, there was no clear
difference in the disruptive effect of LPS with respect to the different membrane
composition (Appendix II 4, Figure A4.5).
4.4.3

Backfilling of LPS-induced membrane holes with lipid vesicles with a
secondary lipid fluorescent tag.

Adams et. al., showed that LPS-generated membrane holes could be backfilled with
secondary lipids in either gel-phase or liquid-phase. Here, we test if a similar process could
take place in membranes supported on microspheres, and more importantly if the changes
in the composition due to the backfilling were detectable and measurable in flow
cytometry.
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Figure 4.5 shows the fluorescence microscopy image of 99.9%mol DOPC + 0.1%mol
Lissamine Rhodamine B-PE membranes supported on silica beads. Figure 4.5A is the
control set; Figure 4.5B shows the membranes after a 30-minute LPS treatment (500
μg/ml); and Figure 4.5C shows the LPS treated membranes after being backfilled with gelphased liposomes (99.5% DSPC + 0.5%mol NBD-DSPE). The images visually corroborate
the hole formation after treatment with LPS and the ability of a set of liposomes, with a
secondary fluorescent dye, to backfill those holes.
Control

A

+500 μg/ml LPS

B

+500 μg/ml LPS
and backfilled

C

Figure 4.5. Confocal microscopy images of DOPC+1%mol Lissamine Rhodamine B-DOPE membranes supported on silica
microspheres. A) Control set. B) After treatment with 500 μg/ml for 50 minutes; C) Samples in (B) where the LPS-induced
holes were backfilled with 99.5% DSPC + 0.5%mol NBD-DSPE liposomes.

Figure 4.6A shows the flow cytometric obtained median fluorescence intensity in YL1 channel (Lissamine Rhodamine detection channel) in the absence (blue bars) and
presence of LPS; 5 μg/ml (orange bars), 50 μg/ml (grey bars), and 500 μg/ml (yellow bars).
Starting from the left, the first block of columns shows the samples before the backfilling
process. The second block of columns show the samples that were backfilled with gelphase liposomes and the third block of columns show the samples that were backfilled with
liquid-phase liposomes. The loss of fluorescence intensity observed before and after
backfilling remain the similar and consistent with that of Figure 4.3.
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Figure 4.7. Flow cytometric data of DOPC+0.1%mol Lissamine Rhodamine B-DOPE membranes supported on microspheres,
treated with increasing concentrations of LPS and backfilled with gel-phase (99.5% DSPC + 0.5%mol NBD-DSPE) or liquidphase (99.5% DOPC + 0.5%mol NBD-DOPE) liposomes. A) Median fluorescence intensity in YL-1 channel (Lissamine
Rhodamine detection channel) showing the fluorescence of the membrane; control set (blue bars); treated with 5 μg/ml of LPS
(orange bars); treated with 50 μg/ml of LPS (grey bars), and treated with 500 μg/ml of LPS (yellow bars). B) Median
fluorescence intensity in BL-1 channel (NBD detection channel) showing the integration of the gel-phase or liquid-phase
liposomes; control set (light green bars); treated with 5 μg/ml of LPS (light blue bars); treated with 50 μg/ml of LPS (yellow
bars), and treated with 500 μg/ml of LPS (dark green bars).

Figure 4.6B shows the flow cytometric obtained median fluorescence intensity in BL1 channel (NBD detection channel) of the same samples as in Figure 4.6A. Briefly, plus 0
μg/ml (light green), plus 5 μg/ml (light blue), plus 50 μg/ml (yellow), and plus 500 μg/ml
(dark green). The first block of columns shows the samples before the backfilling process,
and as expected they show no presence of NBD in the samples since they are the samples
before the backfilling process. The second block of columns show the samples that were
backfilled with gel-phase liposomes. There is a clear small increase of fluorescence
intensity, indicating the presence of the gel-phase lipids in the membrane, although the
fluorescence levels are not proportional to the concentration of LPS. This might be
indicative of the fact that the gel-phase lipids backfill only some of the holes and do not
diffuse across the membrane. Finally, the third block of columns show the samples that
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were backfilled with liquid-phase liposomes. There is a large increase of fluorescence
intensity, indicating the presence of the liquid-phase lipids in the membrane. The high NBD
fluorescence levels indicate that there is a presence of the liquid-phase lipids and that they
might be more efficient at backfilling, plus they are able to diffuse across the membrane.
Moreover, the NBD fluorescence level is inversely proportional to the concentration of
LPS used to treat the membranes.
4.5 Summary and Conclusions
Our results demonstrate the viability of membrane disruption assays using non-porous
silica microspheres-supported biomimetic membranes and flow cytometry. The proof-ofprinciple assay results presented here are similar to those previously reported on planar
membrane surfaces, but the assays here were carried out using flow cytometry. This result
proves that membranes supported on microspheres have the potential to serve as platforms
to study the membrane disruptive effect of drugs, antimicrobial peptides, polymers, or other
biomolecules. Importantly, the multiplexable potential of this platform21 can allow for the
simultaneous screening of different lipid compositions against potential disruption agents.
In addition to the assays described in the present work, microsphere-supported membranes
can be used in other types of membrane disruption assays, like lipid protection assays.
Overall, this study presents an alternative method for the screening of biomimetic
membranes against potential membrane disrupting agents by using flow cytometry, and
demonstrates what may ultimately prove to be a rapid and multiplexable new platform for
such studies.
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Chapter 5.
Microsphere-supported polymer membrane as an alternative to lipid
membranes for screening applications
5.1 Abstract
We report the assembly of fluorescently multiplexed block copolymer biomimetic
membranes on 8 μm non-porous silica microspheres, where the amphiphilic diblock
copolymer, poly(ethylene oxide)-block-poly(butadiene), serves as a synthetic alternative
to lipids in the membranes. The membranes are fluorescently tagged with various amounts
of

NBD-DOPE

[1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-

benzoxadiazol-4-yl)] and/or Texas Red - DHPE [1,2-Dihexadecanoyl-sn-Glycero-3Phosphoethanolamine, Triethylammonium Salt]. Using flow cytometry and the
fluorescently multiplexed block copolymer biomimetic membranes on silica microspheres
with increasing concentrations of GM1, we demonstrate the differential binding affinity of
cholera toxin B subunit-Alexa 647 to the ligand target. Analysis of the multiplexed assay
results yields an effective affinity of ~50 nM for binding of cholera toxin B subunit to its
GM1 ligand in these synthetic membranes. These results demonstrate that synthetic block
copolymer membranes on microspheres provide a stable and useful architecture for
multiplexed flow cytometry study of membrane-associated components.
5.2 Introduction
Polymers are some of the most widely used biomaterials, as they have low cost and
their synthesis offers great flexibility in physical properties and functionality.1,2 Polymers
are used in general surgical implants,3 orthopedic implants,4 cardio-vascular intervention,5
dentistry, neurosurgery,6 as drug delivery tools and encapsulants,7,8, and as biosensors9.
There is one particular group of polymers known as the amphiphilic block copolymers that
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are composed of two domains, one hydrophilic and one hydrophobic. Amphiphilic block
copolymers have proven to have possible biological10 and medical applications.11 For
instance, structures like polymersomes or amphiphilic block copolymer vesicles have been
applied as potential drug carriers.12,13 Polymersomes, like liposomes, are capable of
forming biomimetic membranes or films.14,15 Previous studies showed that biomimetic
block copolymer membrane properties, like permeability and lateral diffusivity, can be
tuned by varying the block copolymer molecular weight,16,17, composition,11,18 pH, or ion
concentration.19 This flexibility makes them a great synthetic alternative to lipids in the
development of biomimetic membranes.20
The amphiphilic block copolymer poly(ethylene oxide)-block-poly(butadiene) (PEOb-PBD) is well-studied,14,16 and the formation and characterization of short-chain length
PEO-b-PBD copolymer membranes on planar silica supports was previously reported.14
Briefly, the amphiphilic nature of PEO-b-PBD favors the formation of biomimetic bilayer
films on hydrophilic support surfaces. The lateral fluidity of PEO-b-PBD biomimetic
bilayers is very limited, similar to that of lipid rafts.21 Moreover, PEO-b-PBD has proven
to form hybrid vesicles with phospholipids, which keeps the versatility of polymersomes
and the biocompatibility of liposomes.22
In principle then, these synthetic polymer-based systems provide an alternative to pure
lipid membranes for biological analysis applications. They are easy to prepare, readily
available, provide options for control of the membrane fluidity and may be much more
stable than lipid membrane systems. In prior work, multiplexed lipid bilayers supported on
silica microspheres were developed as a platform for flow cytometry study of the
interaction of lipid bilayers with membrane-bound components.23 The ability to multiplex
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provides many advantages in assays, including the potential for greater speed and
reliability. However, multiplex lipid systems do have some disadvantages, most notably a
lack of long-term stability due to apparent lipid exchange in a multiplexed solution.24 Here,
we investigate the use of synthetic polymers, to form multiplexed membrane-based
architectures that can be used on silica microspheres in flow cytometry assays.
To that end, this work presents: 1) the technology to assemble hybrid block copolymer
and phospholipid membranes on silica beads; 2) a proof-of-principle flow cytometric
characterization of a preferential binding assay on the copolymer membranes supported on
the silica microspheres; and 3) a comparison of these systems to lipid-based systems in
terms of stability and performance.
5.3 Experimental (Materials and Methods)
5.3.1

Materials.

The poly(ethylene oxide)-block-poly(butadiene) (pEO-b-pBD) with a 1,300/1,200 Da
ratio was purchased from Polymer Source™. The monosialotetrahexosylganglioside (GM1)
and 1,2-dioleoyl- sn-glycero- 3-phosphoethanolamine-N- (7-nitro- 2-1,3- benzoxadiazol4- yl (NBD-DOPE) lipids were purchased from Avanti Polar Lipids in lyophilized form.
The

Texas

Red

1,2-Dihexadecanoyl-sn-Glycero-3-Phosphoethanolamine,

Triethylammonium Salt (Texas Red-DHPE) lipids and the cholera toxin B subunit
(recombinant)-Alexa Fluor 647 (CTxB-Alexa 647) were purchased from Thermo Fisher
Scientific in powder form. As solvents, we used chloroform that contains 1%-5% of ethanol
as a stabilizer, purchased from EMD Millipore, and Tetrahydrofuran (THF) purchased
from Sigma Aldrich. We used phosphate-buffered saline (PBS) as the main buffer, and
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bovine serum albumin (BSA) as a blocking and passivating agent; both were purchased
from Sigma Aldrich. Finally, the non-porous silica microspheres (7.9 μm) suspended in
deionized water with 0.02% sodium azide were purchased from Spherotech.
5.3.2

Copolymer micelle formation.

The lipid stocks were prepared by dissolving and resuspending the lyophilized lipids;
GM1 and NBD-DOPE (in chloroform), or Texas Red-DHPE (in THF). Then, the lipid
stock solutions were stored in glass vials, sealed and wrapped with parafilm, at -20 °C in
the dark until use. The powdered pEO-b-pBD was dissolved in THF to a final concentration
of 20mM and it was stored in a glass vial, at 2 °C until use.
In the work presented here, we prepared copolymer micelle assemblies that included
the amphiphilic block copolymers (pEO-b-pBD) and small amounts of phospholipids to
add fluorescent tags (NBD-DOPE and/or Texas Red-DHPE) and increasing concentrations
of the binding ligands (GM1). This was done by following previously reported protocols.25
Briefly, in different glass vials, the desired amounts of copolymer and lipids were dissolved
in THF. Then, the THF solvent was exchanged with molecular biology grade water by
gradual injection (2 ml/hr rate) to a final volume of 2.5 ml and a final micelle concentration
of 1mM, while the THF is removed by rotary evaporation. Then, once the THF was
completely evaporated, the samples were covered, sealed with parafilm and stored in the
dark at 4 °C until use.
5.3.3

Formation of polymer membranes on silica microspheres.
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Similar to the formation of lipid membranes on silica microspheres,26 polymer
membrane formation relies on the spontaneous fusion of the copolymer micelles to the
surface of the non-porous silica microspheres.27
The formation of polymer membranes on silica microspheres was done by mixing, in
separate Eppendorf tubes, the different solutions of 1mM pEO-b-pBD micelles (with
varying concentrations of GM1, NBD-DOPE and Texas Red-DHPE) with the silica
microspheres suspended in PBS pH 7.35, at a concentration of 106 beads/ml. The samples’
incubation process consisted on vortexing the tubes for 1 hour at medium speed and 37 °C.
Afterwards, for blocking purpose, BSA was added to each sample to a final concentration
of 0.5 mg/ml. Then, the samples were vortexed on low speed for 20 minutes at room
temperature. Finally, all the samples were washed and rinsed three times to remove the
unbound micelles and extra BSA in solution. This was done by centrifuging the samples
for 45 seconds at 10,000 rpm, removing the supernatant and resuspending the polymercoated microspheres with fresh PBS buffer, bringing the samples back up to volume.
5.3.4

Multiplex set formation.

Once the assembly of the polymer membranes with different compositions on the silica
beads was completed, a multiplex set was formed by adding equal volumes of each set to
a single Eppendorf tube.
5.3.5

Differential binding assays.

First, five different sets of 1mM pBD-b-pEO micelles were prepared, each tagged with
a different concentration of a lipid fluorophore NBD-DOPE (0 – 2mol%) and/or Texas
Red-DHPE (0 – 1mol%) and different concentrations of GM1 (0 – 1mol%). Then,
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copolymer membranes were formed on silica microspheres using the individual sets of
copolymer micelles previously prepared, and a combination of all the individual sets
formed a multiplexed sample. Second, powdered CTxB-Alexa 647 was dissolved and
suspended in PBS pH 7.35 to a final stock concentration of 17,5nM, and a dilution of
concentration to 17.5nM was also prepared. Both CTxB-Alexa 647 solutions were stored
at 4 °C until use. Third, both single samples and multiplexed samples were incubated with
increasing amounts of CTxB-Alexa 647 (0−100nM) for 1 hour. Finally, the flow
cytometric data was collected for each sample.
5.3.6

Microscopy.

Fluorescence microscopy image collection and the Fluorescence recovery after
photobleaching (FRAP) experiments were performed using a Fluoview FV-1000 confocal
laser scanning microscope (Olympus, Tokyo, Japan). The images were acquired with a
40X objective (NA = 0.95) and a 6.0 zoom. The samples containing NBD were imaged by
exciting them by a 488 nm Multi Argon laser and collecting the emitted light with a
bandpass (BP) filter (505-525 nm). The samples containing Texas Red were imaged by
exciting them by a 559 nm LD559 laser and collecting the emitted light with a bandpass
(BP) filter (655-755). The collected images had a resolution of 512 x 512 pixels. The FRAP
experiment was performed on samples that contained Texas Red as a fluorescent tag;
therefore, the preferential bleaching was achieved by using the LD559 laser. The FRAP
analysis was done using ImageJ software.
5.3.7

Flow cytometry.
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Flow cytometric data was collected using an Attune® NxT acoustic focusing flow
cytometer by Thermo Fisher Scientific. This flow cytometer has four lasers (405, 488, 561,
and 638 nm) with independent optical paths, and 14 different detection channels. Here
listed are only the detection channels used in the present studies; BL-1: 488 nm laser
excitation, and emission 530 nm center/30 nm bandpass (BP); YL-2: 561 nm laser
excitation, and emission 620 nm center/15 nm BP; and RL-1: 638 nm laser excitation, and
emission 670 nm center/14 nm BP. The flow cytometer underwent regular maintenance,
cleaning and calibration before and after use.
For each sample, 10,000 events were collected, out of which about 80% or more
corresponded to the main events (copolymer membrane-coated silica microspheres). For
each sample, the data collected in all 14 detection channels, in the forward scatter channel,
and the side scatter channel were saved as Flow Cytometry Standard (FSC) files. Then, the
data analysis was done using FlowJoV10 software. The gating was generated by the autogating tool, the compensation matrix was modified manually, and the statistical values
were automatically recomputed once a gate was created or modified. Further numerical
analysis and graph plotting was done using Microsoft Excel and Matlab.
5.4 Results and Discussion
5.4.1

Formation of polymer membranes on silica microspheres.
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Figure 5.1 shows a sketch depicting the formation of polymer membrane on silica
microspheres. Briefly, the micelles were formed by suspending the block copolymer and

Figure 5.1. Schematic of formation of block copolymer membranes on non-porous silica microspheres.

lipids first in THF and after a solvent exchange, the micelles were suspended in molecular
biology grade water. Then, the micelles were incubated with silica microspheres and due
to spontaneous fusion, copolymer membranes are formed on the surface of the silica beads.
Polymer membranes on silica microspheres constitute a biomimetic system that can be
used in flow-based analysis, potentially including high throughput screening processes. In
the present work, copolymer micelle assemblies containing pEO-b-pBD, GM1 and
fluorescently-tagged phospholipids were assembled. More specifically, following the
protocol in the materials and methods section, five different compositions of polymer
membranes supported on silica microspheres were prepared: 1) 1mM pBD-b-pEO, 0 mol%
GM1, 1 mol% Texas Red-DHPE; 2) 1mM pBD-b-pEO, 0.05 mol% GM1, 0.2 mol% NBDDOPE; 3) 1mM pBD-b-pEO, 0.1 mol% GM1, 2 mol% NBD-DOPE, 1 mol% Texas RedDHPE; 4) 1mM pBD-b-pEO, 0.5 mol% GM1, 0.01 mol% Texas Red-DHPE; and 5) 1mM
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pBD-b-pEO, 1 mol% GM1, 2 mol% NBD-DOPE. Figures 5.2(A-E) shows the
fluorescence microscopy images of each individual sample. Uniform coverage of the silica

Figure 5.2. Block copolymer membrane composition present in his study. Confocal microscopy image of: A) 1mM pBD-pEO,
0% GM1, 1%mol Texas Red-DHPE. B) 1mM pBD-pEO, 0.05% GM1, 0.2%mol NBD-DOPE. C) 1mM pBD-pEO, 0.1%
GM1, 2%mol NBD-DOPE, 1%mol Texas Red-DHPE. D) 1mM pBD-pEO, 0.5% GM1, 0.01% Texas Red-DHPE. E) 1mM
pBD-pEO, 1% GM1, 2%mol NBD-DOPE. Flow cytometry fluorescence histograms of: F) YL-2 fluorescence of the
population shown in A). G) BL-1 fluorescence of the population shown in B). H1) BL-1 and H2) YL-2 fluorescence of the
population shown in C). I) YL-2 fluorescence of the population shown in D). J) BL-1 fluorescence of the population shown
in E).

beads with copolymer membrane can be observed, similar to the uniform coverage offered
by lipid bilayers.24
The same samples were analyzed using the Attune® NxT acoustic focusing flow
cytometer. Briefly, the microsphere populations were gated on the side scatter versus
forward scatter plot. The gated population was then observed on a BL-1 (NBD detection)
versus YL-2 (Texas Red detection) plot and gated again to select only the well-coated
beads. The signal from that secondary gate can later be observed in any other detection
channel. Figures 5.2(F-J) shows the flow cytometric data in the form of histograms
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depicting the florescence intensity of each sample in the detection channel corresponding
to their fluorescent tag.
The lateral fluidity of the copolymer membranes was tested in a FRAP experiment,
where silica microspheres coated with a copolymer membrane (1mM pBD-b-pEO, 0%
GM1, 1%mol Texas Red-DHPE). The sample was imaged with a fluorescent microscope,
and a small spot on one of the copolymer membranes was bleached using the LD559 full
laser intensity. (Appendix II 5, Movie A5.1). The bleached region did not display
fluorescence recovery over a period of 30 minutes, which means that the pBD-b-pEO
membrane bilayers have little lateral fluidity. (Appendix II 5, Figure A5.1). This is
consistent with previously reported data on pBD-b-pEO films on planar supported silica.
5.4.2

Multiplex set formation.

The five different populations of copolymer membranes coated on beads were mixed
in equal volumes to form a multiplexed set (Figure 5.3A), and split into aliquots. The flow
cytometric analysis for multiplex samples was the same as for individual samples. The
multiplexed samples seen in the BL-1 vs YL-2 bivariate plot (Figure 5.3B) shows the five
different sub-populations, which are clearly distinguishable from one another and can be
independently gated.
The time stability of the fluorescent signals of the individual and multiplexed samples
were tracked over time (Appendix II 5, Figure A5.2). Both sets of samples showed to be
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A

C

B
0.05% GM1 0.1% GM1 0.5% GM1

1% GM1

BL-1 (NBD detection)

0% GM1

YL-2 (Texas Red detection)

RL-1 (Alexa Fluor 647 detection)

Figure 5.3. A) Schematic of the multiplex formation of supported block copolymer biomimetic membranes on non-porous
silica microspheres. The five different populations of silica beads coated with different polymer and phospholipid membrane
composition and fluorescence tags are mixed in equal amounts. B) Bivariate plot BL-1 (NBD detection) versus YL-2 (Texas
Red detection) where all the five populations are distinguishable and therefore can be gated. C) Histograms on RL-1 (Alexa
Fluor 647 detection) of the gated population in B).

stable over a period of 8 hours, where the populations show stable fluorescence levels, and
distinguishable sub-populations in the multiplexed set. This stability is much greater than
observed for similar multiplexed sets containing lipids, where substantial mixing occurs on
a time scale of about one hour.23
5.4.3

Differential binding of CTxB-Alexa to GM1.

The interaction between cholera toxin and GM1 has been characterized and studied
extensively.28,29 As a proof-of-principle demonstration, we analyze the interaction between
CTxB-Alexa 647 and GM1-containing copolymer membranes supported on silica
microspheres. A similar study was reported on silica microsphere-supported lipid
bilayers,23 and the analysis was done on a similar way. Briefly, the individual and
multiplexed sets (described in the last two sections) were incubated with increasing
concentrations of CTxB-Alexa 647 (0, 5, 10, 50 and 100 nM) for 1 hour, immediately
followed by the flow cytometric analysis of each sample.
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The samples were first gated on the side scatter vs forward scatter to select the silica
bead population. The fluorescent tags on the copolymer membranes (NBD and Texas Red)
and the fluorescent tag on the cholera toxin (Alexa Fluor 647) have some spectral overlap,
so compensation on the channels BL-1 (NBD detection), YL-2 (Texas Red detection), and
RL-1(Alexa Fluor 647 detection) was applied (Appendix II 5, Figure A5.3 and Figure
A5.4). After compensation, the gated bead population was observed on a BL-1 (NBD
detection) versus YL-2 (Texas Red detection) bivariate plot (Figure 5.3B), where each
sample set was gated again to refine the selection of well-coated beads. Finally, the data
from the selected events are shown in histograms of the fluorescence intensity in the RL-1
channel (Alexa Fluor 647 detection) (Figure 5.3C).

Figure 5.4. Histograms in RL-1 (cholera toxin-Alexa Fluor 647 detection) of the five sub-populations in the presence of
increasing concentrations of cholera toxin-Alexa Fluor 647. A) Control for individual sets. F) Control for multiplex sets. Plus
5 nM CTxB: B) Individual set. G) Multiplex set. Plus 10 nM CTxB: C) Individual set. H) Multiplex set. Plus 50 nM CTxB:
D) Individual set. I) Multiplex set. Plus 100 nM CTxB: E) Individual set. J) Multiplex set.
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Figure 5.4 shows the histograms of the fluorescence intensity in the RL-1 channel
(cholera toxin detection) of the individual (Figure 5.4A-E) and multiplexed (Figure 5.4FJ) samples after 1-hour incubation with increasing concentrations of CTxB-Alexa (0 –
100nM). On both individual and multiplex sets, the samples with no GM1 (red-labeled)
have low fluorescence levels in RL-1 in the presence of 5nM and 10nM CTxB-Alexa, and
in the presence of 50nM and 100nM CTxB-Alexa the RL-1 fluorescence has a very broad
distribution, but still lower than samples with higher concentrations of GM1. This is
indicative of low non-specific binding of CTxB-Alexa to pBD-b-pEO and the fluorescently
tagged-phospholipids. For the remaining samples, 0.05 mol% GM1 (light blue-labeled),
0.1 mol% GM1 (orange-labeled), 0.5 mol% GM1 (light green-labeled), and 1 mol% GM1
(dark blue-labeled), there is a steady increase of fluorescence in RL-1 as the concentration
of GM1 and concentration of CTxB-Alexa increased. This result is indicative of selective
binding of CTxB to GM1.
The quantitative analysis was done as previously reported.23 The data was fit to a firstorder Hill equation, where the maximum signal (M) was predicted by model for the
maximum GM1concentration of 1 mol%. Figure 5.5A (individual samples) and Figure 5.5B
(multiplexed samples) show the normalized fractional signal for each data set with respect
to M versus the total concentration of CTxB-Alexa in solution [CTxB-Alexa]. The
experiment was repeated three times; the values in Figure 5.5 represent the averaged
values, and the error bars are calculated based on standard deviation. A model fit was
included for each set of GM1 concentrations, which provided the calculation of effective
association constant (Keff) of each set.
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Figure 5.5. Fractional binding of cholera toxin (CTxB-Alexa 647) after 1 hour of incubation of samples containing block
copolymer membranes containing 1mM pBD-pEO, 0% GM1, 1%mol Texas Red-DHPE (black); 1mM pBD-pEO, 0.05%
GM1, 0.2%mol NBD-DOPE (blue); 1mM pBD-pEO, 0.1% GM1, 2%mol NBD-DOPE, 1%mol Texas Red-DHPE (pink);
1mM pBD-pEO, 0.5% GM1, 0.01% Texas Red-DHPE (red); and 1mM pBD-pEO, 1% GM1, 2%mol NBD-DOPE (green).
The x-axis is concentration of CTxB-Alexa 647 added to the system. Data shown are the average of three replicates, and error
bars are plus/minus one standard deviation. Solid lines are fits of the averaged data to Hill’s equation. A) Individual samples.
B) Multiplex samples.

The analysis of the individual samples resulted in an averaged Keff = 0.022 ± 0.005 nM1

(uncertainties are 95% confidence), which corresponds to an effective or apparent affinity

of 1/ Keff = 46.02 ± 8.6 nM. Similar results were obtained for the multiplexed set: Keff =
0.21± 0.04 nM-1 and 1/ Keff = 48.16 ± 10.4 nM. These values are ~ 10-fold weaker than
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those reported by Lauer, et al., and by our group23 in fluid lipid membranes with multivalent
binding (~5nM); and ~ 80-fold stronger than the one reported for single-site binding of the
soluble pentasaccharide portion of GM1 (~4μM).28 They are however, closer to single-site
affinities estimated by Lauer et al. for GM1 presented in a membrane, where an
approximate value of ~12.5 nM is obtained from models of multivalent binding. The
apparent affinity values we determine here are thus consistent with a non-multivalent
binding process of GM1 presented in a membrane with low lateral fluidity, which is
consistent with the results obtained in the FRAP experiment.
5.5 Summary and Conclusions
Our results demonstrate the use of a multiplexed block copolymer biomimetic
membrane supported on silica microspheres for a binding assay using flow cytometry and
microscopy. While the use of pBD-b-pEO has proven to be a good synthetic alternative to
lipid rafts, the use of different biodegradable block copolymers could expand this platform
to ensemble more fluid membranes, monolayers, or more complex hybrid
copolymer/phospholipids. The expansion of the number of sub-populations in the
multiplex set could also be achieved by the use of copolymer giant polymer vesicles, as
they have been explored as possible flow cytometry amenable system,30 However, their
self-assembly still results in polydisperse populations.31 A different alternative could be
the use of different solid supports, such as commercially available indexed polymer
microspheres. To conclude, our results show the viability of assembling stable
fluorescently indexed block copolymer biomimetic membranes on silica microspheres,
which enable multiplexed differential binding assays using flow cytometry. Overall, this
study presents a high-throughput alternative to the screening of copolymer biomimetic
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membranes against membrane-bound components using flow cytometry and it may
ultimately prove to be a robust and versatile new platform.
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Chapter 6.
Summary and Future Directions

Overall, the results of the present work demonstrate the viability of assembling stable
biomimetic membranes on microspheres for flow-based screening applications, similar to
those required for screening applications.
First, we built fluorescently indexed lipid membranes on silica microspheres that use
different concentrations of fluorescently tagged lipids and potentially different
compositions to enable multiplexed differential binding assays using flow cytometry. More
specifically, we demonstrated this multiplexed approach by measuring specific affinity of
two well-characterized protein-membrane systems. In that work we successfully assessed
the preferential binding of fluorescently labeled proteins to microsphere-supportedmembranes containing different amounts of ligand targets. The present work reports the
development of a small multiplex, but with the potential of being expanded. Furthermore,
this study provides a stepping stone towards the development of a flow-based,
multiplexable and high-throughput screening assays involving membrane-associated
components. For instance, collaborators of ours have reported the successful use of
multiplexable microsphere-supported lipid bilayers in the screening of DNAzyme
reactions by implementing DNA nanotechnologies on a fluid lipid surface.
Second, we used fluorescently-tagged lipid membranes on silica microspheres to
screen the membrane disruption effects of surfactants and toxins using flow cytometry,
with results corroborated using microscopy. We developed and tested a membrane
disruption assay where we relied on the loss of fluorescence of the fluorescently-tagged
lipid membranes supported on microspheres in the presence of the surfactant or toxin to
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determine the perturbation, disruption or elimination of the membranes. The results
obtained are consistent with previously reported data from similar studies done on planarsupported membranes. Moreover, we explored the option of backfilling or repairing the
disrupted membranes supported on microspheres with a secondary set of liposomes, as
previously done by other groups on planar-supported membranes. The present work on
membrane disruption assays has the potential of being a platform that will allow us to test
membrane-disrupting agents, proteins, toxins, lipases and antimicrobial peptides. Studies
can be performed against different membrane compositions, and also to investigate the
effect of varying environmental factors like pH, ionic strength, and buffers.
Third, we built and characterized multiplexed fluorescently indexed membranes on
silica microspheres using block copolymers as a synthetic alternative to lipids. The
properties of block copolymer membranes like permeability and lateral diffusivity, can be
tuned by varying the block copolymer molecular weight. Furthermore, we demonstrated
the ability of microsphere-supported block copolymer biomimetic membranes with
different compositions to enable multiplexed differential binding assays using flow
cytometry. The present work presents a promising alternative to lipids in the development
of biomimetic membranes supported on microspheres for flow-based studies of membranebound components, one that may ultimately prove to be a robust and versatile new
platform.
Future directions
Fluorescently-indexed biomimetic membranes on silica microspheres have proven to
be an effective platform for the high-throughput screening of the interactions of membranes
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with membrane-bound and membrane-associated components. However, most of the work
presented here tested proof-of-principle assays as a way of assessing the efficacy of our
platform. Future experiments should use our newly developed fluorescently-indexed
biomimetic membranes on silica microspheres to explore more complex and innovative
approaches in areas such as protease assay development, drug screening and antimicrobial
peptide screening.
Although effective, the multiplexed sets of microsphere-supported membranes
presented here are small sets (of 3 to 5 components). Future expansion of these sets to much
larger multiplexed sets would provide an important improvement for screening
applications. This long-term goal can be achieved by following two different paths. First,
one could explore by fluorescently-indexing the silica microspheres, instead of the
membranes. Provided that the labeling does not alter the silica’s ability to support
membranes, this would present itself as a more stable and robust platform. Alternatively,
one could assemble biomimetic membranes on commercially available highly multiplexed
polymer microspheres. However, this approach will likely require extensive modification
of the surface of the polymer beads to support model membranes. In either approach, the
successful achievement of this goal would provide an ideal platform to investigate
membrane protection assays, and biomolecular interactions with membranes or membranesupported molecules.
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Appendix I.
Additional work
Appendix I. 1 Introduction
Appendix I presents additional work done in the course of this overall study, but which
is still in progress or presented some challenges that have not yet been overcome. First, we
investigated the development and use of membranes supported on naturally buoyant
microspheres such as functionalized polystyrene. Polystyrene microspheres are widely
commercially available in different sizes and with different fluorescent tags which
increases the multiplexing opportunities. To overcome the hydrophobic nature of
polystyrene, we worked with different functionalized polystyrene beads (carboxylated or
biotinylated). Unfortunately, that did not result in reproducible or reliable membrane
structures supported on the beads. Therefore, we also attempted to modify the bead
polystyrene surface via UV or ozone exposure, an approach that was not successful either.
In spite of our inability to fully characterize the lipid structure built on the polystyrene
microsphere’s surface, we attempted to run a lipid protection assay. This assay relies on
the quenching effect of propidium iodide (PI) on FITC. FITC was coated on the surface of
the bead using BSA-FITC, and we investigated the ability of PI to diffuse across the
membrane. We were able to obtain some positive results; however, they were not fully
reproducible.
The material presented in chapter 5 also inspired some work exploring the interaction
of differently structured polymers such as chitosan and poly-L-lysine (fluorescently
tagged) with varying lipid composition and charge on the microsphere-supported
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membrane structures. The results were not conclusive, as we observe very high nonspecific binding of the polymers to any membrane composition or charge, as well as to the
bare silica microspheres.
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Appendix I. 2 ADDITIONAL WORK FOR CHAPTER 4 – DETECTION OF
MEMBRANE DISRUPTION ON MICROSPHERE SUPPORTEDBIOMIMMETIC MEMBRANES
In addition to the work presented in chapter 4 and chapter 5, there is a different set of
experiments that were inconclusive

Appendix I. 2.1 Membrane disruption assay using the surfactants SDS and Triton
X-100.
Introduction. Based on the background and motivations reported on chapter 4, we
explored and tested this set of experiments as our first attempt at studying the interaction
between surfactants or toxins and biomimetic membranes supported on microspheres.
After careful consideration, we later moved to the use of different surfactants.
Materials. The lipids 1,2-dioleoyl- sn-glycero- 3-phosphoethanolamine-N- (7-nitro- 2-1,3benzoxadiazol-4-

yl

(NBD-DOPE),

and

1-palmitoyl-2-

oleoyl-sn-

glycero-3-

phosphocholine (POPC) were purchased from Avanti Polar Lipids in lyophilized form. As
solvent for lipids, we used chloroform that contains 1%-5% of ethanol as a stabilizer,
purchased from EMD Millipore. All the experiments were performed using phosphatebuffered saline (PBS) as the main buffer, and bovine serum albumin (BSA) as a blocking
and passivating agent; both were purchased from Sigma Aldrich. The sodium dodecyl
sulfate (SDS) was purchased from Bio Rad at 10% (w/v), and the Triton X-100 was
purchased from OmniPur via Sigma Aldrich. The non-porous silica microspheres (3.14
μm) suspended in deionized water with 0.02% sodium azide were purchased from
Spherotech. Finally, the samples were screened using a BD Accuri C6 flow cytometer.
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Methods. The membrane disruption assay was performed following the same protocol
reported in chapter 4. Briefly, fluorescently-tagged membranes (DOPC + 0.2%mol NBDDOPE) were assembled on silica microspheres and were exposed to increasing
concentrations of Triton X-100 (0.0024 – 0.24 mM) and increasing concentrations of SDS
(0.08 – 8 mM) for about 15 minutes. The loss of fluorescence in the samples presented to
the surfactants was calculated and analyzed as an indication of membrane disruption.
Results and Discussions. SDS has a c.m.c. of ~ 8-8.5mM and Triton X-100 has a c.m.c. ~
0.22 -0.24 mM. The surfactant’s concentration ranges were chosen to include values way
below the c.m.c and one value around the c.m.c. Figure AI-1A shows the median
fluorescence intensity in the FL-1 channel (NBD detection channel) in the absence and

Figure AI-1. Silica microsphere-supported POPC + 0.2%mol NBD-DOPE membranes’ median fluorescence intensity in the
FL-1 channel (NBD detection channel) in: A) the absence and increasing presence (0.0024, 0.024, and 0.24 mM) of Triton X100. B) the absence and increasing presence (0.08, 0.8, and 8 mM) of SDS.

increasing presence of Triton X-100. The data shows that even in the presence of 0.0024
mM of Triton X-100 (a hundredth of the c.m.c. value) there is some loss of fluorescence
indicating some level of membrane disruption, while in the presence of 0.24 mM Triton X100 (about the c.m.c. value) the fluorescence value drops close to the background level
indicating a complete destruction of the membrane. Figure AI-1B show the median
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fluorescence intensity in the FL-1 channel (NBD detection channel) in the absence and
increasing presence of SDS. Similar to the Triton X-100 case, the data in Figure AI-1B
shows that even in the presence of 0.08 mM of SDS (a hundredth of the c.m.c. value) there
is some loss of fluorescence indicating some level of membrane disruption, while in the
presence of 8 mM Triton X-100 (about the c.m.c. value) the fluorescence value drops close
to the background level indicating a complete destruction of the membrane.
Conclusions. The data in Figure AI-1 indicates that both Triton X-100 and SDS are harsh
surfactants, which even at small concentrations can cause serious disruptions on the
membrane. Moreover, the high viscosity of Triton X-100 makes it a difficult chemical to
work with. Hence, we concluded that other surfactants (like LDAO) would be better
candidates to show the gradual disrupting effect on microsphere-supported biomimetic
membranes.
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Appendix I. 2.2 Lipid protection assays

Appendix I. 2.2.1 Preliminary results
Introduction. As useful as it has proven to be, silica is a good but not optimal material for
flow cytometric and high-throughput analysis. A significant limitation is that silica’s high
density compared to water makes silica microspheres precipitate in several seconds, thus
requiring the need for constant mixing or shaking of the samples. As an alternative, we are
working on the introduction of a second multiplexable platform built on naturally buoyant
carboxylated-polystyrene

microspheres.

Polystyrene

microspheres

are

widely

commercially available in different sizes and with different fluorescent tags which
increases the multiplexing opportunities. Membranes supported on polystyrene have not
been extensively studied and they will require characterization to assess the quality and
uniformity of the membrane bilayer, information obtained through membrane disruption
studies. Hence, we will concurrently test both the silica and functionalized polystyrene
microspheres for their potential use as platforms for membrane disruption assays. Thus,
success in this aim will yield technology for important membrane disruption screening and
also help demonstrate new material constructs that may lead to improved general flow
cytometry studies using model membranes on naturally buoyant microspheres.
Materials. The lipid 1-palmitoyl-2- oleoyl-sn- glycero-3- phosphocholine (POPC) was
purchased from Avanti Polar Lipids in lyophilized form. As solvent for lipids, we used
chloroform that contains 1%-5% of ethanol as a stabilizer, purchased from EMD Millipore.
All the experiments were performed using phosphate-buffered saline (PBS) as the main
buffer, bovine serum albumin (BSA) as a blocking agent, BSA-FITC a passivating agent,
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and propidium iodide (PI) as a FITC quencher. All of these materials were purchased from
Sigma Aldrich. The non-porous silica microspheres (3.14 μm) and the carboxylatedpolystyrene microspheres (5 μm) both suspended in deionized water with 0.02% sodium
azide were purchased from Spherotech. Finally, the samples were screened using a BD
Accuri C6 flow cytometer.
Methods. As a first step, the microspheres’ (either silica or carboxlated-polystyrene)
surface was passivated with 0.4mg/ml Bovine serum albumin tagged with Fluorescein

Figure AI-2. Schematic of the lipid protection assay on membrane supported on microspheres.

isothiocyanate (BSA-FITC) overnight at 4 °C. The next day, the sample with the passivated
beads was rinsed twice by centrifugation at 10,000 rpm for 45 seconds removing the
supernatant, and replacing the buffer. Then, the sample was split into 2 equal parts; one of
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the parts will serve as control and the other will later be liposome-coated. Following the
same procedure described in chapters 3 and 4. The second set (liposome-coated) was
incubated with liposomes (1 mM lipid concentration of 100% POPC), later incubated with
BSA as a blocking step and then rinsed. The control group was incubated with PBS buffer,
BSA as blocking step and later rinsed. Both sets were kept treated under the same rotation
and temperature conditions. Finally, both sets were split into aliquots of equal volume and
incubated with increasing concentrations of propidium iodide (PI), which is a FITC
quencher (Figure AI-2 shows a schematic of the process). After a 30-minute incubation at
room temperature the samples were analyzed in the flow cytometer to obtain the loss of
fluorescence in both sets, to later compare them to one another.
Results and Discussions. Figure AI-3 shows the results of the experiment in the form of
Stern-Volmer plots. These show the relative fluorescence F0/F (F0 fluorescence intensity
without quencher and F is the fluorescence intensity with quencher) with respect to the
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Figure AI-3. Stern-Volmer plots (fluorescence intensity without quencher over fluorescence intensity with quencher) vs.
concentration of quencher in solution. A) In carboxylated-polystyrene microspheres. B) In silica microspheres.

concentration of the quencher present in solution.1 Figure AI-3A shows the results of the
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lipid protection assay performed in carboxylated-polystyrene microspheres done in
triplicate; the error bars represent plus/minus one standard deviation. Figure AI-3B shows
the results of the lipid protection assay performed in silica microspheres. In both cases we
can observe there is more quenching in the absence of lipids membranes (red lines) versus
in the microspheres bearing membranes (blue lines). Consequently, given the PI is not
permeable to the lipid membrane we can conclude that there is a continuous membrane
structure supported on BSA-FITC coated microspheres.
Conclusion (Part 1). Although encouraging at first, unfortunately the results were not
reliably reproducible. This could have been due to poor or non-uniform BSA-FITC
passivation of the silica microspheres or by the formation of non-uniform or irregular lipid
structures (neither bilayers or monolayers) on the carboxylated-polystyrene microspheres.
We explored these possibilities by running the following experiments.
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Appendix I. 2.2.2 BSA-FITC and fluorescein passivation of silica microspheres
The formation of lipid bilayer on silica surfaces via spontaneous fusion of lipid vesicles
onto the silica surface has been widely reported, previously,2 and in the present work
(chapter 3 and chapter 4). However, the membrane disruption assay as described here,
relies on the uniform coating of the bead by a fluorescent component before the assembly
of the biomimetic membrane on the surface. Here, we tested the effectiveness of the silica
bead passivation process with BSA-FITC and with fluorescein.
Briefly, silica microspheres in PBS buffer at pH 7.35 were incubated with ~0.5mg/ml
BSA-FITC (Figure AI-4A) or with ~0.5mg/ml Fluorescein (Figure AI-4B) at different
temperatures overnight. The samples were screened using a flow cytometer, before and
after some washing and rinsing cycles.
Figure AI-4A shows the bar graphs showing the median fluorescence intensity in FL1 of all the samples after passivation with BSA-FITC in the hot room at 37 °C (blue bars),
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Figure AI-5. Passivation of silica microspheres at different temperatures before rinsing, after 2 rinses and after 4 extra rinses.
The data shows the median fluorescence intensity in the FL-1 channel. A) BSA-FITC as a passivating agent. B) Fluorescein
as a passivating agent.

at room temperature (orange bars), and in the cold room at 4°C (gray bars). The samples
were analyzed right after incubation, after a couple of rinse steps and after four additional
rinse cycles. The data indicates that under the three different incubation temperatures the
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beads have a high initial fluorescence, but after only a couple of rinse steps, the
fluorescence levels drop to only a couple thousand. Finally, after the 4 additional rinse
cycles, the fluorescence drops close to background level.
Figure AI-4B shows the bar graphs showing the median fluorescence intensity in FL-1
of all the samples after passivation with fluorescein in the hot room at 37 °C (blue bars), at
room temperature (orange bars), and in the cold room at 4°C (gray bars). The samples were
analyzed right after incubation, after a couple of rinse steps and after four additional rinse
cycles. The data indicates that under the three different incubation temperatures the beads
have a high initial fluorescence, and unlike the BSA-FITC case, the fluorescence levels
decreases only minimally right after a couple of rinses. However, after the 4 additional
rinse cycles, the fluorescence drops to very low values.
Conclusion (Part 2). Silica has a small negative charge and so does BSA; hence, the BSA
passivation of silica has proven to be difficult as shown in Figure AI-4. Although
fluorescein adsorbed onto the surface seems more resistant to a couple of rinses, having
the sample undergo further washing steps, as required by the reported protocols, removes
the fluorescein from the bead’s surface. Therefore, it is necessary to find a different
fluorescent compound that is compatible with silica, preferably slightly positively charged
and hydrophilic, which at the same time would not alter the properties of silica as a great
lipid membrane support. Even if stable and uniform passivation is achieved, the surface of
the coated bead should be screened for possible modifications that would prevent the
assembly of biomimetic membranes. The success in this aim would provide the opportunity
of producing indexed highly-multiplexed sets of non-porous silica microspheres, similar to
the commercially available polystyrene ones. This would provide a new and innovative
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platform to explore the interaction of biomimetic membranes with different
biocomponents.
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Appendix I. 2.2.3
BSA-passivated carboxylated-polystyrene coated with
fluorescently-tagged (99.8%mol POPC + 0.2%mol NBD-DOPE) lipids
Briefly, we incubated the carboxylated-polystyrene with BSA instead of BSA-FITC
and then incubated with 99.8%mol POPC + 0.2%mol NBD-DOPE liposomes instead of
100%mol POPC. Later, the fluorescence level of the sample was screened with a flow
cytometer at times 0, 15, 30 and 60 minutes. The purpose of this test was to compare the
fluorescence levels of the lipid structures on the carboxylated-polystyrene beads (5 μm) to
the fluorescence levels of the lipid structures on the silica beads (7.9 μm), where we know
that lipid structure formed is a bilayer.
Figure AI-5A shows the median fluorescence intensity in FL-1 channel (NBDdetection channel) of the samples with POPC + 0.2%mole NBD-DOPE lipids supported
on the carboxylated-polystyrene microspheres at times 0, 15, 30 and 60 minutes. The
fluorescence level stabilizes after 15 minutes to ~ 3,000 to 4,000. These values are very
low compared to the fluorescence observed on the silica beads (Figure AI-5B) and even
accounting for the difference in the beads’ sizes, we can conclude that the structures formed

B

DOPC+0.2%NBD-DOPE on COOH-Polystyrene beads
(5 μm)

Median Fluorescence Intensity FL-1

Medium Fluorescence Intensity FL-1

A

7000

6000
5000
4000

3000
2000
1000

0
0 min

15 min

30 min

1 hr

DOPC+0.2%NBD-DOPE on silica beads (8 μm)
80000
70000
60000
50000
40000
30000
20000
10000

0
Control (15 min)

Figure AI-5. Assembly of lipid structures (DOPC + 0.2%mol NBD-DOPE) on A) BSA-passivated carboxylated-polystyrene
microspheres (5 μm), and B) non-porous silica (8 μm) microspheres.

on the carboxylated-polystyrene beads are neither bilayers, nor monolayers.
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Conclusion (Part 3). Polystyrene is a highly hydrophobic material, therefore not an ideal
support for lipid bilayer membranes. To mitigate this problem, we chose functionalized
(carboxylated) polystyrene microspheres. The carboxyl groups on the surface of the beads
should make it less hydrophobic. Moreover, we passivated the surface of the beads with
BSA in the hopes of helping reduce the hydrophobicity of the polystyrene. Unfortunately,
the data observed on Figure AI-5 indicates otherwise. Hence, different approaches should
be explored to form biomimetic membranes on polystyrene microspheres. For instance, an
option would be to test different functional groups on polystyrene beads and at higher
concentrations. In addition, the possibility of covalently binding the lipids to functionalized
polystyrene beads should be researched an explored.
Acknowledgments. The work done on lipid protection assay was done in collaboration
with Dr. Nesia A. Zurek and Mirella Galvan-De La Cruz.
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Appendix I. 2.3 Surface modification of polystyrene microspheres
Introduction. As stated in the conclusion (part 3) of the last section, there is a need to
further modify the surface of functionalized polystyrene microspheres to achieve a more
hydrophilic surface. In order to achieve it, we treated the surface of the polystyrene beads
with UV-ozone exposure,3,4 and with O2 plasma,5,6 as both methods are generally used to
functionalize polystyrene surfaces.
Materials. The silica microspheres (3.14 μm), the plain polystyrene microspheres (5 μm)
and the carboxylated-polystyrene microspheres (5 μm) were purchased from Sphertotech.
Pieces of Fisherbrand Plastic Petri Dishes were used as control. The samples were treated
using the UVO-Cleaner by Jelight Company, Inc. Model No 144AX or a Harrick Plasma
Cleaner PDC-32G. The flow cytometric data was obtained using either the BD Accuri C6
flow cytometer or the ThermoFisher Scientific Attune NxT.
Methods. In both sets of experiments, small pieces of a petri dish were first treated, and
the surface modification was determined by a qualitative change in the water contact angle.
If the treatment process resulted in a better wetting ability of polystyrene, then the sample
treatment was applied to the microspheres, which were later coated with fluorescentlytagged liposomes to test their ability to support biomimetic membranes by measuring the
fluorescence intensity using a flow cytometer.
Results and Discussions.
•

UV-ozone treatment of polystyrene samples.

First, a piece of petri dish polystyrene served as a control (Figure AI-6A), a second piece
was directly exposed to UV-ozone for 30 minutes (Figure AI-6B), and a third one was
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submerged in DI water and exposed to UV-ozone for 30 minutes (Figure AI- 6C). Figure

A

B

C

Figure AI-6. Modification of polystyrene surface via UV-ozone. A) Control (0 minutes of exposure). B) Direct exposure (30
minutes). C) Under-water exposure (30 minutes).

AI-6 shows the three different pieces as a support of 100 μl of water. Figure AI-6A shows
the control, and as expected the observed contact angle is very high, due to the high
hydrophobicity of the untreated polystyrene. Figures AI-6B and AI-6C show that the UV
treatment of the sample (either directly or under water) reduces the water contact angle
significantly.
The microspheres come already suspended in a solution, so to expose the beads directly
becomes challenging as the beads need to be dried before treatment and resuspended after
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treatment. Therefore, we decided to place the beads submerged on DI water on a watch
glass and expose it to UV-ozone for 0, 2, 5, 10 and 15 minutes. After the treatment, the
beads were re-suspended in PBS buffer, and then analyzed in the flow cytometer. Figure
AI-7A shows the fluorescence intensity in FL-1 (Laser 488, Filter 533/30nm band pass)
after treatment. Unfortunately, the data clearly indicates that the exposure to UV is making
the beads fluorescent and it is detectable in the channel that we primarily used to detect the
presence of fluorescent membranes. Figure AI-7B shows the fluorescence levels in FL-1
as a function of the time of exposure has a quadratic nature. Hence, until we are able to

Figure AI-7. A) Fluorescence of UV treated beads at different times: 0 minutes (red), 2 minutes (blue), 5 minutes (orange),
10 minutes (light green) and 15 minutes (dark green). B) Fluorescence intensity as a function of time of UV exposure.

better understand the aspects of this chemistry process that make the beads fluorescent as
function of UV time exposure, another surface modification method should be pursued.
•

O2 plasma treatment of polystyrene and carboxylated-polystyrene samples.
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First, a piece of petri dish polystyrene served as a control, and a second piece was

O2 plasma treated

Untreated

Figure AI-1. Modification of polystyrene surface via O2 plasma treatment. Exposure time ~1 minute.

directly exposed to O2 plasma for 1 minute. Figure AI-8 shows the two different pieces as
a support of 100 μl of water. In the control, and as expected, the observed contact angle is
very high, due to the high hydrophobicity of the untreated polystyrene. Figures AI-8 also
shows that the O2 plasma treatment of the sample reduces the water contact angle
significantly.
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The plain polystyrene and carboxylated-polystyrene beads in storage solution were
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Figure AI-9. Median fluorescence intensity of carboxylated-polystyrene microspheres (5 μm) in all the detection channels of
the Attune NxT flow cytometer. Untreated beads or control (red), O2 plasma treated beads (light blue).

placed on a watch glass and exposed to O2 plasma for 1 minute. Given the results from the
surface treatment with UV-ozone, we decided to evaluate the fluorescence of beads before
and after treatment in all the detection channels available on the Attune NxT. Figure AI-9
shows the fluorescence levels of the untreated carboxylated-polystyrene beads (red
histograms) and treated carboxylated-polystyrene beads (light blue histograms), and no
major difference in fluorescence can be observed in any of the detection channels. Similar
results were obtained using plain polystyrene microspheres (Figure AI-Extra-1, located at
the end of this Appendix). Hence, the next step was to try to assemble membrane structures
on the treated beads’ surfaces. We attempted to assemble lipid membranes with 99.8%mol
DOPC + 0.2%mol NBD-DOPC liposomes on silica beads (for control) and on the O2
plasma treated polystyrene (plain and carboxylated) microspheres by following the
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protocol reported on chapters 3 and 4, except for the final rinsing steps to minimize sample
to sample variability.
Figure AI-10 shows the fluorescence intensity in the BL-1 channel (NBD detection
channel) of the different samples tested. Figure AI-10A shows the fluorescence of bare
silica beads (red) and of the lipid-coated silica beads (light blue), which shows a very
narrow distribution with high fluorescence, both indicative of the formation of uniform
complete membranes on the beads.
Figure AI-10B shows the fluorescence of plain polystyrene beads (red), the O2 plasma

A
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(~3 μm diameter)

BL-1

B

Plain polystyrene microspheres
(~5 μm diameter)

BL-1

C

Carboxylated-polystyrene
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Lipid-coated silica beads

O2 plasma modified beads

O2 plasma modified beads
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Lipid-coated O2 plasma modified beads
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Figure AI-10. Fluorescence levels in the BL-1 channel (Excitation 488 nm; Emission 533/30 nm) of bare, modified, lipid-coated
bare beads or lipid-coated modified beads. A) In non-porous silica microspheres (3 μm). B) In plain polystyrene microspheres
(5 μm). C) In carboxylated-polystyrene microspheres (5 μm).

treated plain polystyrene beads (light blue), the lipid-coated plain polystyrene beads
(orange), and the lipid-coated- O2 plasma treated plain polystyrene beads (green). Contrary
to intuition, the fluorescence levels observed in the untreated beads is higher than the one
observed on the treated ones, but in both cases the fluorescence distribution is very broad.
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These two observations might be explained by the possible formation of aggregates of
liposomes on the beads’ surface instead of a biomimetic membrane, especially considering
that we omitted the final rinsing steps to remove the excess liposomes. Figure AI-10C
shows the fluorescence of carboxylate-polystyrene beads (red), the O2 plasma treated
carboxylate-polystyrene beads (light blue), the lipid-coated carboxylate-polystyrene beads
(orange), and the lipid-coated- O2 plasma treated carboxylate-polystyrene beads (green).
The obtained results are very similar to those observed in Figure AI-10B, and the possible
explanations remain the same.
The inability of the plasma treated (plain and carboxylated polystyrene) beads to
support membrane bilayers can be due the fact that the O2 plasma treatment can reduce the
contact angle to ~ 35°, as reported by Guruventket, et al.,6 which is not a low enough angle
compared to the contact angle on silica surfaces of ~20° or less.7 Another possibility is that
surface modification of the beads was not uniform, a difficulty hard to overcome given the
small and colloidal nature of the samples.
Conclusion. The successful modification of the surface of polystyrene microspheres could
represent an important stepping stone towards the development of a multiplexable,
naturally-buoyant and high-throughput compatible platform to present biomimetic
membranes against other biomolecules. Nevertheless, the surface modification methods
explored in this section have proven not to be effective or still require some re-designing
in the protocol to optimize the results. Therefore, some alternative ways of modifying the
surface of polystyrene microspheres should be pursued.
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Appendix I. 3 ADDITIONAL WORK FOR CHAPTER 5 – DETECTION OF
MEMBRANE-POLYMER INTERACTIONS ON MICROSPHERE
SUPPORTED-BIOMIMMETIC MEMBRANES

Appendix I. 3.1 Chitosan interaction with microsphere-supported membranes with
different lipid compositions.
Introduction. The aim of chapter 5 is to perform flow cytometry studies of polymermembrane interactions on multiplexed microspheres. The interaction of polymers with
lipid membranes and cell membranes is of key importance for the development of novel
medical devices, drug delivery mechanisms, and the discovery of antimicrobials and
antimicrobial surfaces.8 Polymers are used for various biomedical purposes such as drug
delivery, as biosensors, and for surgical sutures and implants.9 The polymer-membrane
interaction seems to be dictated by the membrane composition and charge and the
polymer’s charge and structure.10 Among the polymers that have been reported to interact
with different lipid composition is chitosan, which is an extensively studied cationic
polymer with non-toxicity, antibacterial activity, antioxidant activity, and high
biocompatibility.11,12 Chitosan is used in different areas such as cosmetics and foods,13 but
most importantly it has a variety of pharmaceutical and biomedical applications. For
instance, chitosan is used as a drug delivery agent,14,15 in tissue engineering,16,17 and in
gene delivery.12,18 Chitosan’s adhesion to different substrates as a function of pH and
contact time has been characterized.19,20 Furthermore, chitosan has been reported to interact
with anionic lipids, such as DPPG.21,22 Moreover, chitosan has the advantage of being
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widely commercially available at a low cost. Hence, we decided to screen the preferential
binding of fluorescently-tagged chitosan to microsphere-supported membranes with
different lipid composition and charge (non-ionic, cationic, and anionic lipids).
Fluorescently-labeled chitosan is commercially available for high prices; therefore, we
chose to do the fluorescent tagging ourselves.
Materials. The lipids 1-palmitoyl-2- oleoyl-sn- glycero-3- phosphocholine (POPC), 1,2dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)
trimethylammonium-propane

(DOTAP),

and

(DPPG),
1,2-dioleoyl-

1,2-dioleoyl-3sn-glycero-

3-

phosphoethanolamine-N- (7-nitro- 2-1,3- benzoxadiazol-4- yl) (NBD-DOPE) were
purchased from Avanti Polar Lipids in lyophilized form. As solvent for lipids, we used
chloroform that contains 1%-5% of ethanol as a stabilizer, purchased from EMD Millipore.
The phosphate-buffered saline (PBS), the bovine serum albumin (BSA), the dehydrated
methanol, and the low molecular weight chitosan (50-190 kDa) were purchased from
Sigma Aldrich. The acetic acid and the sodium hydroxide were purchased from EMD
Millipore. The assays were performed in PBS pH 4.5 – 5.5. The non-porous silica
microspheres (7.9 μm) were purchased from Spherotech. The chitosan fluorescent tagging
measurements were performed with the Perkin Elmer Lambda 35 UV/VIS Spectrometer,
and the assay measurements were performed with the Accuri C6 flow cytometer.
Methods.
Fluorescent tagging of chitosan. First, chitosan was covalently modified by linking the
isothiocyanate group of FITC to the primary amine group of the d-glucosamine residue in
chitosan, following the protocol reported by Qaqish et al.,23 and by Yuqing et al.24 Briefly,
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0.2 g of chitosan was dissolved in 20 ml of 0.1M acetic acid, followed by the additions of
20 ml of dehydrated methanol to the solution. Then, 20 ml of FITC solution (1mg/ml FITC
in methanol) were added to achieve a d-glucosamine: FITC residue ratio of ~ 1:50. The
reaction was allowed to proceed for 3 h in the dark at room temperature. Afterwards, the
FITC-labeled chitosan was precipitated in 0.1 M sodium hydroxide solution. The
precipitate was extensively washed with deionized distilled water and separated by
centrifuge until there is complete absence of free FITC fluorescence signal in the washing
medium. The last washing step needs to be with acetic acid instead of water, since chitosan
is soluble in acetic acid and not in water. The resulting stock and dilutions should be kept
in the dark at ~ 4 °C. Finally, the FITC labeling efficiency was determined by measuring
the absorbance intensity of FITC-chitosan solution against standard solutions of FITC
using UV-Vis spectrometer.
Screening of preferential binding of chitosan-FITC to different membrane compositions
and charges. Second, we assembled different sets of biomimetic membranes on silica
microspheres following the protocol reported in chapters 3 and 4, including the BSA
passivation and rinsing steps. The tested membranes compositions were: 100%mol POPC,
90%mol POPC+10%mol DOTAP, and 90%mol POPC+10%mol DPPG. Each set of
samples was incubated with increasing amounts chitosan-FITC (0, 0.2, 2, 20 μM) for ~30
minutes and immediately analyzed on the flow cytometer.
Disruption effects of chitosan on differently-charged fluorescently tagged membranes.
Third, the potential disruption effect of chitosan on the membranes was tested by first
assembling membranes with the following compositions: 99.8%mol POPC+0.2%mol
NBD-DOPE, 89.8%mol POPC+0.2%mol NBD-DOPE+10%mol DOTAP, and 89.8%mol
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POPC+0.2%mol NBD-DOPE+10%mol DPPG. Then, each set of samples was incubated
with increasing amounts chitosan (0, 0.2, 2, 20 μM) for ~30 minutes and immediately
analyzed on the flow cytometer.
Results and Discussions.
Fluorescent tagging of chitosan. Figure AI-Extra-2 shows A) the schematic illustration of
the chemical synthesis of FITC-labeled chitosan, B) a picture of the last centrifuge step in
the fluorescent-tagging process, where it can be observed that the precipitate has a
yellow/orange color indicative of the presence of FITC and the supernatant is clear and
FITC-free. C) pictures of a 10X and a 100X dilution of chitosan-FITC in PBS buffer.
Figure AI-Extra-3 shows that 2.5μM FITC in PBS has an absorbance of 0.165 at
494nm, it also shows that 100X dilution of chitosan-FITC in PBS has an absorbance of
0.130 at 497nm. Based on this information and using Beer-Lambert Law, we can calculate
the initial concentration FITC in the chitosan-FITC solution.
𝐴 = 𝜀𝑐𝐿 .

𝐴𝐹 = 𝜀𝑐𝐹 𝐿 and 𝐴𝐶𝐹𝐷 = 𝜀𝑐𝐶𝐹𝐷 𝐿

where, AF and CF are the absorbance and the concentration (2.5μM) of FITC in PBS,
respectively; and ACFC and CCFD are the absorbance and the concentration of the 100X
diluted chitosan-FITC in PBS, respectively.

𝜀𝐿 =

𝐴𝐹 𝐴𝐶𝐹𝐷
=
𝑐𝐹
𝑐𝐶𝐹𝐷

→ 𝑐𝐶𝐹𝐷 =

𝐴𝐶𝐹𝐷 ∗ 𝑐𝐹
0.130 ∗ 2.5𝜇𝑀
=
𝐴𝐹
0.165

→ 𝑐𝐶𝐹𝐷 ≈ 2𝜇𝑀

Therefore, the concentration of the original solution of chitosan-FITC dissolved in
acetic acid has a concentration of approximately 0.2mM of FITC.
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Assuming we did not lose any chitosan in the washing process, we started with 0.2 g of
low molecular chitosan in 50 ml of solution. The molecular weight of the chitosan subunit
is ~ 178 g/mole. Then,
0.2𝑔𝑐ℎ𝑖𝑡𝑜𝑠𝑎𝑛 1 𝑚𝑜𝑙𝑒 𝑐ℎ𝑖𝑡𝑜𝑠𝑎𝑛 1000𝑚𝑙 𝑠𝑜𝑙.
∗
∗
≈ 0.02𝑀 = 20𝑚𝑀
50𝑚𝑙 𝑠𝑜𝑙.
178 𝑔 𝑐ℎ𝑖𝑡𝑜𝑠𝑎𝑛
1𝐿 𝑠𝑜𝑙.
𝑐ℎ𝑖𝑡𝑜𝑠𝑎𝑛 20𝑚𝑀 100
=
=
𝐹𝐼𝑇𝐶
0.2𝑚𝑀
1
Then, the chitosan/FITC ratio is 100:1.
Screening of preferential binding of chitosan-FITC to different membrane compositions
and charges. Figure AI-11 shows the 10% scatter plot of side scatter versus FL-1 (FITC
detection channel on the Accuri C6) of the BSA-passivated silica microspheres and the
Control

+0.2 μM Chit-FITC

+2 μM Chit-FITC

+20 μM Chit-FITC

Bare
beads

Side Scatter

100%
POPC

10%
DOTAP

10%
DPPG

FL-1
Figure AI-11. Scatter plots (side scatter vs. FL-1) showing three sets of silica microsphere-supported membranes: 100%mol
POPC (non-ionic), 90%mol POPC+10%mol DOTAP (cationic), and 90%mol POPC+10%mol DPPG (anionic) in the presence
of increasing concentration of chitosan-FITC (0.2, 2, 20 μM).
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differently-charged membranes supported on silica beads in the presence of increasing
concentration of chitosan-FITC.
The BSA-passivated silica microspheres show a double population of in the presence
of 0.2 and 2 μM chitosan-FITC both with higher fluorescence than the background. This
can be due to the poor BSA passivation of silica, or it could be due to the low concentration
(below of the saturation point) of FITC. However, the BSA-passivated silica microspheres
in the presence of 20 μM chitosan-FITC shows very low fluorescence, which can be
indication of saturation of FITC on the beads resulting on self-quenching. Moreover, these
results show very high non-specific binding of the chitosan-FITC to the silica beads. In the
presence of 0.2 μM chitosan-FITC, the non-ionic membranes (100% POPC) and the
anionic membranes (POPC+10%mol DPPG) show a more significant increase in the FL-1
fluorescence compared to the increase observed on the cationic membranes (POPC+
10%mol DOTAP). This can be due to the electrostatic interaction between the cationic
chitosan and the cationic membranes. In the presence of 2 μM chitosan-FITC, the nonionic membranes present less dispersed population compared to the anionic and cationic
membranes where double populations can be observed. The lower population fluorescence
is comparable to the one observed in the non-ionic membranes, whereas the higher
population fluorescence in the anionic lipids shows a higher concentration of beads and a
better-defined distribution. In the presence of 20 μM chitosan-FITC all the membranes
show a single population with a broad distribution in the FL-1 channel. The non-ionic
membranes show a higher fluorescence level, in the FL-1 channel, compared to the anionic
and cationic membranes, which show fluorescence levels comparable to one another.
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Disruption effects of chitosan on differently-charged fluorescently tagged membranes.
Figure AI-12 shows the 10% scatter plot of side scatter versus FL-1 (NBD detection
channel on the Accuri C6) of the BSA-passivated silica microspheres and the differentlycharged NBD-labeled membranes supported on silica beads in the presence of increasing
concentration of chitosan.

Control

+0.2 μM Chitosan

+2 μM Chitosan

+20 μM Chitosan

100% POPC
+0.2%NBD

Side Scatter

10% DOTAP
+0.2%NBD

10% DPPG
+0.2%NBD

FL-1
Figure AI-12. Scatter plots (side scatter vs. FL-1) showing three sets of silica microsphere-supported fluorescently-tagged
membranes: POPC+0.2%mol NBD-DOPE (non-ionic), POPC+2%mol NBD-DOPE+10%mol DOTAP (cationic), and
POPC+2%mol NBD-DOPE+10%mol DPPG (anionic) in the presence of increasing concentration of chitosan (0.2, 2, 20 μM).

The initial FL-1 fluorescence level is the same for all three sets of samples: non-ionic
membranes (POPC + 0.2%mol NBD-DOPE), cationic membranes (POPC+ 0.2%mol
NBD-DOPE+ 10%mol DOTAP), and anionic membranes (POPC+ 0.2%mol NBDDOPE+ 10%mol DPPG). The three sets of membranes show that in the presence of either
0.2, 2, or 20 μM chitosan, the fluorescence FL-1 level remains the same as the one observed
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initially, and the distributions remain tight for the non-ionic and cationic membranes,
whereas on the anionic membranes the samples show a slightly broader distribution, but
the median fluorescence remain the same. These data indicate that chitosan does not act as
a disrupting agent on the biomimetic membranes.
Conclusion. Chitosan is a polymer of great interest as it serves many biomedical purposes.
However, the data obtained here shows that it has a very high non-specific binding to silica
and to different membrane compositions. Another problem is the fact that chitosan is
soluble in acidic solutions and it aggregates in PBS pH 7.4, while FITC as a fluorescent
tag for chitosan requires to work in a small pH range close the physiological range, as FITC
has pH-dependent absorption.25 Also, BSA (what we use for blocking) is positively
charged under acidic conditions,26 which can also be electrostatically interacting with the
chitosan in solutions. Hence, the protocol for the study of the interaction of chitosan with
differently-charged membrane presented on silica microspheres needs to be further refined.
If the new approaches prove to be effective, a broader range of different compositions
membranes could be screened against chitosan. However, for the time purposes, choosing
a different biologically relevant polymer is a better alternative.
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Appendix I. 3.2 Poly-L-lysine (PLL) interaction with bead-supported membranes
with different lipid compositions.

Introduction. The need for the study of the interaction between polymers and membranes
was discussed in chapter 5 and the previous section of this chapter (Chitosan interaction
with microsphere-supported membranes with different lipid compositions). Poly-L-lysine
is a cationic polymer used in food, and with several biomedical applications,27 including
tissue culture,28 drug delivery,29 as a gene carrier,30 and as a lipase inhibitor,31 among many
others. The interaction of poly-L-lysine and charged lipid membranes has been studied.
For instance, it has been reported that Poly-L-lysine differentially interacts with
anionic/zwitterionic and neat zwitterionic bilayer membranes supported on planar cleaved
mica.32 It has also been reported that poly-L-lysine can pass through anionic lipid
bilayers.33 Hence, we decided to screen the preferential binding of low molecular weight
fluorescently-tagged poly-L-lysine to microsphere-supported membranes with differently
charged lipids.
Materials. The lipids 1-palmitoyl-2- oleoyl-sn- glycero-3- phosphocholine (POPC), 1,2dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol)
trimethylammonium-propane

(DOTAP),

and

(DPPG),
1,2-dioleoyl-

1,2-dioleoyl-3sn-glycero-

3-

phosphoethanolamine-N- (7-nitro- 2-1,3- benzoxadiazol-4- yl) (NBD-DOPE) were
purchased from Avanti Polar Lipids in lyophilized form. As solvent for lipids, we used
chloroform that contains 1%-5% of ethanol as a stabilizer, purchased from EMD Millipore.
The phosphate-buffered saline (PBS), the bovine serum albumin (BSA), the poly-L-lysine
(PLL) and poly-L-lysine hydrobromide–FITC Labeled (PLL-FITC) were purchased in
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powder form from Sigma Aldrich. The assays were performed in PBS pH 7.4. The nonporous silica microspheres (7.9 μm) were purchased from Spherotech. The assay
measurements were performed with the Accuri C6 flow cytometer.
Methods.
Screening of preferential binding of PLL-FITC to different membrane compositions and
charges. We assembled different sets of biomimetic membranes on silica microspheres
following the protocol reported in chapters 3 and 4, including the BSA passivation and
rinsing steps. The tested membranes compositions were: 100 mol%l POPC, 90 mol%
POPC+10 mol% DOTAP, and 90 mol% POPC+10 mol% DPPG. Each set of samples was
incubated with increasing amounts PLL-FITC (0, 0.02, 0.2, 2 μM) for ~10 minutes and
immediately analyzed on the flow cytometer.
Disruption effects of PLL on differently-charged fluorescently tagged membranes. The
potential disruption effect of PLL on the membranes was tested by first assembling
membranes with the following compositions: 99.8%mol POPC+0.2%mol NBD-DOPE,
89.8%mol

POPC+0.2%mol

NBD-DOPE+10%mol

DOTAP,

and

89.8%mol

POPC+0.2%mol NBD-DOPE+10%mol DPPG. Then, each set of samples was incubated
with increasing amounts PLL (0, 0.02, 0.2, 2 μM) for ~10 minutes and immediately
analyzed on the flow cytometer.
Results and Discussions.
Screening of preferential binding of PLL-FITC to different membrane compositions and
charges. FigureAI-13 shows the 10% scatter plot of side scatter versus FL-1 (FITC
detection channel on the Accuri C6) of the BSA-passivated silica microspheres and the
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differently-charged membranes supported on silica beads in the presence of increasing
concentration of PLL-FITC.

Control

+0.02 μM PLL-FITC

+0.2 μM PLL-FITC

+2 μM PLL-FITC

Bare
beads

Side Scatter

100%
POPC

10%
DOTAP

10%
DPPG

FL-1
Figure AI-13. Scatter plots (side scatter vs. FL-1) showing three sets of silica microsphere-supported membranes: 100%mol
POPC (non-ionic), 90%mol POPC+10%mol DOTAP (cationic), and 90%mol POPC+10%mol DPPG (anionic) in the presence
of increasing concentration of PLL-FITC (0.02, 0.2, 2 μM).

Similar to the chitosan case, the BSA-passivated silica beads show a double population
of in the presence of 0.02 and 0.2 μM PLL-FITC, both with higher fluorescence than the
background. Meanwhile, the presence of 2 μM PLL-FITC presents a single narrow
population with high fluorescence in FL-1, showing saturation of PLL-FITC and high nonspecific bidding to silica. In the presence of 0.02 μM PLL-FITC, the three sets of
membranes: non-ionic (100% POPC), cationic (POPC+ 10%mol DOTAP), and anionic
(POPC+10%mol DPPG) show no increase in the FL-1 channel, indicating very low to nointeraction of that concentration of PLL-FITC with the membranes. In the presence of 0.2
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μM PLL-FITC the three sets of membranes show higher fluorescence in FL-1, and very
broad population distributions that resulted in similar median fluorescence intensities. This
indicates non-specific binding of PLL or FITC to the differently-charged membranes.
Finally, in the presence of 2 μM PLL-FITC the non-ionic membranes show what seems to
be a very broad single population, with the highest concentration of bead at the higher
fluorescence level, showing high non-specific binding. The cationic membranes show a
clear double population where the lower fluorescence level corresponds to the background
level and the higher fluorescence level is similar to the one observed on the non-ionic
membranes. Finally, the anionic membranes show a single population with a not-so broad
distribution with high FL-1 fluorescence level, which can be indicative of electrostatic
interaction of DPPG with PLL.
Disruption effects of PLL on differently-charged fluorescently tagged membranes. Figure
AI-14 shows the 10% scatter plot of side scatter versus FL-1 (NBD detection channel on
the Accuri C6) of the BSA-passivated silica microspheres and the differently-charged
NBD-labeled membranes supported on silica beads in the presence of increasing
concentration of PLL.
The initial FL-1 fluorescence level is the same for all three sets of samples: non-ionic
membranes (POPC + 0.2%mol NBD-DOPE), cationic membranes (POPC+ 0.2%mol
NBD-DOPE+ 10%mol DOTAP), and anionic membranes (POPC+ 0.2%mol NBDDOPE+ 10%mol DPPG). The three sets of membranes show that in the presence of either
0.02, 0.2, or 2 μM PLL, the fluorescence FL-1 level remains the same as the one observed
in the control samples. Moreover, the distributions of the three sets of membranes remain
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tight. These data indicate that chitosan does not act as a disrupting agent on the biomimetic
membranes.

Control

+0.02 μM PLL

+0.2 μM PLL

+2 μM PLL

POPC
+0.2%NBD

Side Scatter

25% DOTAP
+0.2%NBD

25% DPPG
+0.2%NBD

FL-1
Figure AI-14. Scatter plots (side scatter vs. FL-1) showing three sets of silica microsphere-supported fluorescently-tagged
membranes: POPC+0.2%mol NBD-DOPE (non-ionic), POPC+2%mol NBD-DOPE+10%mol DOTAP (cationic), and
POPC+2%mol NBD-DOPE+10%mol DPPG (anionic) in the presence of increasing concentration of PLL (0.02, 0.2, 2 μM).

Conclusion. The double populations in the presence of certain concentrations of PLLFITC remain a setback and something that needs to be further explored for better
understanding. In addition, membranes with higher concentrations of DOTAP and DPPG
should be screened against PLL-FITC in an attempt to test the possible electrostatic
interactions. Moreover, different fluorescent dyes could be used as tag for PLL; dyes that
are known to have little to no interaction with lipid membranes. Finally, an alternative nonionic blocking agent could be used instead of BSA to mitigate non-specific interactions.
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Appendix I. 5 EXTRA FIGURES

Appendix I, Figure AI-Extra-1. Plain polystyrene beads after O2 plasma treatment.
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Figure AI-Extra-1. Median fluorescence intensity of plain-polystyrene microspheres (5 μm) in all the detection channels of
the Attune NxT flow cytometer. Untreated beads or control (red), O2 plasma treated beads (light blue).
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Appendix I, Figure AI-Extra-2. FITC-labeling of chitosan.

A

Schematic illustration of the chemical synthesis of
FITC-labeled chitosan. FITC was reacted with chitosan,
dissolved in 0.10 M acetic acid-methanol (1:1)
mixture, for 1 h at room temperature.

B

Last centrifuge step in the fluorescently-tagging of
low molecular chitosan with FITC in acetic acid

C

Chitosan-FITC
10X dilution in PBS

R.B. Qaqish, M.M. Amiji / Carbohydrate Polymers 38 (1999) 99-107

Chitosan-FITC 100X
dilution in PBS

Figure AI-Extra-2. Fluorescein labeling of chitosan. A) Schematic illustration of the chemical synthesis of FITC-labeled
chitosan. B) Last centrifuge step in the fluorescently-tagging of low molecular chitosan with FITC in acetic acid. C) 10X and
100X dilution of chitosan-FITC in PBS buffer.
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Appendix I, Figure AI-Extra-3. Absorbance of chitosan-FITC and FITC in PBS.
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Figure AI-Extra-3. Absorbance of 2.5μM FITC in PBS and 100X dilution of chitosan-FITC in PBS.
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Appendix II.
Extra Figures for Chapters 3, 4 and 5.
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Appendix II 3
Figure A3.1: Time stability of individual and multiplex sets. The stability of the multiplexed
sample over time is shown by comparison of individual and multiplexed samples.

Figure A3.1. Side Scatter vs FL-1 channel (Laser 488, Filter 533/30nm band pass) of individual and multiplexed samples
containing: 0% NBD-DOPE, 0.2% NBD-DOPE and 2% NBD-DPE. A) Individual samples at time 0. Here, the results of three
individual samples are overlaid in a single bivariate plot, color coded according to the legend given on the right side of the figure.
B) Individual samples after 30 minutes. C) Individual samples after 1 hour. D) Multiplex at time 0. E) Multiplex after 30 minutes.
F) Multiplex after 1 hour.
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Figure A3.2: Cholera toxin B subunit-Alexa 647 does not have specific interactions with the NBDDOPE multiplex label. Bivariate plots of Cholera Toxin B subunit and NBD-DOPE indicate that
no concentration-dependent interaction occurs between CTxB and the labeled lipid used for
multiplexing.

Figure A3.2. Bivariate contour plots (FL-4 vs. FL-1). Individual samples: 0 mol% NBD-DOPE: A) Plus 0 nM CTxB-Alexa 647.
B) Plus 2 nM CTxB-Alexa 647. C) Plus 20 nM CTxB-Alexa 647. 0.2 mol% NBD-DOPE: D) Plus 0 nM CTxB-Alexa 647. E) Plus
2 nM CTxB-Alexa 647. F) Plus 20 nM CTxB-Alexa 647. 2 mol% NBD-DOPE: G) Plus 0 nM CTxB-Alexa 647. H) Plus 2 nM
CTxB-Alexa 647. I) Plus 20 nM CTxB-Alexa 647. Multiplexed samples: J) Plus 0 nM CTxB-Alexa 647.K) Plus 2 nM CTxBAlexa 647. L) Plus 20 nM CTxB-Alexa 647.
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Figure A3.3: Compensation details for biotin-streptavidin assays. Details of the compensation
matrix applied to the biotin-streptavidin assay are presented.

Figure A3.3. Bivariate plots before and after compensation and compensation matrix used in the biotin-streptavidin assay. The left
panel is a bivariate plot of FL-3 versus FL-1 signal intensity, and the right panel is the same data following application of
compensation.
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Figure A3.4: Interaction of Biotin-DOPE and Streptavidin-PE/Cy5 in the individual sample and
multiplex approaches. Bivariate plots of streptavidin-biotin assay are shown for individual and
multiplex samples.

Figure A3.4. Bivariate contour plots (compensated FL-3 vs. FL-1). Individual samples: 0 mol% Biotin: A) Plus 0 nM SAv-Cy5.
B) Plus 0.05 nM SAv-Cy5. C) Plus 0.25 nM SAv-Cy5. D) Plus 0.5 nM SAv-Cy5. E) Plus 2.5 nM SAv-Cy5. 0.05 mol% Biotin:
F) Plus 0 nM SAv-Cy5. G) Plus 0.05 nM SAv-Cy5. H) Plus 0.25 nM SAv-Cy5. I) Plus 0.5 nM SAv-Cy5. J) Plus 2.5 nM SAvCy5. 0.5 mol% Biotin: K) Plus 0 nM SAv-Cy5. L) Plus 0.05 nM SAv-Cy5. M) Plus 0.25 nM SAv-Cy5. N) Plus 0.5 nM SAvCy5. O) Plus 2.5 nM SAv-Cy5. Multiplexed samples: P) Plus 0 nM SAv-Cy5. Q) Plus 0.05 nM SAv-Cy5. R) Plus 0.25 nM SAvCy5. S) Plus 0.5 nM SAv-Cy5. T) Plus 2.5 nM SAv-Cy5.
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Figure A3.5: Streptavidin-PE/Cy5 does not have specific interactions with the NBD-DOPE
multiplex label. Bivariate plots of Streptavidin-PE/Cy5 and NBD-DOPE indicate that no
concentration-dependent interaction occurs between streptavidin and the labeled lipid used for
multiplexing.

Figure A3.5. Bivariate contour plots (FL-3 vs FL-1). Individual samples: 0 mol% NBD-DOPE: A) Plus 0 nM SAv-Cy5. B)
Plus 0.25 nM 0nM SAv-Cy5. C) Plus 2.5 nM 0nM SAv-Cy5. 0.2 mol% NBD-DOPE: D) Plus 0 nM SAv-Cy5. E) Plus 0.25
nM SAv-Cy5. F) Plus 2.5 nM SAv-Cy5. 2 mol% NBD-DOPE: G) Plus 0 nM SAv-Cy5. H) Plus 0.25 nM SAv-Cy5. I) Plus
2.5 nM SAv-Cy5. Multiplexed samples: J) Plus 0 nM SAv-Cy5.K) Plus 0.25 nM SAv-Cy5. L) Plus 2.5 nM SAv-Cy5.
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Figure A3.6: Compensation details for cross reactivity assays. Details of the compensation
matrix as applied in the cross-reactivity assay are presented.

Figure A3.6. Bivariate plots before and after compensation and compensation matrix used in the cross-reactivity assay seen in: A)
FL-3 versus FL-1 of the multiplex system with no added protein, before (left) and after (right) compensation. B) FL-4 versus FL-3
of the multiplex system plus SAv-Cy5, before (left) and after (right) compensation. C) Compensation matrix.
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Figure A3.7: Cross-reactivity median fluorescence intensities – Median fluorescence intensities in
FL-4 and FL-3 in cross-reactivity assay are presented.

Figure A3.7. Median fluorescence Intensity in a fluorescently indexed multiplex system with lipids containing: 100% POPC
(blue bars); 99.3% POPC, 0.5% GM1, 0.2% NBD-DOPE (orange bars); 97.5% POPC, 0.5% Biotin-DOPE, 2% NBD-DOPE.
A) FL-4 channel (Laser 640nm, Filter 675/25) after 10-minute incubation with: 20 nM CTxB-Alexa 647, 2.5 nM SAv-Cy5,
and 20 nM CTxB-Alexa 647 and 2.5 nM SAv-Cy5. B) FL-3 channel (Laser 488nm, Filter 670 LP) after 10-minute incubation
with: 20 nM CTxB-Alexa 647, 2.5 nM SAv-Cy5, and 20 nM CTxB-Alexa 647 and 2.5 nM SAv-Cy5. These data are the average
of four replica experiments, each normalized to the highest intensity observed in the fluorescence channel for that replicate,
and where the data of each replicate correspond to gated populations similar to those of Figure 5 of the main text.
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Appendix II 4
Figure A4.1: Fluorescent membranes supported on planar glass after LDAO treatment.
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Figure A4.1. Fluorescent microscopy images (40X magnification, zoom 2.0) of lipid membranes (99.8%mol
DOPC+0.2%mol NBD-DOPE) supported on planar glass and incubated with 1.5 mM LDAO. A) Control (0 mM LDAO) at
time 0 minutes. B) After 25 minutes. C) After 30 minutes. D) After 45 minutes.

Fluorescent microscopy images (40X magnification, zoom 2.0) of lipid membranes (99.8%mol DOPC+0.2%mol NBDDOPE) supported on planar glass and incubated with 1.5 mM LDAO. A) Control (0 mM LDAO) at time 0 minutes. B) After
25 minutes. C) After 30 minutes. D) After 45 minutes.
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Figure A4.2: LDAO effect on different membrane compositions. Fluorescently-tagged membranes
supported on microspheres after treatment with LDOA
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Figure A4.2. Median fluorescence intensity in the BL-1 channel (NBD detection channel) of silica microsphere-supported
membranes tagged with 0.2%mol NBD-DOPE and different membrane compositions in the presence of 0 mM LDAO (blue
bars), 0.1 mM LDAO (red bars), 0.5 mM LDAO (gray bars), and 1 mM LDAO (yellow bars). A) After a 20-minute incubation.
B) After a 40-minute incubation. C) After a 60-minute incubation.
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Figure A4.3. Derived count rate as a function of LPS concentration.

Figure A4.3. Determination of LPS critical micelle concentration.
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Figure A4.4: Fluorescent membranes supported on planar glass after LPS treatment.
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Figure A4.4. Fluorescent microscopy images (40X magnification, zoom 2.0) of lipid membranes (99.8%mol DOPC+0.2%mol
NBD-DOPE) supported on planar glass. A) Control (0 μg/ml LPS) at time 0 minutes. B) After a 30-minute incubation with
500 μg/ml of LPS.
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Figure A4.5: LPS effect on different membrane compositions. Fluorescently-tagged membranes
supported on microspheres after treatment with LPS
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Figure A4.5. Median fluorescence intensity in the BL-1 channel (NBD detection channel) of silica microsphere-supported
membranes tagged with 0.2%mol NBD-DOPE and different membrane compositions in the presence of 0 mM LPS (blue bars), 50
μg/ml LPS (red bars), 250 μg/ml LPS (gray bars), and 500 μg/ml LPS (yellow bars). A) After a 40-minute incubation. B) After a 60minute incubation.
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Appendix II 5
Movie A5.1: Fluorescence recovery after photobleaching.

Movie A5.1. Preview image of the movie showing fluorescence recovery after photobleaching (FRAP) in biomimetic
membranes (1 mM pEO-b-pBD + 0%mol GM1 +1%mol Texas-Red-DHPE) supported on silica microspheres.
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Figure A5.1: Data of the fluorescence recovery after photobleaching.
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Figure A5.1. Analysis of the fluorescence recovery after photobleaching (FRAP) in biomimetic membranes (1 mM pEO-bpBD + 0%mol GM1 +1%mol Texas-Red-DHPE) supported on silica microspheres.
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Figure A5.2: Time stability of polymer membranes supported on silica beads.
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Figure A5.2. Time stability (at 0, 0.5, 1, 2, 4, 8 and 24 hours) of individual and multiplex of microsphere supported containing
1mM pBD-pEO, 0% GM1, 1%mol Texas Red-DHPE (red); 1mM pBD-pEO, 0.05% GM1, 0.2%mol NBD-DOPE (light blue);
1mM pBD-pEO, 0.1% GM1, 2%mol NBD-DOPE, 1%mol Texas Red-DHPE (yellow); 1mM pBD-pEO, 0.5% GM1, 0.01%
Texas Red-DHPE (light green); and 1mM pBD-pEO, 1% GM1, 2%mol NBD-DOPE (dark green).
2
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Figure A5.3: Samples before and after compensation.
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Figure A5.3. Individual and multiplex samples before and after compensation in the RL-1 channel (Excitation 638 nm;
Emission 670/14 nm) and the YL-2 channels (Excitation 561 nm; Emission 620/15 nm).
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Figure A5.4: Compensation matrix.

Figure A5.4. Compensation matrix.
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